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Abstract 
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INVESTIGATION OF SMALL MOLECULE INHIBITORS OF TUMOUR PROGRESSION 
Subtitle: Development and validation of a 3-dimensional tumour spheroid 
invasion model to evaluate the pharmacological effects of novel small molecule β3 
integrin antagonists 
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Tumour dissemination is a major reason for failure of therapy for many tumour 
types therefore there is a requirement for novel targets & therapies. The αIIbβ3 and 
αvβ3 integrins have been demonstrated to have significant involvement at many 
stages of the tumour dissemination process including, tumour cell adhesion, 
migration, metastasis and angiogenesis, and thus the β3 integrins are a potential 
target for therapeutic antagonism with small molecules. Because of the clear 
interaction between the different integrin types, targeting integrins as a 
therapeutic strategy requires targeting more than one integrin type. 
Consequently, the ICT is developing a group of novel new αIIbβ3 and αvβ3 integrin 
dual antagonists. One of the main challenges is having a relevant, validated 
experimental model that expresses these integrins. The aim of the work 
presented here is to develop and validate an in vitro αIIbβ3 and αvβ3 integrin 
expressing assay of tumour cell invasion. The spheroid invasion assay has the 
advantage over standard monolayer transwell chamber invasion assays of being 
a 3-dimensional assay, and thus mimics better the cell-cell interactions and 
architecture that are present in a tumour compared to the monolayer-based 
assay. A panel of human cancer cell lines known to express one of the molecular 
targets of interest, αvβ3 integrin was evaluated for the ability to form spheroids and 
to invade through collagen matrices. One glioma cell line, U87-MG, demonstrated 
consistent spheroid formation and invasion and was thus selected for further 
studies. Optimum conditions were established for use of U87-MG in the invasion 
assay, and the assay was validated using a known inhibitor of invasion, LiCl and 
ii 
 
known β3 antagonist, cRGDfV. Subsequently a group of novel small molecule β3 
antagonists were evaluated at nontoxic concentrations using the assay. Both LiCl 
and cRGDfV inhibited spheroid invasion through the gel in a dose-dependent 
manner, thus validating the assay. Furthermore, when the novel small molecule 
β3 antagonists were evaluated using the model, a dose and time dependent 
reduction in U87-MG spheroids invasion in collagen was observed. In further 
work initial steps were taken to construct a cell line which expresses both αIIbβ3 
and αvβ3 integrin to use in the model to assess for dual integrin antagonism. In 
conclusion, this work has established a validated assay which has been utilised 
for some compounds to evaluate a group of novel small molecule β3 integrin 
antagonists with encouraging results. 
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1. Chapter 1: Introduction 
1.1 Cancer 
Cancer or neoplasia is a variety of distinct diseases that result in unregulated 
cell growth as a result of gene defects resulting in either loss or gain of gene 
functions. This leads to the formation of malignant cells that are able to invade 
and metastasise to nearby parts of the body (Hanahan and Weinberg, 2011). 
Cancer is a major human health problem worldwide and cancer dissemination 
is the major cause of death for most kinds of cancer (Talmadge and Fidler, 
2010).  
According to CRUK 2014 the number of people diagnosed with cancer was 
331,487 in the UK in 2011. Furthermore, in 2011 396.2 people per 100,000 of 
the UK population were diagnosed with cancer. The cancers of the breast, 
lung, prostate and bowel in 2011 represented over 54% of new cancer cases in 
the UK. 
According to the GLOBOCAN 2008 estimates, the cancer cases were about 
12.7 million and the cancer deaths were about 7.6 million globally. 56% of the 
cancer cases and 64% of the deaths were in the economically developing 
countries (Jemal et al., 2011). A total of 1,638,910 new cancer cases and 
577,190 deaths from cancer have occurred in the United States in 2012. In 
Europe alone, in 2006 3, 191, 600 cancer cases were diagnosed with 
1, 703, 000 cancer related deaths occurring in the same year (Ferlay et al., 
2007). Furthermore, 3.45 million new cancer cases and 1.75 million deaths 
from cancer have been estimated in 2012 in Europe. (Ferlay et al.) 
Cancer is a process which needs steps to progress which have been described 
as the hallmarks of cancer. The hallmarks of cancer include six hallmarks 
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required during the multistep development of human tumours. These are 
sustaining proliferative signalling, evading growth suppressors, resisting cell 
death, enabling immortality, inducing angiogenesis, and activating invasion and 
metastasis (Hanahan and Weinberg, 2011). Furthermore four other hallmarks 
were recently added including the genome instability, the inflammation, 
metabolic energy reprogramming and evading immune destruction (Hainaut 
and Plymoth, 2013). 
Metastasis and angiogenesis result from the interaction between the tumour 
cells in the tumour microenvironment. The detailed picture of tumour and the 
tumour microenvironment interaction however is not fully understood due to a 
lack of representative models (Donner, 2012, Kessenbrock et al., 2010). 
The stages at which the cancer is diagnosed and its type are the main 
determinants for the selection of therapy. There are currently three main types 
of cancer therapy: surgery, radiotherapy, and chemotherapy. Other therapeutic 
modalities include immunotherapy, hormonal therapy, antibody and gene-
based therapies. These tend to be highly disease-specific (Glickman and 
Sawyers, 2012). 
Whilst the current cancer therapies have demonstrated considerable success, 
there are still many fatalities from the disease. This can be explained by several 
reasons including inability to prevent or control tumour dissemination once it 
happens, the development of drug resistance, and the off-target toxic effects on 
normal cells (Glickman and Sawyers, 2012). 
Non-specificity is one of the major problems associated with cytotoxic anti-
cancer agents as it results in a wide-range of toxic side-effects. The cells most 
affected by the non-specificity are the rapidly dividing epithelial cells like the 
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cells lining the intestine, bone marrow and hair follicles and organs like the 
kidneys (Glickman and Sawyers, 2012). Immune system suppression and 
alopecia, digestive problems, nausea, vomiting, decreased appetite, 
nephrotoxicity, neurotoxicity and hepatic toxicity are among the common side 
effects that are associated with non-specificity of chemotherapy that result in 
limiting the therapeutic dose used in the clinic (Lindley et al., 1999). 
Multi drug resistance (MDR) is another drawback for the use of chemotherapies 
in cancer treatment as the tumour cells become resistant to a range of 
anticancer drugs not only limited to the initially used drug (Gottesman et al., 
2002). MDR is associated with molecular pumps in tumour-cell membranes that 
are responsible for pumping chemotherapy drugs from the interior of the tumour 
cells to the exterior, making the tumour cells resistance to the toxic effect of the 
drug. There are many examples of efflux pumps such as P-glycoprotein pump, 
the multidrug resistance–associated protein (MRP) pump (Gottesman et al., 
2002) and ABC transporters (Fletcher et al., 2010).  
1.2 The tumour dissemination process 
The tumour dissemination process covers metastasis, including migration, 
invasion, adhesion, and angiogenesis. Metastasis is a multistep process which 
involves the detachment of cells from the primary tumour, movement of the 
cells on the basement membrane (migration), and penetration through the 
basement membrane by degradation of the ECM proteins (invasion) (see 
Figure 1). Tumour angiogenesis is a process which involves the formation of 
new blood vessels after the tumour size reaches 2 mm3 where a state of 
cellular hypoxia begins due to the lack of vasculature and results in subsequent 
oxygen starvation (Egeblad et al., 2010, Barkan et al., 2010). 
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One of the main requirements of metastasis is the loss of anchorage-
dependent growth which allows the cell to leave the primary tumour, seed and 
start tumour growth in another part of the body (see Figure 1) (Hanahan and 
Weinberg, 2011).  
Figure 1 Metastasis is a multistep process that begins with detachment of the 
cells from the primary tumour and penetration through the basement 
membrane by degradation of the ECM proteins. Tumour cells are shed from the 
original tumour and travel through the circulation to reach vital organs such as 
the lungs to form new secondary tumours and metastasise to other parts of the 
body. This figure was from (Francia et al., 2011). 
1.2.1 Adhesion 
Cell adhesion is an important part in the cellular migratory machinery. Adhesion 
occurs due to localized actin polymerization resulting in the formation of 
filaments. These filaments lead to the extension of cytoplasmic protrusions 
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which adhere to ECM via adhesion molecules and form one or several focal 
adhesion sites. The proteases then become recruited to attachment sites and 
initiate proteolytic cleavage of the matrix (Kleinman et al., 1981, Friedl et al., 
2004). 
The integrin family is an example of the adhesion molecules that are involved in 
the cell adhesion to ECM structures. Integrins participate in cellular adhesion 
by forming structural links between cells and the ECM (Hood and Cheresh, 
2002). 
Integrins attract adaptor molecules such as focal adhesion kinase (FAK), 
actinin, talin, tensin, paxillin and vinculin which work by connecting integrins to 
the filamentous actin cytoskeleton thus forming a focal adhesion. After binding 
to the ECM, integrins are associated with adaptor proteins and signalling 
molecules that allow phosphorylation and dephosphorylation events for the 
regulatory molecules causing downstream signalling known as outside-in 
signalling. Depending on the nature of the ECM structures surrounding the 
migrating cells, forward movement, cell adhesion, proliferation and survival 
could be the result of this signalling (Hynes, 2002). 
The cadherin family molecules are also important examples of the molecules 
which are involved in the adhesion process. Cadherins such as catenin 
mediate the intercellular adhesion at sites termed adherens junctions (Bates et 
al., 2000). Adherens junctions are highly expressed at connections and gap 
junctions and work to support cell–cell adhesion during the collective cell 
invasion process; the most observed type of tumour invasion (Friedl et al., 
2012). In addition to regulating the cell-cell adhesion, the E-cadherins are 
involved in regulating the contact inhibition of cell growth which is considered 
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an important property involved in tissue maintenance and its loss is an 
important characteristic that leads to loss of cell cycle regulation and inducing 
tumour growth, (Kim et al, 2011). 
1.2.2 Migration and invasion. 
Migration is defined as the directed physiological or pathological movement of 
cells on a substrate such as the basal membrane or ECM fibres on a 2D level 
with no restructuring effects (Kramer et al., 2012). Tumour cell movement or 
migration involves five interdependent steps repeated in a cyclical manner 
including: i) protrusion of the initial pseudopodia; ii) focal contact formation 
through attachment of integrin to ECM; iii) secretion of protease in the sites of 
focal contact; iv) cell body contraction, and v) movement of the cell body 
(Figure 2) (Friedl 2004). Invasion is defined (Kramer et al., 2012) as the 
physiological or pathological movement of the cell through a 3D matrix, 
accompanied by a restructuring of the 3D environment (Friedl et al., 2012). 
There are two main types of morphological or functional cell migration termed 
collective and single cell migration. The latter can further be divided into 
fibroblast-like spindle-shaped migration, mesenchymal migration and 
leukocyte-type ‘amoeboid’ migration (see Figure 3) (Friedl, 2004). In the 
absence of cell–cell adhesion, tumour cells invade as single cells (Friedl et al., 
2012). Cells that migrate in a mesenchymal fashion originate mostly from 
connective-tissue sarcomas or dedifferentiated carcinomas. (Hackett et al., 
2009). Some cells like stem cells, leukocytes and cells of haematopoietic origin, 
utilize more short lived and less adhesive cell–matrix interactions displaying a 
migration type termed amoeboid migration (Friedl et al., 2012, Friedl et al., 
2001) (see Figure 3). Collective migration results from the movement of cells 
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that retain cell–cell junctions as they move, either remaining connected to the 
primary tumour or as detached cell groups or clusters. Collective migration can 
be seen in basal cells (Wolf and Friedl, 2006). The migrating cells can switch 
between mesenchymal and amoeboid modes in what is called mesenchymal-
amoeboid transfer [MAT] resulting in a switch from elongated, polarized 
morphology to a roundish shape (Sahai and Marshall, 2003). 
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Figure 2. Hep3 adenocarcinoma cells responding to insulin stimulation by forming lamellipodia towards the chemotactic gradient. This 
figure was adapted from (Hood and Cheresh, 2002). This figure demonstrates the five stages involved in the process of cellular 
migration. The first stage (a) is the initiation of cell polarization due to localized actin polymerization to form filaments leading to the 
extension of cytoplasmic protrusions forming what are known as invadopodia which contain proteases and proteinases responsible for 
degrading the matrix during the process of invasion (b). (Friedl, Hegerfeldt et al. 2004). The cell protrusions then adhere to ECM via 
adhesion molecules leading to the formation of one or several focal adhesion sites. Proteases such as matrix-degrading proteases 
(MMP) become recruited to the attachment sites and initiate cleavage of ECM proteins to allow the forward-expanding of the cell body 
(c) (Mott and Werb 2004). After the integrin binding, the fourth step starts by initiating an interaction between the actin filaments and the 
integrin cross-linking (d). Finally the fifth stage starts by the shortening of the membrane-anchored actin filaments resulting in local 
contraction and forward motion of the cell (e, f) (Etienne-Mandeville and Hall 2002). 
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Figure 3Different types of cell migration depending on differences in cell-cell 
contacts and cell-matrix adhesions. Migration is divided into two forms including 
collective and single cell migration. The latter can further be divided into 
mesenchymal migration and leukocyte-type ‘amoeboid’ migration, adapted from 
(Friedl et al., 2012) 
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1.2.3 Molecules involved in the tumour dissemination process. 
During cancer progression, the expression of molecules such as integrins, 
cadherins, proteases and oncoproteins are relevant to invasion (Hanahan and 
Weinberg, 2011). 
Integrins are the major focus of this thesis and covered in detail below. 
changes in integrin expression are associated with the migration process, for 
example the αvβ3 integrin is highly expressed on actively invasive melanoma 
cells, but weakly expressed on quiescent cells (Felding-Habermann et al., 
2002). Induction of the expression of α6β4 integrin on thyroid cancer cells is 
associated with the transfer of the thyroid cells towards the invasive mode 
(Serini et al., 1996).  
Proteases, such as MMPs are a family of enzymes that are either secreted or 
anchored to the cell membrane and are involved in cell migration and invasion 
in addition to integrins. MMPs are typically absent in many normal adult cells, 
but a variety of stimuli, such as cytokines, growth factors, and alterations in 
cell-cell and cell-ECM interactions, can induce their expression. The expression 
of MMPs is frequently localized to the stromal cells surrounding malignant cells 
(Bird and Wolffe, 1999). MMPs start the local proteolysis towards ECM proteins 
to allow the forward-expanding of the cell body (Mott and Werb, 2004, 
Desgrosellier and Cheresh, 2010). 
Over-expression of the epithelial growth factor receptor (EGFR) family and c-
Met are important characteristics of metastatic cells (Mitsudomi and Yatabe, 
2010). Transformation of the cell by the v-Src, v-Jun, v-Myc, and k-Ras, 
induces activity of proteases such as calpain which promotes focal adhesion 
remodelling and induce cell migration (Carragher, 2006). Downregulation of 
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cadherins like catenins could lead to the detachment of single cells from the 
primary mass and invade through the basement membrane and entering the 
bloodstream through intravasation process resulting in epithelial–mesenchymal 
transition (EMT) from collective to mesenchymal migration (Han et al., 2005). 
When tumour cells form micrometastases the tumour cells exit the blood and 
go through mesenchymal–epithelial transition (MET) in the new sites of 
metastasis. Consequently, EMT and MET are considered as the start and the 
end of the metastasis process (Chaffer and Weinberg, 2011). 
1.3. Integrins 
Integrins are heterodimeric glycoprotein cell surface receptors that mediate 
adhesion to the extracellular matrix (ECM). Integrins are formed by the 
combination of 18 α-subunits and 8 β-subunits (Desgrosellier and Cheresh, 
2010). Every integrin is composed of a noncovalently linked α and β subunit. 
Each subunit has a large extracellular domain with single membrane-spanning 
domain and a non-catalytic cytoplasmic tail (Figure 4).  
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Figure 4 Schematic representation of the integrin structure demonstrating 
ligand binding of the integrin near the cell surface and the short cytosolic 
domain that binds the cytoskeleton via anchor proteins such as actinin and 
talin. 
 
The extracellular matrix ECM is composed of stromal fibroblasts and epithelial 
cells. In cases of inflammatory conditions the stromal fibroblasts induces the 
upregulation of matrix metalloproteinases (MMPs) that induces the invasion of 
immune cells leading to over production of proliferative growth factors. Tumour 
growth factors up regulate expression of integrins such as α1β1, α2β1, α4β1, 
α5β1 and αvβ3 on epithelial cells of the blood vessels. These factors stimulate 
quiescent vascular endothelium to enter the cell cycle (Zhu, et al, 2002). 
Specific integrin heterodimers preferentially bind to a unique set of ECM 
proteins. For example, αv integrins recognize the tripeptide arginine-glycine-
aspartic acid (RGD) sequence (Pytela et al., 1985). Integrins can be divided 
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into four families based on ligand specificity. These are leukocyte receptors, 
laminin receptors, RGD receptors and collagen receptors (Figure 5) (Hynes, 
2002, Goodman and Picard, 2012). 
Figure 5 Different families of integrins including: the RGD-binding integrins, the 
laminin-binding integrins, the leukocyte integrins, and the collagen receptors. 
This figure from (Sheldrake and Patterson, 2014). 
14 
 
1.3.1. Integrins and the tumour cell migration. 
Integrins have different effects on cell attachment, movement, growth, 
differentiation, and survival (Hynes, 2002). Most integrins have short 
cytoplasmic tails and no intrinsic enzymatic or kinase activities. They promote 
cell migration by leading to cytoplasmic flow in the direction of cell migration 
through activating focal adhesion kinase (FAK) which binds growth-factor-
receptor-bound protein 2 (GRB2) (Schlaepfer et al., 1994) and phosphorylates 
SRC-dependent SHC (Schlaepfer et al., 1997) leading to interaction with the 
actin filaments and shortening of the membrane-anchored actin (see Figure 6). 
This results in local contraction and formation of the lamellipodium projection 
(Etienne-Manneville and Hall, 2002, Schmidt et al., 1993). 
15 
 
Figure 6 The integrin interaction with the actin filament. Adapted from (Vicente-
Manzanares et al., 2009). Integrins bind the talin head and vinculin protein, 
which both bind directly to the actin filament. Vinculin also binds the actin 
cross-linker α-actinin which both interacts with actin and is anchored to the cell 
membrane. The activity of talin head and vinculin is modulated by interactions 
with phosphatidylinositol (4,5)-bisphosphate (PIP2). 
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To complete the translocation of the cell, integrin affinity to the extracellular 
matrix is reduced to allow the formation of new cell–ECM contacts and forward 
cell body movement (Kiosses et al., 2001a).  
Integrins also change the behaviour through which cancer cells migrate and 
affect the tumour dissemination process. Integrins, especially β1 and β3, result 
in converting the collective cell migration to single-cell migration through 
collective–amoeboid transition (Friedl, 2004). Furthermore β1 integrin down 
regulation enhances metastasis to the lungs in human and mouse through 
inducing a change in the type of the invasion from collective invasion to single 
migration. This includes changes in the TGFβ-BMP signalling pathway leading 
to blocking the E-cadherin transcription. (Danen, 2014). 
Integrins also affect the tumour dissemination process through co-localizing 
with other molecules involved in the process such as matrix degrading 
enzymes such as the MMPs. Integrins such as β1 or β3 co-localize with MT1-
MMP, thereby gaining the ability to cleave ECM substrates such as collagen 
fibres. MMP-1 specifically interacts with α2β1 integrin and thereby becomes 
recruited to points of cell contact with collagen (Dumin et al., 2001) as a result 
of which, cells invading 3D tissue generate degradation tracks bordered by 
processed ECM (Wolf and Friedl, 2005). 
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1.3.2 Integrin downstream signalling 
Integrins exist mainly in an inactive non-functional unbinding conformation 
known to be the bent V-shaped closed integrin conformation. Upon being 
activated through inside outside signalling, integrins start to be functional and 
able to bind most ligand through being driven into activated state associated 
with conformational rearrangements leading to integrin extension into open 
conformation (Figure 7) (Ye et al., 2012, Hynes, 1992).  
iiIntegrin binding 
domain
Figure 7 Integrins present in inactive, intermediate and active conformations. 
Integrin active form is represented in the open extended conformation. The 
inactive form is represented in the closed conformation. The figure was 
adapted from (Ye et al., 2012, Hynes, 1992). 
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Integrins are activated either by outside-inside signalling or by inside-outside 
signalling. The outside-inside signalling includes the extracellular factors that 
result in integrin activation such as ligand binding, mechanical stress, divalent 
cation concentration, and chemokine signalling. The inside-outside signalling 
includes the intracellular signalling events that covers the cytoplasmic domain 
of the integrins and leads to the extension of the integrin extracellular domain 
resulting in increased integrin affinity to ECM substrates (Ginsberg et al., 2005). 
Upon cell adhesion to ECM structures, integrins cluster at the emerging 
adhesion site and recruit intracellular signalling and adaptor molecules. Adaptor 
molecules, such as actin, talin, tensin, paxillin and vinculin connect integrins to 
the filamentous actin cytoskeleton then form structures known as focal contact 
or focal adhesions which lead to downstream signalling cascades. Among the 
most important events are increased nuclear factor-κB (NF-κB), PI3K–AKT 
activity, decreased p53 activation, inactivation of JNK, BcL-2 increased 
expression (Stulic et al., 2007, Avraamides et al., 2008, Bader et al., 1998). 
The RAF-RAS pathway is also among the important pathways which are 
activated downstream of integrins resulting in phosphorylation of ERK which 
affects gene transcription and cell functions (Hood and Cheresh, 2002). 
Activation of RAS leads also to PI3K activation. This in turn leads to the 
activation of RAC which also can be activated by phosphorylated CRK-
associated with CAS upon activation of SRC (DOCK-180). Activated RAC 
leads to modulations in gene transcription and results in the induction of cell 
invasion and migration (Figure 8) (Hood and Cheresh 2002). 
Integrins participate in cell migration both as adhesion molecules and as 
inducers for cell contraction and movement. Integrins (Kiosses et al., 2001b) 
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and cytoskeletal proteins interacting with integrins localize at the extended part 
of the cell towards the direction of cell migration leading to the formation of the 
lamellipodium projection (Schmidt et al., 1993). To complete the translocation 
of the cell, integrin affinity to the extracellular matrix is reduced to allow the 
formation of new cell–ECM contacts. Contractile forces are formed up on 
intracellular actin–myosin motor units generation leading to the cell body 
moving forward (Lauffenburger and Horwitz, 1996) . 
In addition to many vital signalling pathways, integrins modulate the activity of 
many cellular growth factors including vascular endothelial growth factor 
receptor 2 (VEGFR2), platelet-derived growth factor receptor (PDGFR) and 
epidermal growth factor receptor (EGFR) (Somanath et al., 2009). 
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Figure 8 Upon cell adhesion to ECM structures, integrins cluster at the 
emerging adhesion site and recruit intracellular signalling and adaptor 
molecules, leading to numerous pathways and modulations in gene 
transcription and alterations in integrin affinity for ligands. This results in the 
induction of cell invasion and migration. This figure was adapted from (Hood 
and Cheresh, 2002). 
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1.3.3 Targeting Integrins in therapy 
Cancer is complex collection of tumour cells, stromal cells, angiogenic 
endothelia and immune cells interacting with the ECM. Integrins are considered 
vital regulators of this interaction between cancer cells and the 
microenvironment. Integrins are attractive targets for therapy because of their 
over expression in many tumours, their ability to crosstalk with growth factor 
receptors and their ability to be pharmacologically blocked (Ye et al., 2012, 
Hynes, 1992). 
Integrins such as αvβ3, αIIbβ3, α4β1, and LFA-1 are targeted because of their 
involvement in many pathological diseases including Multiple sclerosis, 
autoimmune, Crohn’s disease (α4β1), Thrombosis, stroke, myocardial ischemia 
(αIIbβ3), Cancer, osteoporosis (αvβ3), inflammation, psoriasis, stroke, ischemia, 
fibrosis (LFA-1) (Goodman and Picard, 2012). In this thesis, the main focus will 
be on αvβ3 and αIIbβ3 integrins due to their roles in the cancer dissemination 
processes.  
1.3.4 The αIIbβ3 Integrin 
αIIbβ3 (also known as GpIIbIIIa) is an RGD-binding integrin which binds 
fibrinogen and is involved in mediating platelet binding to fibrinogen. The αIIbβ3 
integrin is composed of the αIIb subunit which is 136 kDa in size, and the non-
covalently associated β3 subunit which is 92kDa. The αIIbβ3 integrin recognises 
the arginine-glycine-aspartic acid (RGD) sequence found in components of the 
ECM such as fibrinogen and fibronectin (Hynes, 1992). The αIIbβ3 integrin also 
binds the lysine-glutamine-alanine-glycine-aspartate-valine sequence which is 
present in fibrinogen (Hawiger et al., 1982). 
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The αIIbβ3 integrin forms around 80% of the proteins expressed on the surface 
of platelets. Platelet activation results in ligation of αIIbβ3 and represents the 
final step in the blood coagulation pathway resulting in increased platelet–
platelet and platelet-matrix contacts (Phillips et al., 1991). The interaction 
between tumour cells and platelets has been linked to increased tumour 
metastasis. The αIIbβ3 integrin on platelets and αvβ3 integrin on tumour cells 
interact with each other through a fibrinogen bridge resulting in facilitating the 
tumour cell arrest in the vasculature and inducing metastasis to various sites of 
the body (Phillips et al., 1991, Bakewell et al., 2003, Gay and Felding-
Habermann, 2011). The platelets were found to interfere with a vital step of the 
metastasis process through promoting adhesion between melanoma cells and 
platelets. In an in vitro model, the melanoma cells adhesion to the αIIbβ3 integrin 
expressing Chinese Hamster Ovary cells in the presence of fibrinogen was 
increased. However, up on blocking αvβ3 integrin on melanoma cells or 
blocking αIIbβ3 a significant reduction in melanoma cell adhesion to the αIIbβ3 
integrin expressing cells was observed emphasizing the important role of the 
platelets in the process of metastasis through the engagement of αIIbβ3 with 
αvβ3 integrin and mediating tumour cell-platelet interactions (Lonsdorf et al, 
2012). Furthermore, significant reduction in the melanoma cell adhesion to the 
injured vascular resulted from platelet depletion in vivo (Lonsdorf et al, 2012). 
The αIIbβ3 integrin is not only expressed on the surface of platelets but also in 
some types of tumour cells (Millard et al., 2011b). Prostate carcinoma cell lines 
such as PC-3 and DU-145 are characterized by the expression of αIIbβ3 integrin, 
which plays an important role in tumour cell invasion (Hynes, 2002, Gay and 
Felding-Habermann, 2011). αIIbβ3 integrin could be a promising cancer 
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therapeutic target due to the interactions between tumour cells and platelets 
expressing αIIbβ3 that lead to metastasis (Bakewell et al., 2003). 
1.3.4.1 The αIIbβ3 Integrin as therapeutic target 
There are three FDA approved αIIbβ3 antagonists given intravenously that work 
by preventing platelet aggregation; Abciximab, Eptifibatide and Tirofiban. All 
three drugs are currently in use for treatment of various syndromes such as 
unstable angina and non-ST elevated myocardial infarction.  
Abciximab is a Fab fragment of humanised monoclonal bodies active against 
both αIIbβ3 & αvβ3 integrins (Cohen et al., 2000). Abciximab was approved in 
1995 and is an example of the drugs that target αIIbβ3, in patients with acute 
coronary syndromes (Coller and Shattil, 2008). Abciximab is administered 
parentally and goes through rapid metabolic cleavage leading to a short plasma 
half-life. To solve this problem, Abciximab is given as a single bolus followed by 
continuous infusion over 12-96 hours (Mager et al., 2003).  
Eptifibatide is a cyclic peptide designed based on barbourin, a snake venom 
cyclized by the addition of a disulfide bridge and modified to homo-ArgGD. This  
works as a competitive antagonist to αIIbβ3 (Coller, 2001). Eptifibatide is given 
parenterally as a single or double dose in combination with continuous infusion. 
Modifications of the dose must be done in the cases of patients who suffer from 
renal impairment due to the extensive renal clearance of Eptifibatide (Charo et 
al., 1992). 
Tirofiban was the first small molecule integrin antagonist to be developed. 
Tirofiban is a non-peptide RGD-mimetic antagonizes αIIbβ3 integrin 
administered intravenously. It competes with fibrinogen for binding RGD-
sequence of fibrinogen (Cook et al., 1999). Tirofiban has a large distribution 
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volume and a plasma half-life of around 1.5-2 h. Because, Tirofiban is excreted 
unchanged through renal system, a dose reduction is required for patients with 
renal insufficiency (Schrör and Weber, 2003). 
All the above mentioned drugs are intravenously delivered for acute indications. 
The orally delivered αIIbβ3 antagonists never progressed to the clinic, due to lack 
of efficacy and some actually caused deaths in phase III trials. The most 
common accepted explanation for the high levels of adverse effects associated 
with the orally delivered αIIbβ3 antagonists is mostly due to the partial agonist or 
reversible antagonist properties which made them associated with sudden 
death cases. These properties are mostly due to the variation in the drug 
plasma concentration which emerges during the dose intervals (Cox, 2004, 
Hartman et al., 1992). Furthermore, these properties are associated with the 
drug binding to receptor which causes it to be activated then the drug unbinds 
from receptor when its blood levels fall leading to make the active receptor now 
free to promote thrombosis . 
1.3.5 The αvβ3 Integrin 
The αvβ3 integrins are highly expressed on the surface of some solid tumour 
cells and activated endothelial cells. αvβ3 is highly expressed in many tumours 
such as melanoma, glioblastoma, prostate and breast cancers, and plays an 
important role in inducing metastasis, migration, invasion, angiogenesis in 
these cancers (Cheresh, 2014). 
There are many mechanisms through which αvβ3 performs its activity such as 
being involved in (FAK)–Src signaling pathways that result in inducing cell 
motility (Desgrosellier and Cheresh, 2010). Furthermore, the αvβ3 integrin is 
reported to induce tumour metastasis through activation of ligand-dependent 
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and ligand-independent signals leading to activation of oncogenes such as 
KRAS and RalB that are involved in inducing formation of  primary tumours 
(Cheresh, 2014).  
Among the αvβ3 integrin mechanisms inducing tumour metastasis involved in 
inducing the tumour–platelet interactions  For example, the αvβ3 integrin in 
breast cancer tumour cells has been found to be involved in the interaction with 
lysophosphatidic acid (LPA) which is generated by the platelets during the 
tumour cell platelet activation process resulting in induction of breast cancer 
skeletal metastasis (Leblanc et al, 2014) 
The increased expression of αvβ3 integrin during the transition of the tumour to 
the metastatic stage supports the view that this integrin has a vital role in the 
metastasis process (Desgrosellier and Cheresh, 2010). Furthermore, the 
tumours with high expression of αvβ3 demonstrate poorer prognosis than 
tumours with low expression (Pinedo et al., 1998, Goodman and Picard, 2012).  
1.3.5 1 The αvβ3 Integrin as therapeutic target  
There are currently no FDA-approved anti-cancer antagonists for αv integrins on 
the market but many compounds are under investigation to be used for cancer 
therapy and diseases like rheumatoid arthritis and osteoporosis (Millard et al., 
2011a, Sun et al, 2014) 
LM609 is a monoclonal antibody which targets αvβ3 integrin (Kaul et al., 2000). 
LM609 works by blocking angiogenesis associated with TNFα and bFGF. The 
main problem associated with LM609 is the high immunogenic response that 
limited its use and so encouraged further research to be carried out, resulting in 
Vitaxin (Cheresh, 1987). Vitaxin is a humanized mouse monoclonal antibody 
derived from LM609 and is able to recognize αvβ3. Vitaxin blocks angiogenesis 
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induced by TNFα and bFGF. However Vitaxin did not progress beyond Phase I 
trials as was found to be ineffective (Rader et al., 1998). Etaracizumab (known 
as Abegrin) is a humanized engineered monoclonal antibody against αvβ3 
integrin and has completed Phase I and II clinical trials in prostate cancer and 
melanoma (Hersey et al., 2010, Cai et al., 2006, Heckmann and Kessler, 2007). 
MK-0429 is a small molecule that targets αv integrins and has completed a 
Phase I/II study in solid tumours (Jinushi et al., 2012). MK-0429 is being 
investigated to be used for the treatment of prostate cancer (Rosenthal et al.), 
ophthalmological problems, and osteoporosis (Jinushi et al., 2012).  
Cilengitide, also known as c(RGDf [NMe]V), is designed based on the cyclic 
peptide cyclo-RGDfV and works as an αvβ3 (IC50 = 2.3nM) and αvβ5 (IC50 = 
37nM) integrin antagonist (Ruoslahti and Pierschbacher, 1986) and was 
investigated for glioblastoma treatment . There have been promising in vitro 
antiangiogenic effects of Cilengitide for treatment of melanoma (Nisato et al., 
2003), brain tumour (Taga et al., 2002), breast cancer (Burke et al., 2002) and 
head and neck cancer (Raguse et al., 2004). However, low concentrations 
(nanomolar) of Cilengitide in vivo in mouse models resulted in stimulating 
tumour growth and angiogenesis due to promoting VEGF through alterations on 
αVβ3 indicating the complex role of integrins in tumorigenesis (Reynolds et al., 
2009). Cilengitide phase I, phase II and phase III clinical trials have been 
finished. According to phase I, doses of 2,400 mg/m2 were well tolerated by 51 
patients and four patients demonstrated stability in the disease (Nabors et al., 
2007). Results in Phase I and II clinical trials were promising for Cilengitide as 
monotherapy and in combination with other compounds for glioblastoma 
treatment (Mas-Moruno et al., 2010, Reardon et al., 2011). Based on phase I/ 
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phase II clinical study, cilengitide addition to standard glioblastoma 
chemoradiotherapy demonstrated promising activity in glioblastoma patients 
(Stupp et al, 2014). However, based on a phase III clinical study, the addition of 
cilengitide to glioblastoma standard therapy failed to meet the primary endpoint 
of increasing overall survival; this, and similar failure in a Phase II trial in 
HNSCC led to the decision that cilengitide will not be developed as an 
anticancer drug in the future (Stupp et al, 2014). Among the proposed reasons 
behind this fail is that low doses of cilengitide could result in inducing tumour 
angiogenesis and because of the short half-life of Cilengitide which is round 2–4 
h reaching the optimum dose might be not fulfilled always. In addition to that, no 
biomarker of this drug activity has been determined to help determining activity. 
Furthermore, little heterogeneous information is known about the effects of 
cilengitide on tumour cell apoptosis. The reason behind previously mentioned 
problems could be that no control group was present in any of the three phase 2 
trials done in glioblastoma. Furthermore, these trials were restricted to patients 
with methylated MGMT promoter which have shown better results compared to 
others although no association between integrin biology and MGMT status has 
been documented before (Stupp et al.2014). 
1.3.6 αIIbβ3 and αvβ3 dual antagonism 
As described above, αIIbβ3 and αvβ3 integrins are involved in the tumour 
dissemination and angiogenesis processes. Whilst αvβ3 integrin up-regulation 
on the endothelial cell surface is important in inducing angiogenesis (Trikha et 
al., 2002b, Browder et al., 2000), αvβ3 up-regulation on the tumour cell surface 
results in tumour cell migration, proliferation and invasion (Dayam et al., 2006). 
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Furthermore, αvβ3 induces metastasis to bone and lungs in addition to induce 
bone deposition in osteoblastic lesions (Sheldrake and Patterson, 2014).  
The αIIbβ3 integrin was considered to be expressed only in platelets but it was 
found later to be expressed in other tumour tissues from different histological 
origins such as prostate carcinoma tissue and melanoma tissue (Chen et al., 
1997, Trikha et al., 1996). The αIIbβ3 integrin has been suggested to be 
involved in the metastatic process through its expression both on the platelets 
and on the tumour cells (Trikha et al., 1998). The monoclonal antibodies to 
αIIbβ3 integrin have been found to inhibit the invasion of prostate cancer cells 
through a reconstituted basement membrane (Trikha et al., 1996). Unlike the 
other αIIbβ3 antagonists abciximab is not selective as it is able to antagonize 
both β3 integrins leading to decrease inflammation and this is the reason 
behind its better effect compared to other αIIbβ3 specific antagonists. However, 
the problems associated with abciximab such as bleeding and immunogenicity 
indicate the need to develop small molecules as more attractive alternative 
(Sheldrake and Patterson, 2014). 
There has been a correlation between an increase in platelet count and 
increasing cancer incidence although the platelet count is not directly related to 
integrin-mediated processes (Cox et al., 2000b, Gücer et al., 1998). Platelets 
play an important role in inducing tumour dissemination as interaction between 
αvβ3 on tumour cells and αIIbβ3 on activated platelets results in adhesion of the 
tumour cells to the capillary walls and protecting them from being trapped by an 
anti-tumour host response resulting in inducing the metastatic process (Gay 
and Felding-Habermann, 2011). On the other hand the tumour itself can also 
induce platelet granules to secrete angiogenesis inducing factors such as 
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VEGF, platelet growth factor and tumour growth factor (TGF-β) that are 
responsible for inducing the angiogenesis process (Tang and Honn, 1994). 
The focus of this thesis is on developing models that can be used to test dual 
antagonists for both αIIbβ3 and αvβ3 integrins. It has been found that blocking 
αvβ3 alone is not enough to eliminate the tumour dissemination process and 
that combined blocking for αIIbβ3 and αvβ3 resulted in inducing anti-tumour and 
anti-angiogenesis effect in an in vivo model (Zhao et al, 2014, Trikha et al., 
2002b). Tumour cells that express both αIIbβ3 and αvβ3 (Sheldrake and 
Patterson, 2014, Sun, et al, 2014) have been found to have higher 
angiogenesis and proliferation ability in vivo with lower αvβ3 effect as a result of 
inhibition by αIIbβ3 indicating that selective anti-αvβ3 antagonists will not be 
effective in dual β3 integrin expressing tumours (Zhao et al, 2014, Trikha et al., 
2002b, Sheldrake and Patterson, 2014). Furthermore, the combination of two 
small-molecule αIIbβ3 and αvβ3 antagonists demonstrated a better effect than 
any of them alone (Liu et al., 2009). There have been trials in order to develop 
dual antagonists such as cyclic peptides that have been developed in order to 
target both αIIbβ3 and αvβ3 but found unfortunately nonspecific (Barker et al., 
1992). Furthermore the compound (MN447) which has been the only small 
molecule which was developed as a dual β3 antagonist has shown a relatively 
ineffectiveness in inhibiting αvβ3 induced cell adhesion to vitronectin (Kubota et 
al., 2006).  
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1.4 Assays for screening therapies targeted at aspects of the tumour 
dissemination pathway 
Whilst standard chemotherapeutic agents that have a cytotoxic effect are 
readily monitored, it is difficult to evaluate the molecules which interfere with 
the tumour dissemination process such as dual integrin antagonists as they 
may work at several points in the process, or may not even target the tumour 
cells themselves. Studying the molecules which interfere with the tumour 
dissemination process needs appropriate assays that can cover different 
stages of the process. Such assays can be concerned with adhesion, migration 
or invasion of tumour cells, or may evaluate effects on tumour angiogenesis or 
the extracellular matrix. I will give an overview of the various assays below, 
focusing on the assays relating to tumour invasion. 
1.4.1 Angiogenesis assays 
There being a large complement of assays for angiogenesis which cover in 
vitro, ex vivo and in vivo studies. The following sections explain some of the 
angiogenesis assays used at different levels of testing (Rezzola et al, 2010) 
1.4.1.1 In vitro assays of angiogenesis 
Endothelial cell differentiation assays are considered in vitro assays of 
angiogenesis and simulate the formation of capillary-like tubules. The main 
principle of this assay depends on the plating of endothelial cells onto a layer of 
extracellular matrix,  stimulating cell migration and formation of tubule-like 
structures (Kanzawa et al., 1993). The formation of tubules and tight junctions 
by endothelial cells is observed over a specific period of time using light or 
electron microscope (Muthukkaruppan and Auerbach, 1979). 
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An essential part of the study of angiogenesis is the interaction between 
endothelial and tumour cells. The simplest co-cultures involve seeding the cells 
simultaneously or allowing one cell to adhere first and then seeding the second 
cell type on top. In order to assess the influence of one cell type on the others 
behaviour, it is necessary to label at least one population prior to seeding 
(Hirschi et al., 1998). 
1.4.1.2 Ex vivo assays (organ culture) 
The rat aortic ring assay is an example of an ex vivo assay that depends on the 
isolation of rat aorta and cutting it into segments placed in Matrigel which is a 
gelatinous protein mixture represents the ECM that presents in many tissues. 
Over a 7–14 day period, the explants are monitored for the outgrowth of 
endothelial (and other) cells (Staton et al., 2009). 
The chick aortic arch assay is another example of an ex vivo assay in which the 
aortic arches are dissected from 12–14 day old chick embryos, cut into rings 
and placed on Matrigel. Outgrowth of cells is measured within 48 h (Staton et 
al., 2009). 
The chorioallantoic membrane (CAM) is formed during the chick embryo 
incubation and described as a developed ectoderm composed of small 
capillaries network that connects the venous blood vessel with arterial ones 
providing a tumour inducing environment through being a source for angiogenic 
vessels formation (Deryugina and Quigley, 2008). Furthermore the CAM with 
its surrounding capillaries network provides dissemination inducing 
environment that induce the tumour cells to extravasate in an aim to form micro 
metastatic foci. The CAM assay importance arises from its inclusion of many 
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steps of the metastatic cascade in a short time period (Deryugina and Quigley, 
2008)  
1.4.1.3 In vivo assays 
The corneal angiogenesis assay is an in vivo angiogenesis assay which is 
based on the fact that the cornea itself is avascular. Thus, any vessels seen in 
the cornea after stimulation by angiogenesis-inducing tissues or factors are 
new vessels. The original method was developed on rabbit eyes (Gimbrone et 
al., 1972), but has been adapted to mice (Muthukkaruppan and Auerbach, 
1979). The method involves making a pocket in the cornea, introducing tissues 
into this pocket, and observing the growth of new vessels. Slow-release 
materials such as ELVAX (ethylene vinyl copolymer), Hydron or sponge 
materials are used to introduce test substances into the corneal pocket (Kisker 
et al., 2001). 
In the sponge Matrigel assay, Matrigel containing test cells or substances is 
first injected subcutaneously, where it solidifies to form a plug. A sponge or 
tissue fragment is then inserted into the plug. This plug can be recovered after 
7–21 days in the animal and examined histologically to determine the extent to 
which blood vessels have entered it (Passaniti et al., 1992). 
The hollow fibre assay developed by the US National Cancer Institute has been 
reported to be an in vitro solid tumour model that can be easily translated in 
vivo (Hall et al., 2000). The hollow fibres are composed of a biocompatible 
polymer (polyvinylidenefluoride) that is formed into cylindrical fibres with a 
diameter of one millimetre and walls with pore size cut off of 500kDa. The 
hollow fibre assay involves preparing the tumour cells and seeding them into 
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compatible hollow fibres which are then sealed into 1-5 cm segments, divided 
and cultured (Hollingshead et al., 1999).The hollow fibre assay has been used 
to observe formation of new vascular networks surrounding the hollow fibres 
containing tumour cells implanted subcutaneously compared to control hollow 
fibres that contain no tumour cells (Shnyder et al., 2005).  
1.4.2 Cell adhesion assays 
Adhesion is an important cell property that is related to the maintenance of 
tissue structure, and the promotion of cell migration. It involves different 
molecular interactions, such as receptor-ligand binding, changes in the 
intracellular signalling pathways, and changes in the structure of the cell 
cytoskeleton (Weitz-Schmidt and Chreng, 2012).  
Adhesion assays measure the cell-extracellular contacts and cell-cell adhesion 
to give essential information about other cellular properties such as cellular 
flattening, and differences in signalling leading to changes in cellular fluxes. 
Adhesion assays are usually used for testing the ability of a specific cell line to 
adhere to a specific substrate, (Humphries, 2009). The attachment assay is 
among the important adhesion assays which detect bound cells (Kueng et al., 
1989). The spreading assay is another kind of adhesion assays that uses 
phase contrast microscopy to determine the flattening of adherent cells 
(Yamada and Kennedy, 1984). 
1.4.2.1 Spreading assays 
The spreading assay is an example of adhesion assays which measure the 
flattening of adherent cells on an immobilized substrate. The assay includes 
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seeding the cells of interest on a cover slip for 1 hour before taking microscopic 
images of the speeded cells to be analyzed later using a computer based 
software (Donaldson et al., 1984). Spreading assays take longer to perform but 
they are more specific compared to other adhesion assays for reasons such as 
the fact that many molecules can mediate attachment of cells even in non-
physiological conditions but very few of these molecules are able to mediate 
spreading (Drees et al., 2005, Humphries, 2001). 
1.4.2.2 Attachment assays 
The attachment assay is an example of adhesion assays which detect the 
ability of cells to bind to an immobilized surface. The cell attachment assay 
includes applying different concentrations of the protein of interest such as 
fibrinogen in the proper well plates. Blocking agent such as BSA are used to 
block the unbound sites. Before seeding the cells of interest in the coated wells 
they are treated with different inhibitors. The coated wells are washed to 
remove unbound cells after 1-4 hours incubation depending on the experiment. 
The adherent cells are noticed through colourimetric quantification and counted 
by microscope 10X objective lens (Sriramarao et al., 1993). In many cases the 
attachment assay is considered as the only and best choice as some cells are 
unable to spread at all, whereas other cells can only spread on specific 
substrates. The level of adhesion depends on the cell type and adhesive 
substrate under study (Weitz-Schmidt and Chreng, 2012, Humphries, 2001). 
1.4.3 Cell migration assays 
There are many migration assays, the most common of which are described 
below.  
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1.4.3.1. Transwell migration assay (Boyden chamber assay) 
The transwell assay or Boyden chamber assay was first introduced to analyze 
the chemotactic responses of leukocytes (Boyden, 1962). The Boyden 
chamber assay depends on the presence of two chambers containing medium 
and separated by a porous membrane through which cells migrate (see Figure 
9 [A]). The required pore size of the membranes is determined by the size of 
the cells to be analyzed. The pore diameter chosen should be suitable to the 
cell size to avoid unspecific dropping of the cells through the pores rather than 
invasion through the matrix. Pores are available with diameters between 3 and 
12 µm. Cells are seeded in medium in the upper part so they can migrate in a 
vertical direction towards an attractant in the lower compartment, through the 
pores of the membrane. The cells which pass the membrane are fixed, stained 
with cytological dyes such as haematoxylin, and quantified. The incubation time 
is usually overnight but it could be optimized depending on the cell type 
(Auerbach et al., 2003, Chen, 2005, Albini and Benelli, 2007, Liang et al., 2007, 
Cox et al., 2008). 
1.4.3.2 Wound-healing assay (scratch assay) 
This assay is one of the most widely used 2D migration assays. The scratch 
assay simply involves a confluent plate of any attached cell type which is 
‘‘wounded’’ by scraping off an area of the cells. Cell migration can then be 
monitored microscopically while the cells are travelling through the scratched 
region (Figure 9 [B]) (Liang et al., 2007). Cell migration can be analysed by 
measuring the decrease in wound area. The plates can be coated with e.g. 
fibronectin, collagen I or collagen IV before cell seeding to allow the study of 
migration on different substrates (Rodriguez et al., 2005). Cell migration in 
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scratch assays appears as either single cells, loosely connected population or 
collective sheets of cells (Wu et al., 2012). There are many advantages of the 
scratch assay such as simplicity, cheapness, easy readout, rapid setup, and 
analysis. Among the main drawbacks of the assay however, is that the 
migration speed of cells just prior to wound closure  increases resulting in 
variations in results (Kam et al., 2008). 
1.4.3.3 Cell exclusion zone assay (stopper based assay) 
The cell exclusion assay depends on creating cell exclusion zones by fitting 
small silicone stoppers into each well of a 96-well plate. These stoppers are 
inserted before seeding the cells to create an exclusion zone with the tip of the 
stopper. After cell adhesion the stoppers are removed, resulting in circular cell-
free areas of 2 mm in diameter wherein the cells will then migrate (Figure 9 
[C]). The advantages of the cell exclusion zone assay are that the wound sizes 
are similar and with sharp borders. Also there is no damage to the cells from 
mechanical scraping as in the scratch assay (Omelchenko and Hall, 2012). 
1.4.3.4. Fence assay (ring assay) 
 The fence assay involves seeding the cells in the inner area of a Teflon, glass 
or metal ring placed on a cell culture dish (see Figure 9 [D]) after detaching the 
ring, the non-attached cells are removed by gentle washing. The cells in the 
ring are then allowed to migrate out from the circular area in a radial way. The 
cell migration is measured as an increase of the area covered by migrating 
cells (Cai et al., 2000).  
1.4.3.5. Microcarrier bead assay 
The microcarrier bead assay measures the cell migration from microcarrier 
beads onto 2D cell culture vessel surfaces (see Figure 9[E]). The microcarrier 
37 
 
beads are coated with cells grown to confluence on the surface of the beads. 
These are then placed on the culture dishes and incubated for a specific period 
of time. The beads are then removed and the cells which have migrated from 
the beads to the vessel surface area are fixed, stained and microscopically 
analysed. An advantage of this assay is that it allows the cells to perform close 
cell–cell interactions on the beads to mimic the tight contact of cells in vivo. 
Another advantage of this assay is that relatively equal numbers of cells are 
present on the bead surface when confluence is reached, making results 
comparison easier (Kjøller et al., 1997). 
1.4.3.6 Single cell motility assay (colloidal particle assay, colloidal gold 
single cell migration assay) 
This assay aims to measure migration of single cells through colloidal gold 
particle coated surfaces (Niinaka et al., 2001). In this assay the cells are 
seeded at low density onto tissue culture plates coated with colloidal gold, seen 
as a homogenous layer of small dark dots under the microscope. White tracks 
appear under the microscope as a result of cell migration (see Figure 9[G]) 
(Gu et al., 2007). The main advantage of this method is that it is suitable for 
automation and for monitoring single cell migration, chemokinesis movement 
and real-time path to determine the absolute speed of cell migration (Kramer et 
al., 2012). 
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Figure 9 Demonstration of the most commonly used migration assays adapted 
from (Kramer et al., 2012). (A) The transwell migration assay which 
demonstrates the migration of a cell through a pore in the porous membrane. 
(B) The wound healing assay which demonstrates the migration of the cells in 
the cell free area formed after scratching off cells from a dense monolayer. (C) 
The cell exclusion zone assay which depends on forming cell free area by 
seeding using silicone stoppers, removed before the experiment starts. (D) The 
fence assay in which the cells migrate from the circular area formed after 
seeding the cells inside a ring-shaped plastic device. (E) The microcarrier bead 
assay in which the cells migrate from confluence coated microcarrier beads 
placed and incubated onto cell culture dishes. (F) The spheroid migration assay 
which measures the increase in the spreading area for the cells moving 
outward from the spheroids seeded in a proper tissue dish. (G) The single cell 
motility assay which measures the bright tracks left behind cells while they are 
moving across colloidal layer of gold particles. 
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1.4.4 Invasion assays 
Cell invasion assays test the ability of the cell to transfer through an ECM or 
basement membrane extract (BME) barrier by enzymatically degrading the 
barrier in a new location, thus mimicking invasion during tumour dissemination. 
There are many invasion assays, which can be classified as 2D or 3D, the most 
common of which are described in the following sections below.  
1.4.4.1. The 2D invasion assays 
1.4.4.1.1 Modified Boyden chamber assay (Transwell invasion assay) 
This assay is a modification of the transwell migration assay described 
previously in 1.6.3.1 and is carried out in transwells, into which membrane 
filters are inserted (see Figure 10 [A]). These filters have 5–12 µm size pores, 
overlaid by a thin layer of ECM. The cells are seeded into the top chamber. The 
filters present between chambers restrict the movement of the cells from the 
upper chamber to the lower one. Only the invasive cells can degrade the matrix 
and adhere to the bottom of the filter where they are stained with haematoxylin. 
The stained cells are counted with a light microscope or analysed using 
fluorimetric detection. The invasion level is defined as the percentage of cells 
passing through the filter and so to calculate the invasive index, the ratio of 
invaded versus the migrated cells is calculated (Albini and Benelli, 2007, 
Taraboletti and Giavazzi, 2004, Connolly and Maxwell, 2002). 
The advantages of the method are the availability of different insert sizes, the 
relative ease of the experimental setup and the relatively small chemokine 
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gradient between the upper and the lower compartments (Zhang et al., 2012, 
Leblond and Inoue, 1989, Elsdale and Bard, 1972, Bracke and Mareel, 2002). 
1.4.4.1.2 Cell exclusion invasion assay 
 The cell exclusion invasion assay involves small silicone stoppers fitted in 96-
well plates coated with thin layer of BME. As a result, the stoppers form 
exclusion zones when cells are seeded. The stoppers are removed after the 
cells adhere to the first layer of BME. The cells and the formed cell-free circles 
are then, overlaid by another relatively thick layer of BME. As a result of that, a 
layer of cells embedded between two layers of ECM and a centre of cell-free 
ECM are formed (see Figure 10 [B]). Cell invasion towards the centre can be 
seen using light microscopy over time as well as using confocal microscopy 
after immunofluorescent staining. Among the main advantages of this assay is 
possible kinetic analysis and live-imaging. At the end of the assay the gels can 
also be fixed and processed for immunofluorescence analysis (Lim et al., 
2010). 
1.4.4.2. The 3D invasion assays 
The use of animal and humans models in research is usually hindered by the 
availability of test subjects, difficulty of testing procedures, and ethical concerns 
regarding pain caused to live subjects. The two-dimensional (2D) monolayer 
models have been used as an alternative to animal models and have been a 
huge addition to research; however there have been limitations for using those 
models. One of the biggest problems associated with the 2D model is the 
inability to reflect the real situation in the tumour microenvironment. The 3D 
models arise as an alternative to the previously used assays. Unlike the 2D 
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models, the 3D models are able to provide a cellular microenvironment that is 
able to mimic the original microenvironment found in tissues or represent the 
single cell behaviour on the 3D level more closely. This feature is vital for more 
comprehensive drug testing experiments. 
1.4.4.2.1. 3D cell tracking 
This assay involves 3D analysis of single cell invasion through ECM using 
computer-aided time-lapse video microscopy (see Figure 10 [C]). There are 
many ways to analyse either labelled or unlabeled cells at the 3D level using 
different microscopy techniques such as confocal microscopy, contrast or 
digital microscopy. Among the major advantages of this assay is the possibility 
to analyse the cell tracking in real time the possibility to determine the exact 
length of the invading cell paths (Hamilton, 2009).  
1.4.4.2.2. Gelatine degradation assay 
The gelatine degradation assay allow the analysis of invasion at the sub-
cellular level rather than the whole cellular level (Ayala et al., 2006). In this 
assay cells are seeded on top of a thin layer of a fluorescently labelled matrix. 
The fluorescence is lost in the regions where the matrix is degraded by the 
invading cells consequently the sub-cellular invading structures can be 
detected by high resolution pictures (see Figure 10 [D]) (Artym et al., 2009). 
The main advantage of this method is that it provides high resolution data of 
sub-cellular structures of invading cells although cells cannot be followed as a 
whole during their movement (Nascimento et al., 2011). 
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1.4.4.2.3 Vertical gel 3D migration/invasion assays 
The vertical invasion assay aims to investigate the downward movement of 
cells from a monolayer through a layer of ECM. This assay involves preparation 
of a thick collagen layer with the cells seeded on the top of the gel surface. 
Stromal subcutaneous fibroblasts are embedded in the collagen gel to 
investigate the effect of fibroblasts on the invasion of tumour cells (see Figure 
10 [E]) (Rocha et al., 1984). The vertical invasion of the cells from the cell layer 
can be followed by monitoring the optical sectioning and counting the cells by 
radioactive labelling or quantified by immunohistochemical staining or by using 
image analysis software (Timpson et al., 2011, Nurmenniemi et al., 2009). 
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Figure 10 Demonstration of the most commonly used invasion assays adapted 
from (Kramer et al., 2012). (A) The transwell invasion assay is the same as the 
transwell migration assay, with a thin ECM coating fills the pores in the filter. 
(B) The platypus invasion assay in which the cells seeded between two layers 
of ECM invades from an outer ring into the center. (C) The 3D cell tracking 
assay in which the routes of the cells through 3D space of ECM are recorded 
and measured fragment. (D) The gelatine degradation assay in which the loss 
of fluorescence due to the invadopodia mediated matrix degradation is 
quantified by microscopic imaging. (E) The vertical gel invasion assay in which 
the invasion of the epithelial cells into the collagen matrix from the epithelial 
cells layer at the liquid–air interface on top of a collagen gel is quantified by 
light microscope this assay could include fibroblast cells in addition to the 
epithelial cells to study the effect of the fibroblasts on the invasion.  
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1.5: Spheroids 
Spheroids are considered as one of the best examples of 3D culture models as 
they better represent the in vivo tumour structure in comparison to 2D cell 
monolayer cultures (Gottfried et al., 2006). In this thesis I am going to 
investigate the use of tumour spheroids as a 3D invasion model to study the 
effect of novel cancer therapeutics.  
Spheroids are defined as spherical cell aggregates which are formed in dishes 
spontaneously or by culturing on treated substrates. The spherical model is 
applied on normal and tumour cell lines (Durand, 1990, Sutherland and 
Durand, 1976).  
The 3D spheroid structure is one of the best ways to reflect the solid 
microenvironment. This is because spheroids are characterized by 
heterogeneous cell populations with intermediate, necrotic areas mimicking the 
avascular stages of solid tumours including transport of oxygen, nutrient, and 
metabolite inside the microenvironment (Figure 11) (Bowden et al., 1999, 
Hirschhaeuser et al., 2010, Walenta et al., 2000). 
Spheroids mimic the proliferation gradient of solid tumours as the outer layer of 
the spheroid contains the proliferating cells while the innermost layer contains 
non cycling, differentiated or dead cells due to necrosis (Kunz‐Schughart, 1999, 
Pampaloni et al., 2007). 
45 
 
Figure 11 The spherical structure demonstrates graduation in nutrient and 
oxygen accumulation. The outer shell of the spheroid demonstrates high 
numbers of cells in S phase, reflecting high proliferation rate compared to the 
centre which has high numbers of necrotic cells. This figure was adapted from 
(Hirschhaeuser et al., 2010). 
 
1.5.1 Methods for generating spheroids. 
There have been many methods reported for culturing spheroids based on the 
nature of the cells and their ability to form spheroids. These methods include 
the hanging drop method (Emfietzoglou et al., 2005), spinner flasks (Casciari et 
al., 1992), spontaneous aggregation (Kelm et al., 2003) and growing cells in 
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methylcellulose containing media (Jessup et al., 2000). The expression of 
certain molecules such as E-cadherin (Day et al., 1999) and integrins such as 
αv integrin subunit (He et al., 2009) on the surface of the cells could promote of 
spheroid formation 
1.5.1.1 Hanging drop method 
This method results in formation of relatively small uniformly sized spheroids. It  
involves setting up 20-30 µL drops containing certain cell concentrations on the 
inner surface of the lid of a Petri dish and leaving this in an incubator for a few 
days until the formation of spheroids occurs (see Figure 12 [A]). The main 
advantage of this method is that it produces homogenous sizes of spheroids in 
relatively short period of time. However the main disadvantage associated with 
this method is that it is not suitable for all cell lines; in addition to that this 
method is not suitable to form multilayer spheroids (Del Duca et al., 2004, 
Emfietzoglou et al., 2005). 
1.5.1.2 Spinner flask method (rotary systems) 
The cells are grown as suspensions in culture medium in Petri dishes coated 
with agar to prevent the attachment of the spheroids to the surface of the flask, 
leading to the production of high numbers of micro-spheroids. The spheroids 
are then transferred into spinner flasks in which the spheroids grow until they 
reach the required diameter size (Casciari et al., 1992). The cell suspensions 
could also be directly transferred to a rotating 6-well plate or a 250 ml spinner 
vessel stirred by a magnetic stir bar until the spheroids are formed (see Figure 
12 [B]).The main advantage of this method is that is suitable to produce 
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multilayer spheroids. However the main disadvantage is the resulting spheroids 
are heterogonous in size.  
1.5.1.3 Spontaneous aggregation 
The cells are cultured at a high seeding density in non-adherent culture dishes 
or coated with agar until they spontaneously form spheroids. The spheroids of 
certain diameter size are then selected and grown in new dishes (see Figure 
12 [C]) (Kelm et al., 2003). The main advantage of this method is that it is 
relatively easy to perform compared to other methods. The main disadvantage 
is that it is not applicable to all cell lines. 
1.5.1.4 Spheroids grown in methylcellulose containing media 
The cells are plated in non-adherent round bottom wells in methylcellulose-
containing medium to form spheroids of defined cell number and composition. 
At this stage, the spheroids can be transferred to collagen to be observed for 
different characteristics such as invasion (Figure 12 [D]) (Jessup et al., 2000). 
The main advantage of this method is that it produces homogenous sizes of 
spheroids. However the main disadvantage associated with this method is that 
it is not suitable for all cell lines. 
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Figure 12 The different ways to make spheroids adapted from (van Zijl and 
Mikulits, 2010). 
1.5.2 Spheroid use in 3D tumour models of invasion 
Spheroids are among the best in vitro options to mimic the 3D tumour 
structures in vivo (Sutherland et al., 1971). In this section I will discuss some of 
the 3D spherical models which are used as invasive models.  
1.5.2.1. Spheroid/mono dispersed cell invasion assay 
The main principle of this assay is that non-invasive spheroids are co-cultivated 
with a single cell suspension of invasive cells, which attach to the spheroid 
surface and start to invade into it (Wolf et al., 2007) (Figure 13 [A]). 
Fluorescently labelled cells can be used to demonstrate the 3D invasion with 
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(confocal) fluorescence microscopy imaging. The analytical quantification of 
cells attached to the spheroids can be done using flow cytometry or by 
immunofluorescence staining of the spheroid sections. The importance of this 
assay is that it mimics the cell–cell interactions and multicellular 3D structures 
of the tissues through which the tumour cells invade (Nummer et al., 2007).  
1.5.2.2 Spheroid confrontation assay 
This assay studies the invasive behaviour at a 3D level through co-cultivating 
spheroids composed of invasive cells side by side with spheroids of non-
invasive cells. The invasive cells start to invade through the non-invasive ones 
and the behaviour of these cells is investigated (Figure 13 [B]). The invasive 
spheroid may invade as single cells, collectively or display a non-invasive 
behaviour (Hattermann et al., 2011). Among the important advantages of this 
method is the consideration it takes of the cell–cell interactions and the 3D 
structure of the tumour tissue and the surrounding tissue, leading to a more 
successful reflection of the in vivo situation when studying the cancer cells 
invasion to surrounding tissues and organs (Hattermann et al., 2011). 
1.5.2.3 Spheroid gel invasion assay 
This assay involves embedding spheroids into 3D ECM such as collagen I 
(Figure 13 [C]). If the spheroid is composed of non-invasive cancer cells it will 
stay as a compact spheroid but if the spheroid is composed of invasive cells it 
will start to invade into the surrounding matrix and demonstrate cell-line specific 
modes of invasion. 
Spheroids that result from hanging drops are homogenously sized making them 
very suitable for 3D invasion assays (Timmins and Nielsen, 2007, Nowicki et 
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al., 2008, An et al., 2010). Briefly, spheroids that result from hanging drops are 
allowed to invade into neutralized collagen layer. The invasion is observed over 
4-7 days and is analysed or by simply calculating the number of cross points 
covered by invading cell using a grid (Figure 14). The gels containing the 
invaded spheroids could also be fixed, immunofluorescently stained and 
analysed by confocal microscopy (Wolf et al., 2007) 
Among the main advantages of this method is that cell invasion within the 3D 
matrix mimics very closely the invasion in vivo, especially as  this assay takes 
in to consideration the cell-cell interactions between the tumour cells in the 
tumour mass in vivo (De Ridder et al., 2000).  
1.5.2.4 Spherical co-cultures 
Co-culturing tumour cells with different kinds of stromal cells is the best way to 
understand the cell crosstalk inside the tumour microenvironment. The co-
cultures can be made by preparing mixed spheroids of both tumour cells and 
stromal cells (Hoffmann et al., 2009). The tumour spheroids also could be co-
cultured with fibroblast monolayers or fibroblast suspension or the fibroblast 
cells could be incorporated into the tumour spheroids to form multicellular 
spheroids (Friedrich et al., 2007); (Kunz-Schughart et al., 2001, Hoffmann et 
al., 2009).  
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Figure 13 The spheroids as 3D invasion assays. (A) The 
spheroid/monodispersed cell invasion assay in which the invading cells are 
incubated as single cell suspension with spheroids of another cell type. The cell 
suspension invades into the spheroid and the invasion is measured by methods 
like the confocal microscope. (B) The spheroid confrontation assay in which both 
the invasive and the non-invasive cells are formed into spheroids forced to attach 
to each other and the invasive cells invade into the spheroids of the non-invasive 
cells. The invasion is measured by methods such as the confocal microscopy. 
(C) The spheroid gel invasion assay in which the tumour spheroids are 
embedded into ECM gel such as collagen and the invasive cells invade out from 
spheroids. This figure was adapted from (Kramer et al., 2012). 
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1.6 Aims and objectives 
The tumour dissemination process is a major issue limiting the success of 
therapy. Due to this problem, there has been a huge demand for the 
development of new therapeutic agents that can stop the tumour dissemination 
process, as well as a need for the development of assays that can evaluate 
these therapeutic agents. 
The spheroid gel invasion assay is considered among the best of the currently 
used invasion assays as it takes into consideration the 3D nature of the tumour 
mass in addition to the cell-cell contacts between the tumour cells, furthermore, 
it takes into consideration the cell-ECM interaction due to the presence of 
collagen which is among the most prominent components of the ECM. 
This thesis the key aim is to develop a spheroid gel invasion assay and to use 
this assay to evaluate novel small molecule β3 integrin antagonists, in relevant 
cancer cell models. Furthermore this thesis aims to develop a model that 
express αIIbβ3 and αvβ3 integrins and use this model to evaluate a group of novel 
new dual integrin antagonists.  
This aim will be achieved through the following objectives: 
 Identification of relevant cancer cell line models and establishment of the 
spheroid invasion assay 
 Validation of the assay using a known anti-invasive agent and a known β3 
integrin antagonist. 
 Evaluation of a novel series of small molecule β3 antagonists. 
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 Develop a cell line expressing αIIbβ3 integrin to be utilized in the spheroid 
invasion assay to evaluate novel dual αIIbβ3/αvβ3 integrin antagonists. 
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2. Chapter 2: Development and validation of αvβ3 expressing 3D spheroid 
invasion models 
2.1.1 Introduction 
Invasion is a critical feature of malignancy which involves alteration of many 
proteins, such as integrins which form a link between the cancer cells and the 
extracellular matrix substrates (Hanahan and Weinberg, 2011). The β3 integrins 
are the main focus of this thesis because of their involvement in important 
tumour hallmarks such as angiogenesis (Brooks et al., 1994) and metastasis 
(Natali et al., 1997), making them attractive targets for inhibition of the tumour 
progression process (Danhier et al., 2012); (Ruoslahti and Pierschbacher, 
1986). 
This chapter describes the search for αvβ3 integrin expressing cell line which 
has the ability to produce hanging drop spheroids that are able to invade into 
collagen in order to be used to evaluate αvβ3 integrin antagonists. Model 
selection through selecting the αvβ3 integrin expressing cell line that is able to 
form hanging drop spheroids that are able to invade through type I collagen is a 
crucial step to go forward towards evaluating a novel series of small molecule 
β3 antagonists. 
As reviewed in chapter 1 there is a large range of invasion models, all with 
different strengths and weaknesses. The model which I will focus on in this 
thesis is the in vitro 3D spheroid invasion in collagen. 
The 3D assay was originally developed by (Del Duca et al., 2004) and since 
been used extensively by many authors (Nowicki et al., 2008); (de Sampaio et 
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al., 2012); (Friedrich et al., 2009); (Dolznig et al., 2011). The advantage of this 
assay is that it gives an indication of chemo-resistance and other therapeutic 
problems that are associated with the delivery of the compounds due to 
gradients in proliferation, nutrients and oxygen supply within the spheroids 
which mimics the situation seen in the tumour mass. Furthermore, this assay 
gives a clear idea about cell-ECM interactions which mimic cell-ECM 
interactions in vivo (Friedrich et al., 2009). 
Among the other advantages of this assay is the ability to distinguish invasive 
cancer cells from non-invasive ones. The non-invasive cancer cells grow as 
compact spheroids with a clear borders from the surrounding matrix, and no 
signs of invasion even after 7 days of culture (Dolznig et al., 2011). On the 
other hand, invasive cells start to invade out from the embedded spheroids into 
the surrounding collagen as early as the first day after embedding (Korff and 
Augustin, 1999). 
The spheroid gel invasion assay is ideal in giving an indication of the stromal 
cues that induce the invasive growth of cancer such as the interactions 
between the tumour cells and the stromal cells. Furthermore this assay 
maintains the structural and morphological properties of the cells allowing real-
time monitoring and biochemical analysis of the basic features of the cellular 
invasion during the running time of the assay. Subsequently, computer 
analyses of images taken during the assay allow for calculating important 
parameters such as invasion area (Friedrich et al., 2009). 
Initially, several natural extracellular matrix types were used in the 3D spherical 
invasion assay, such as bone (Kuettner et al., 1978), cartilage (Pauli et al., 
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1981) and amnion membrane (Liotta et al., 1980) These materials suffered 
from not being homogenous, which made the interpretation of invasion difficult. 
The 3D spherical invasion assay has flexibility in that a wide range of different 
gels can be used as the matrix depending on the research question posed such 
as type I collagen, BME and fibrin. Of these, Matrigel (Albini and Benelli, 2007) 
and acid-extracted type I collagen are among the most frequently used 
materials as ECM substrates in 3D spheroid invasion assays to differentiate 
between invasive and non-invasive cells (Sabeh et al., 2009).  
Collagen type I was selected to be used for all studies in this thesis. Collagen is 
the main interstitial matrix component in solid tumours, so it could be used in 
the invasion models to allow for easy observation and quantification in a close 
recapitulation of the in vivo situation (Bruyère et al., 2008). Furthermore, 
collagen type I consists of native non helical telopeptides situated at the N- and 
C-terminal ends, which are important in the formation of intermolecular covalent 
cross-links needed for the formation of the gel architecture that is considered 
as a barrier to tumour cell invasion. This makes the results obtained from this 
assay more reflective to the real drug delivery problems (Sabeh et al., 2009). 
Finally, the 3D spherical invasion model is encouraging due to it is possible with 
this assay to get a good picture of what is going on in real time using live 
imaging compared to 2D transwell assays where this is harder to do. 
Furthermore, the cells invading into the collagen gels can be fixed using 
different fixation procedures and investigated using confocal microscopy 
(Kramer et al., 2013). 
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2.1.2 Aims and objectives  
The aims of this chapter are to identify a suitable cell line for use in the 
evaluation of β3 integrin antagonists and to establish and validate the assay. 
This will be achieved by the following objectives;  
1. Selection of an αvβ3 integrin expressing cell line which can form hanging 
drop spheroids, which can invade through type I collagen.  
2. Optimisation of the suitable conditions to develop the 3D spheroid invasion 
model. 
3. Validation of the developed assay using lithium chloride, a known inhibitor 
of invasion, and cRGDfV, a known β3 antagonist. 
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2.2. Materials and methods 
All tissue culture reagents used were obtained from Sigma-Aldrich (Poole, UK) 
unless otherwise specified.  
2.2.1 Cell lines and Culture conditions. 
The human cell lines M14 melanoma and U87-MG glioma were obtained from the 
European Collection of Cell Cultures ((ECACC), Salisbury, Wiltshire, England). 
The human prostate cancer cell line PC-3 and the human breast cancer cell line 
MDA-MB-231 were obtained from American Type Culture Collection ((ATCC), 
Barton-Hall, UK).  
All cell lines were maintained in complete Roswell Park Memorial Institute 
(RPMI) 1640 medium, supplemented with 10% foetal bovine serum, 2 mM L-
glutamine, and 1 mM sodium pyruvate to form complete growth medium. Cell 
lines were maintained at 37°C in a 5% CO2 humidified atmosphere. 
2.2.2 Cell maintenance 
All cell lines used for experiments and assays described in this thesis were 
between passages 2 to 5. Cells were maintained in exponential growth by regular 
sub-culturing in 75 cm2 cell culture flasks. As cells reached approximately 80% 
confluence, the adherent cells were washed twice using Hanks Balanced Salt 
Solution (HBSS) prior to trypsinisation using a 0.25% Trypsin-EDTA solution. 
Once the cells were detached from the flask, the trypsin solution was diluted and 
inactivated by the addition of 10 ml of complete growth medium. The cell 
suspension was subsequently centrifuged for 5 min at 1000 rpm. The cell pellet 
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was then re-suspended in 10 ml fresh culture medium and the cells were then 
transferred into a new culture flask. 
2.2.3 Determination of cell growth using manual cell counting. 
In order to ascertain when cells were in the log phase, growth curves were 
initially determined for every cell line. Briefly, cell suspensions were prepared 
as described in the previous section. 10 µL of cell suspension was transferred 
to both chambers of a Neubauer haemocytometer (Poole, UK) by carefully 
touching the edge of the cover slip with the pipette tip and allowing each 
chamber to fill by capillary action. The haemocytometer was then observed on 
an inverted microscope at 10X objective magnification and all the cells in 1mm2 
area grid in each chamber of the haemocytometer were then counted and the 
average number was determined. The total number of cells per ml was 
determined using the following formula: 
Cells/ml = average cell count per square x dilution factor x 104 
The cell counts were expressed in number of cells/ml. The average cell count 
was the result of calculation done for two flasks of cells per time point per 
experiment. Growth curves were plotted as time versus cell number.  
2.2.4 Characterization of integrin expression in cells using 
immunocytochemistry. 
1×105 cells/ml were seeded on 22×22 mm cover slips in 6 well plates and 
incubated over night at 37 °C, 5% CO2 to allow cells to adhere. The next day 
the media was removed and the cells were washed twice with HBSS and then 
fixed using 1 ml of 4% paraformaldehyde, a gentle fixative that maintains the 
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structure of intracellular proteins and the plasma membrane in contrast to other 
fixatives such as methanol or acetone (Hoetelmans, Prins et al. 2001). The 
plates were left for 10 minutes at RT in fixative and then washed with 
phosphate buffered saline. The cells were treated with blocking agent for 1 
hour at RT to prevent non-specific binding. Primary antibody was added and 
incubated as described in Table1. 
The cells were washed with blocking agent 3 times for 10 minutes. Finally, the 
cells were incubated with a secondary antibody as demonstrated in Table 1. 
The cells were then washed three times for 10 minutes with PBS. The cover 
slips were then mounted with Vectashield Mounting media containing 1.5 µg/ml 
of DAPI (Vector laboratories, UK) and stored at 4 °C until use. 
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Table 2: Summary of labelling protocol for each antibody used with U87-MG cells 
Antibody αv β3 β-actin 
Fixative 1 ml of 4%  paraformaldehayde 
Time for fixation 15 minutes 
Permeabilization None None 1.0% triton-100 in PBS for 1 
minute 
Blocking agent 300 µL of 5% BSA/PBS 
Primary 
antibody 
10 µL of 1:50 
diluted αv 
antibody (sc-
6617-R) 
100 µL of 1:50 diluted β3 
antibody (sc-46655) 
200 µL of 1:50 diluted β-actin 
antibody (catalogue number a 
2228) 
Washing Blocking agent three washes 10 minute. 
Secondary 
antibody 
10 µL of 1:200 
diluted Alexa ® 
546 donkey anti 
rabbit IgG 
(Invitrogen) 
100 µL of 1:50 diluted polyclonal 
rabbit anti-Mouse 
Immunoglobulins/FITC. code 
No. F0232 (Dako Denmark A/S) 
100 µL of 1:50 Alexa Fluor® 
488 goat anti-rabbit IgG (H+L) 
(Invitrogen) 
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2.2.5 The spheroid invasion assay 
2.2.5.1 Formation of spheroids using a hanging drop method.  
The number of cells  was adjusted to 200, 500, 1000, 2000 or 4000 cells in 20 
or 30 µL of complete medium depending on the experiment. 20 μL or 30 μL 
drops of cell suspension were seeded on the inner side of the lid of a 10 cm 
Petri dish with 5 ml of HBSS added into the dish below the drops to maintain a 
humidified atmosphere and to prevent dehydration. The drops were left in the 
incubator at 37°C, 5% CO2 for 3-7 days with observation (Nowicki et al., 2008). 
2.2.5.1.1 Assessment of Hanging drop spheroid growth using the MTT 
assay 
Spheroids resulting from different seeding densities in hanging drops were 
mechanically broken up by ten to twenty vigorous pipetting actions, transferred 
to the wells of a 96 well plate, centrifuged to remove remaining media and allow 
the cell pellets to adhere. Pellets were then re-suspended by the addition of 
200 µL of fresh MTT solution which was prepared by adding 2 ml of freshly 
prepared MTT (3-(4,5-dimethyl 2-thiazolyl) 2,5 diphenyl-2H-tetrazolium) 
solution (5 mg/ml in PBS) to 18 ml of complete media. The plates were 
incubated for 4 hr at 37°C in a humidified 5% CO2 atmosphere. In the presence 
of viable cells in the spheroids, the yellow MTT in the solution was converted to 
insoluble formazan crystals (purple). After complete removal of the 
supernatant, 100 µL of dimethyl sulfoxide was added to each well to solubilise 
the formazan crystals. The intensity of the purple colour was measured by 
determining the optical density (OD) read using Multiscan Plus 
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spectrophotometer (Lab-systems Group, UK) at a wavelength of 540 nm. This 
process was repeated on days 3, 4 and 7 following cell seeding on day 0. 
2.2.5.1.2 Formation of spheroids by the liquid overlay method. 
In the day before the experiment, 1% Agar Select in liquid PBS was added to a 
10 cm Petri dish and allowed to solidify in tissue culture hood for 30 minutes 
before the Petri dish was closed and stored over night at room temperature to 
be ready for use in the next day. In the day of the experiment, the Agar Select 
was rehydrated with medium for 15 min prior to the addition of the cells 
(Yamamoto et al., 1985). U87-MG cells spheroids were harvested from the 
hanging drops on day three. The rehydration medium was aspirated from the 
Agar Select covered Petri dish and 10 ml of fresh medium was added. The 
harvested spheroids were added to the fresh medium and cultured for up to 3 
days at 37°C in a humidified 5% CO2 atmosphere (Del Duca et al., 2004) 
before being examined by Zeiss LSM510 confocal microscope (Zeiss, Welwyn 
Garden City, UK).  
2.2.5.2. Collagen invasion assay. 
Enough collagen to allow for 1400 µl per 8 wells was made as follows; 1400 µL 
Collagen I (Sigma, 3 mg/ml, ultra-pure bovine, catalogue number C4243) was 
added to a 1 ml Eppendorf tube on ice. Collagen I was supplemented with 0.2 
ml of complete RPMI. Then sufficient amount of 1 N NaOH was added to 
Collagen I to reach a pH 7.4. The pH was measured by pH-indicator paper, 6.4 
– 8.0 (VWR International, JENCONS, UK). The collagen mixture was pipetted 
into each chamber of an 8-chamber cover glass (Nunc, Lab-TeK, Thermo 
scientific). After polymerization at 37°C for 45 minutes, spheroids from hanging 
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drops were carefully removed using a 20 μL pipette set at 5 μL volume and 1 
spheroid was placed in each chamber of the cover glass (see Figure 14). The 
medium was then allowed to evaporate in the cabinet so that the spheroid 
could adhere to the collagen. Another 200 µL layer of collagen gel matrix was 
prepared as above and carefully added to each chamber and then set in a 
37°C incubator (no CO2) for 45 minutes to polymerize. Finally 200 µL of RPMI 
was added to each chamber and incubated at 37°C, 5% CO2 for 7 days. The 
spheroids were observed using inverted light microscopy at 10X objective lens 
and images were captured daily using Nikon Eclipse camera (TE2000-4, 
Panasonic Lumix DMC-GF6). 
Alternatively, each spheroid was suspended in 400 µL collagen I, pH adjusted 
to 7.4 using NaOH, supplemented with (RPMI) 1640, 2% foetal bovine serum in 
eight-well chamber slides (Nunc, Rochester, Noraway) and overlain with 200 
µL (RPMI) 1640, 10% foetal bovine serum. The pH correction to 7.4 using pH-
indicator paper 6.4 – 8.0 was found important to result in consistent invasion of 
the U87-MG spheroids in collagen. This was incubated at 37 °C, 5% CO2 for 7 
days with images captured as described above. 
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Figure 14 Schematic presentation of 3D spherical invasion assay (adapted 
from Nowicki et al., 2008). 
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2.2.5.2.1 Evaluation of the spheroid invasion area 
Two analysis methods were used to evaluate the spheroid invasion area. First 
method used was the manual counting of the cross points which was helpful 
during the optimization process of the model especially when the invasion was 
not fully optimal. After completing the optimization process, ImageJ analysis 
was considered to be used as a second way of analysis to analyze the images 
that result from the invasion of the U87-MG spheroids in collagen. Image J is 
preferred by many authors as it is a computer based method compared to the 
manual counting of the cross points.  
2.2.5.2.1.1 Evaluation of the spheroid invasion area using cross point 
counting. 
Images were taken for the invading spheroids in collagen on days 0, 1, 2, 3, 4 
and 7. The invasion of the spheroids was analysed by placing a 100 µm scale 
bar grid over a captured image of the spheroid and counting the numbers of 
cross points covered by invading cells from the spheroids. The number of the 
cross points is used as an indicator of the invasion area. The invading cells 
were considered separately by calculating the number cross points covering 
the cells invading out from the spheres. The total invasion area is the sum of 
the cross points that covers the spherical mass and the number of the cross 
points covered by the invading cells from the spheroids. Growth curves were 
plotted as time versus the average number of cross points covering invading 
cells from two invading spheroids per well per experiment (see Figure 15). 
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Figure 15 Analysis of U87-MG spheroids invasion using cross point counting 
which is used as indicator of invasion area. Scale bar: 100 µm. The cross 
points which cover invading cells were counted and plotted versus time. 
2.2.5.2.1.2 Evaluation of the spheroid invasion area using ImageJ 
The light microscope pictures captured for the invading spheroids in collagen on 
days 0, 1, 2, 3, 4 and 7 were analysed by ImageJ. The images were changed 
into black and white pictures by Powerpoint software using picture colour icon 
before being converted into binary pictures by ImageJ software using the 
process icon then analysed (Figure 16). The total percentage of invasion for the 
spheroids was calculated by the following equation:  
Total = Spherical mass + Invading cells   
The spherical mass is defined as the spherical body excluding the invading 
cells. 
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Figure 16 Analysis of U87-MG spheroids invasion area using ImageJ. The 
pictures were changed into binary before calculating the total invasion area 
which equals the black invaded spheroid versus the white background.  
2.2.5.2.2 Validation of the invasion assay using LiCl 
Lithium chloride was selected to validate the developed spheroid invasion 
model, as it has been demonstrated as a potent and reversible inhibitor of the 
invasion of glioma cells in a dose-dependent fashion in a glioma spheroid 
model, according to Nowicki et al., 2008. In this study a range of concentrations 
of lithium chloride were prepared including 2 mM, 5 mM, 10 mM, 20 mM and 40 
mM. Lithium chloride powder (Alfa Aesar, UK) was dissolved in 200 µL 
complete media and layered over the second layer of collagen after its 
polymerization. The effect of lithium chloride was investigated as described 
above in section 2.2.5.2.1.1, 2. 
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2.2.5.2.3 Validation of the invasion assay using cRGDfV 
The developed 3D spheroid invasion assay was validated using cRGDfV; a 
known αvβ3 antagonist (Liu et al., 2008). This validation is a required preliminary 
step before using this assay to evaluate a group of novel αvβ3 antagonists. This 
step shows that the U87-MG cells invasion in the model can be inhibited by a 
specific αvβ3 integrin antagonist. Consequently, this assay could be used to 
measure invasion inhibition and considered suitable to be used to validate 
novel αvβ3 antagonists. Different concentrations of cRGDfV were tested to 
determine the effect of this compound on the inhibition of U87-MG cells 
invasion through collagen. In this study the concentrations 100 nM, and 10 μM 
final concentrations of cRGDfV were dissolved in 200 µL complete media and 
layered over the second layer of collagen after its polymerization. The effect of 
cRGDfV was investigated as described above in sections 2.2.5.2.1, 2. 
2.2.5.2.4 U87-MG invasion in gelatine 
5% gelatine concentration was used to test the invasion of U87-MG cell line in 
gelatine as an alternative to collagen. The U87-MG spheroids were inserted 
between two layers of 5% gelatine and incubated under 37°C, 5% CO2 for 7 
days, and images were taken daily using inverted light microscopy.  
2.2.5.3 Histological evaluation of spheroids in collagen. 
2.2.5.3.1 Preparation of APES–coated slides 
Slides were coated with APES to allow cut sections to adhere. Briefly, slides 
were immersed in clean acetone for 2 minutes and allowed to drain before 
being immersed in a freshly prepared 2% solution of 3-
aminopropyltriethoxysilane (APES) (A3648, Sigma, Poole, UK) in acetone for 2 
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minutes. These were allowed to dry and were then washed twice in running 
water for 2 minutes. Finally the slides were dried overnight at 37°C and stored 
at room temperature. 
2.2.5.3.2 Paraffin embedding of spheroids. 
According to Demuth et al., 2007, spheroids in collagen were first allowed to 
settle in a 30 ml universal tube (Nalge Nunc, Denmark). Spheroids were fixed 
using 10% neutral buffered formalin (pH 7.5). Fixation was carried out for 1 
hour at RT. Following this, the spheroids were dehydrated through incubation in 
70% ethanol at RT overnight, 90% ethanol for 1 hour and 100% ethanol for 30 
minutes. The spheroids were then placed in 100% xylene for 30 minutes and 
incubated at RT. Once fixed and fully dehydrated, the spheroids were 
transferred into a suitably sized wax mould, covered within paraffin wax and 
allowed to set at RT. Following processing of the spheroids into wax blocks, 5 
µm sections were cut using a microtome (Leica, RM2155). Sections were 
collected onto APES coated slides prepared as above. 
2.2.5.3.3 Haematoxylin and eosin staining of paraffin embedded spheroid 
sections. 
Spheroid sections were de-waxed and rehydrated prior to staining. This was 
achieved through successive incubations in 100% xylene for 10 minutes, 50% 
xylene/ethanol for 5 minutes, 100% ethanol for 10 minutes, 90% ethanol for 5 
minutes and 70% ethanol for 5 minutes. All incubations were carried out at RT. 
Spheroid sections were stained in Harris's haematoxylin for 5 minutes and then 
washed in running water. The haematoxylin staining was differentiated by 
briefly suspending the sections in acid alcohol for 5 seconds. The sections 
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were then washed briefly in tap water before being stained blue by incubating 
in Scott's Tap Water for 2 minutes. Sections were then counterstained using 
1% eosin (w/v) for 1 minute. Once stained, the sections were dehydrated 
through incubation in 100% ethanol for 4 minutes, 50% xylene/ethanol for 3 
minutes and 100% xylene for 6 minutes. All incubations were carried out at RT. 
Slides were mounted using DPX (VWR International Ltd.UK). 
2.2.5.3.4 Preparation of cryosections of invasion assays 
In addition to wax embedding, spheroids were also processed using 
cryosectioning. After 7 days in collagen, spheroids were embedded in OTC 
embedding matrix form (Cryoteck) and then frozen at -80°C and cryo-sectioned 
at 15μm thickness using a cryo-microtome (LEICA1100). Sections were 
collected on coated slides and stored at -20°C. 
2.2.5.3.5 Haematoxylin and eosin staining of spheroid cryosections 
Sections were fixed in 70% ethanol for 2 minutes and washed in water for 2 
minutes at RT, then stained in Harris's haematoxylin for 1 minute before being 
washed in running water. The haematoxylin staining was differentiated by 
briefly incubating the sections in acid alcohol for 3 seconds. The sections were 
then washed briefly in tap water, before being stained blue by incubating in 
Scott's Tap Water for 30 seconds. Sections were then counterstained using 1% 
eosin (w/v) for 20 seconds. Once stained, the sections were dehydrated 
through incubation in absolute ethanol for 1 minute, 50% xylene/ethanol for 1 
minute and 100% xylene for 1 minute. All incubations were carried out at RT. 
Slides were mounted using DPX (VWR International Ltd.UK). 
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2.2.5.3.6 Visualisation of invading spheroids using confocal microscopy  
On day 7 of the collagen invasion assay most of the media was removed and 
the spheroids in collagen were washed twice with HBSS and then fixed using 
200 µL of 4% paraformaldehayde and left for 15 minutes in RT. The spheroids 
were rehydrated with phosphate buffered saline and then the collagen gels 
were permeabilized using 0.5% Triton X-100 in PBS for 15 min. The blocking 
agent was added, as described in Table 2 to prevent non-specific binding and 
left for 1 h at room temperature before the blocking agent was removed and the 
primary antibody was added as in Table 1 and incubated overnight at 4°C. The 
spheroids were then washed with the blocking agent three times for 10 minutes 
and then incubated with a secondary antibody as described in table 2 Finally 
the cover slips were mounted with (Vectashield Mounting media containing 1.5 
µg/ml DAPI, Vector laboratories.UK) and stored at 4°C until used. 
β-actin labelled spheroids were imaged using Zeiss LSM510 confocal 
microscope (Zeiss, Welwyn Garden City, UK). Two spheroids from two different 
wells were imaged. The Axiovert 200 M inverted microscope (Zeiss. Welwyn 
Garden City, UK) was used to capture the images which were analysed using 
uLSM510 software from the same company. 
2.2.5.3.7 Visualisation of invading spheroids using invert light 
microscopy  
4'6-diamidino-2-phenylindole (DAPI) is a fluorescent stain that binds strongly to 
A-T rich regions in DNA. Hoechst dye like DAPI is a fluorescent stain that binds 
DNA and is used as a nuclear stain. Both stains are used extensively in 
fluorescence microscopy as nuclear stains. The hanging drop spheroids where 
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put on a slide and a drop of 1.5 µg/ml DAPI in Vectashield was put on every 
spheroid. The slides were covered by a cover slip and left for 10 minutes at 
room temperature and then examined by light microscope. 
To visualise invading spheroids in collagen, one drop of 1 μg/ml Hoechst dye 
(Hoechst 33342 Fluorescent Stain) or one drop of 1.5 μg/ml DAPI in 
Vectashield was put in every well containing spheroid and left over night at 4°C 
then seen by the blue channel of invert fluorescence microscopy (Nikon 
Eclipse, TE2000-4, 10X) using 10X magnification.  
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2.3 Results 
2.3.1 Evaluation of the growth characteristics of the different cell types. 
Four cell lines were evaluated for αvβ3 integrin expression. Different growth 
properties were seen after culturing these cells as described in this section. The 
growth curve of M14 melanoma cell line showed log phase starting from the 
fourth day of seeding and continuing until the seventh day (Figure 17 A). The 
MDA-MB-231 cell line showed a growth pattern with log phase starting on the 
second day after seeding and continuing up to the seventh day (Figure 17 B). 
The growth curve of PC3 prostate carcinoma cell line showed log phase starting 
from the third day of seeding and continued until the seventh day (Figure 17 C) 
The U87-MG glioma cell lines showed a growth pattern and showed log phase 
starting from the second day after seeding and continuing up to the seventh day 
(Figure 17 D). 
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Figure 17 Growth curves of the investigated cell lines (A) M14 growth curve. 
(B) MDA-MB-231 growth curve. (C) PC3 growth curve. (D) U87-MG growth 
curve. 
 
2.3.2 Characterization of αv and β3 integrin subunits expression in cells 
using immunocytochemistry. 
Glioblastoma is a tumour characterized by high cell surface expression of the 
αvβ3 integrin (Desgrosellier and Cheresh, 2010). The expression of αv and β3 
integrin subunits in U87-MG cells grown as monolayers was confirmed through 
doing immunolabelling of αv and β3 integrin subunits (Monferran et al., 2008) to 
confirm that the in house U87-MG cell line is expressing αv and β3 integrin 
A B 
D C 
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subunits. U87-MG cell membrane demonstrated high expression of αv and β3 
(Figure 18 [A] and [B]). 
Based on personal communication with colleagues in the same project (F O F 
A Al-Shammari), the other cell lines used during the optimisation process, 
including M14 melanoma cell line and PC3 prostate cancer cell line were 
confirmed to express the αvβ3 integrin. MDA-MB-231 breast cancer cell line 
was confirmed as a negative control. 
A
B
Nuclear labeling
The integrin
A : αv subunit
B β3 subunit
overlay
 
Figure 18 The αv labelling of U87-MG cell [A].The β3 labelling of U87-MG cell 
[B]. Scale bar: 50 µm. 
2.3.3 Determination of the ability of the different cell lines to form 
spheroids in hanging drops 
The M14 cell line grew as relatively compact cell clumps in hanging drops 
(Figure 19 A). M14 cell line growth increased with cell seeding concentration to 
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4000 cells/drop. However, at concentration of 8000 cells/drop, a small 
decrease was seen over the first three days, because of high cell concentration 
(Figure 19 B).  
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Figure 19 (A) M14 clumps in hanging drops demonstrating loose structures 
after the first three days which increase in size and become more compact by 
the seventh day. Scale bar: 100 µm (B) Growth curves of different 
concentrations of M14 cells in 20 µL hanging drops demonstrating relatively no 
increase in viability due to the limited nutritional supply in the 20 µL media. n=3 
 
The MDA-MB-231 cell line demonstrated the best growing pattern with 
concentration of 1000 cells/20 µL compared to the other concentrations (Figure 
20 B). However, The MDA-MB-231 cell line demonstrated less compact 
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structures in the hanging drops compared to the U87-MG and M14 cell lines 
(Figure 20 A). 
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Figure 20 MDA-MB-231 cells in hanging drops demonstrating loose structures 
after the first three days and become more compact by the seventh day. Scale 
bar: 100 µm (A). Growth curves of different concentrations of MDA-MB-231 
cells in 20 µL hanging drops demonstrating relatively no increase in viability due 
to the limited nutritional supply in the 20 µL media (B). n=3 
 
The plot of PC-3 cell line demonstrated little growth at all concentrations 
(Figure 21 B). The PC-3 cell line demonstrated the loosest structures in 
hanging drops compared to the other cell lines (Figure 21 A). 
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Figure 21 PC-3 cells in hanging drops demonstrating very loose structures after 
the first three days and demonstrate relatively no change in size by the seventh 
day indicating that the cells are not growing with time from the initial clump. Scale 
bar: 100 µm (A). Growth curves of different concentrations of PC-3 cells in 20 µL 
hanging drops demonstrating relatively no increase in viability due to the limited 
nutritional supply in the 20 µL media (B).n=3. 
 
The U87-MG spheroids formed by the hanging drop method demonstrated 
round spherical structures with healthy appearance judged from the bright 
colour of the cells and the change in the media colour in the first three days. 
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However, by the seventh day the spheroids had gradually lost their healthy 
appearance due to the limited source of nutrition in the 20 µL hanging drop 
(Figure 22). 
The U87-MG cell line growth in seeding concentrations to 4000 cell/20 µL drop 
demonstrated a decrease in the number of viable cells in 20 µL hanging drops 
over a 7 day period. However, the U87-MG in concentrations (200-1000 cell/30 
µL drop) demonstrated increasing growth in the 30 µL hanging drops (Figure 
22). The 30 µL drops were tried as alternative to the 20 µL drops as the 
decrease in growth in the 20 µL drops could be due to limited nutritional supply 
which was overcome by the 30 µL drops which was enough to keep the U87-
MG spheroids viable for a week.  
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Figure 22 U87-MG hanging drop spheroids. The U87-MG cells demonstrate 
compact spherical structures which can be seen in the hanging drops after 
three days of seeding. Scale bar: 100 µm. (B) MTT growth curves of different 
seeding densities of U87-MG spheroids in 20 µL hanging drops. (C) MTT 
growth curves of U87-MG spheroids in 30 µL drops. n=3. 
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2.3.4 Determination of the ability of the different cell lines to invade in 
collagen  
M14 clumps formed in the hanging drops were transferred to collagen and 
images were taken on days 0, 1, 2, 3, 4, 7. Cell invasion was analysed by 
counting the number of cross points covered by invading cells as described in 
section 2.2.3.3.1. M14 cells were able to form clumps in the hanging drops but 
those clumps were not compact enough to be considered spheroids. M14 
clumps increased in size but with little evidence of cell invasion in collagen 
(Figure 23). 
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Figure 23 M14 clumps in collagen. The M14 clumps did not demonstrate 
invasion in collagen. Scale bar: 100 µm (A). Graphical representation of the 
invasion of the M14 clumps in collagen. The slight increase in the numbers of 
cross points demonstrated above was due to the increase in size of the cell 
clumps (B). n=3 
 
MDA-MB-231 clumps formed in hanging drops were transferred to collagen and 
images were taken over a week for the cells that had clumped. MDA-MB-231 
cells were unable to form compact clumps in the hanging drops and those 
clumps were not able to be transferred to collagen easily (Figure 24). 
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Figure 24 MDA-MB-231 invasions in collagen. Clusters from the poorly forming 
hanging drop clumps are breaking up or moving away from other clusters. 
White arrows demonstrate MDA-MB-231 clusters and black arrows 
demonstrate MDA-MB-231 cells moving away from clusters. Scale bar: 100 µm 
(A). Graphical representation of the total invasion of MDA-MB-231 clumps in 
collagen. MDA-MB-231 clumps did not demonstrate invasion in collagen and 
the slight increase in the numbers of cross points was due to the clusters of 
cells that were breaking up from the poorly formed hanging drop clumps 
(B).n=3  
 
PC-3 clumps formed in hanging drops were transferred to collagen and images 
of these cells were taken over a week. Invasion was analysed by counting the 
number of cross points covered by invading cells. PC-3 cells were unable to 
form compact clumps in the hanging drops and those clumps were not able to 
transfer to collagen easily (Figure 25). 
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Figure 25. PC-3 clumps total invasion curve. PC-3 clumps did not demonstrate 
invasion in collagen and the slight increase in the numbers of cross points is 
due to the clusters of cells that break up from the main hanging drop clumps 
and move away n=3.  
 
U87-MG spheroids which were formed in hanging drops were transferred to 
collagen and the images of these spheroids were taken over a week. The 
invasion of the spheroids was analysed by counting the number of cross points 
covered by invading cells. U87-MG cells were able to form compact spheroids 
in the hanging drops and those spheroids were able to be transferred to 
collagen easily and were able to invade in a significantly detected way (Figure 
26).  
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Figure 26 U87-MG spheroids invasion in collagen. Complete invasion of the 
spheroids in collagen. Scale bar: 100 µm (A). Graphical representation of the 
U87-MG 1000 cell/hanging drop spheroids invasion. Complete spherical 
invasion is seen over time for U87-MG spheroids in collagen (B). The invasion 
of U87-MG spheroids was analysed using the grid by counting the numbers of 
cross points covered by invading cells from the spheroids and the spherical 
mass. The total invasion is a sum of both values of the numbers of cross points 
covered by invading cells from the spheroids and the spherical mass (C). n=3.  
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2.3.5 Model development 
2.3.5.1.Modifications on the original method 
Based on the initial studies carried out to make the hanging drop spheroids, the 
U87-MG cell line was selected as the best option to make the invasion model. 
After success of the invasion of the U87-MG spheroids in collagen, gelatine 
was tried as alternative material to collagen. Furthermore, the source of the 
spheroids was modified by starting with spheroids that originated from a rich 
environment from the beginning using a liquid overlay method (Günther et al., 
2003). Liquid overlay method is a method evolves producing spheroids in larger 
amount of media compared to hanging drops and that could give the cells more 
nutrients and could result in higher viability and invasion of the cells, however 
this method resulted in heterogeneously sized spheroids as will be explained. 
2.3.5.1.1 U87-MG invasion in gelatine 
Gelatine was tested as an alternative to collagen. U87-MG demonstrated no 
invasion in 5% gelatine (see Figure 27). The results demonstrated no spherical 
growth indicating that the gelatine was not suitable to test the invasion of the 
U87-MG spheroids.  
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Figure 27 U87-MG spheroids invasions in gelatine which is tested as a 
cheaper alternative to collagen. U87-MG spheroids have been watched over 
seven days after insertion in gelatine and had no ability to invade in gelatine. 
Scale bar: 100 µm. n=3. 
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2.3.5.1.2 Modification of the source of the spheroids. 
The initial source of the spheroids was modified by growing spheroids in a 
nutritionally rich media (Del Duca et al., 2004) compared to the hanging drop 
method in which the spheroids were grown in 30 µL media drops only. In the 
liquid overlay method (Del Duca et al., 2004) the cell suspension was seeded 
over a 2% agarose layer for 3-4 days until the formation of a microsphere. The 
results of the liquid overlay method were compared to the hanging drop method 
on the third day; the day on which the spheroids were transferred into collagen. 
The hanging drop method resulted in homogenous spheroid size; however the 
liquid overlay method resulted in heterogeneous spherical size (Figure 28). 
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Figure 28 Comparison of the liquid overlay method and the hanging drop method. 
The hanging drop method resulted in homogenous spheroid size, but the liquid 
overlay method resulted in heterogeneous spherical size. Scale bar: 100 µm. n=3. 
**P value<0.01. 
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2.3.5.2 Evaluation of ImageJ software for data analysis 
As a second step after optimizing the conditions of the 3D invasion assay, the 
computer software ImageJ analysis was considered to analyze the images that 
result from the invasion of the U87-MG spheroids in collagen. ImageJ is 
preferred by many authors because it considers whole invasion whereas cross 
points only takes a representative sample of cells that happen to hit cross 
points. Two alternatives options were tried to prepare the images to be 
analysed.The first option was to use the ImageJ software to form black and 
white pictures then convert them into binary pictures before going into further 
analysis, but ImageJ was unable to exclude the dark shadows in selected parts 
of the pictures (Figure 29). The alternative option included black and white 
pictures formed in Powerpoint for further analysis using ImageJ. The images 
were transferred into black and white pictures and ImageJ was used to form 
binary pictures which were later analyzed by calculating the black area versus 
the white background to represent the total invasion area of the spheroids 
(Figure 29). An example experiment analysed in ImageJ is shown in (Figure 
30). 
The ImageJ system is preferable over the cross points counting in analysing 
the invasion of the U87-MG spheroids as the ImageJ system determines the 
total area covered by invading cells and not only counts the number of cross 
points which come over the invading cells making the ImageJ system more 
accurate in evaluating and analysing the data. Therefore for further spheroid 
invasion studies in this thesis ImageJ was used as the methodology for image 
analysis. 
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Figure 29 This diagram demonstrates the way used to analyze the pictures of 
the U87-MG spheroids invasion in collagen. (A) The first option is to use the 
ImageJ software to form black and white pictures. (B) The alternative option 
includes using the power point formed black and white pictures for further 
analysis using ImageJ.  
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Figure 30: The invasion of U87-MG spheroids in collagen over time. The 
analysis was done using ImageJ. The total invasion was calculated by the 
system as the overall black area relative to white background. 
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2.3.5.3 Tracking of the invasion of the U87-MG cell from the spheroids 
over time using time-lapse imaging 
In order to investigate the ability of the U87-MG to move in a velocity due to 
invasion and not due to spherical growth, the U87-MG spheroids were observed 
over 24 hours using a Lumascope 500 imaging system (Etaluma. Carlsbad. 
USA). The U87-MG cells located on the surface of the spheroids were observed 
as well as the spindle shaped mesenchymal invasion characterising these cells 
(Figure 31). The results demonstrated that the U87-mg cells were moving in a 
calculated speed of 0.65µm/min and that the movement of the cells was due to 
invasion through collagen and not due to growth of the spheroids. The forward 
migration index value was calculated as equal the final distance moved by the 
tracked cell / total distance which is the distance the cell actually moved. The 
forward migration index is an indicator to real movement done by the invading 
cells (Meijering et al, 2012).  
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Figure 31 Video observation of the invasion of the U87-MG spheroids through 
collagen. Scale bar: 100 µm. (1) the pictures (A-D) demonstrate the stages of 
invasion over 24 hours taken by Lumascope500 video camera. (2) Graphical 
presentation of the tracking of selected cells invading from the invading U87-
MG spheroids through collagen. The results demonstrated that the U87-mg 
cells were moving in a calculated velocity of 0.65 µm/min.  
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2.3.5.4 Validation of the invasion assay using LiCl an inhibitor of U87-MG 
invasion. 
In order to validate the assay for use with experimental compounds which are 
hypothesised to inhibit invasion, a known inhibitor of invasion; lithium chloride 
(Nowicki et al., 2008) was used. It has been previously demonstrated that 
lithium chloride inhibits invasion of glioma cells potently and reversibly in time 
and in a dose-dependent fashion in the glioma spheroid model (Nowicki et al., 
2008). 
There was a very clear inhibitory effect of lithium on the ability of U87-MG 
spheroids to invade through collagen in a dose dependent manner (see Figure 
32).  
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Figure 32 Validation of the invasion assay. LiCl significantly inhibits U87-MG 
invasion in a time and concentration dependent manner. Scale bar: 100 µm. 
 
For better visualization of the cells the spheroids were stained with a nucleic 
acid binding stains; Hoechst dye and DAPI. Hoechst dye was found to result in 
more clear pictures compared to DAPI stain although both are able to penetrate 
collagen and stain the spheroids (Figure 33). 
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Figure 33 Effect of LiCl on U87-MG invasion. On day 7, cells were stained with 
Hoechst dye to give better visualisation of the invading cells. Scale bar: 100 
µm. The images were captured in the seventh day of the invasion assay. A 
clear reduction in cell invasion was seen with increasing the concentration of 
LiCl. 
 
 
 
 
 
 
99 
 
2.3.5.5 Validation of the suitability of the invasion assay to evaluate β3 
antagonism using cRGDfV; a known β3 antagonist 
As a second step after validation of the invasion assay using LiCl as previously 
demonstrated in Figure 32, the developed 3D spheroid invasion assay was 
validated using cRGDfV; a known β3 antagonist (Liu et al., 2008) as a needed 
preliminary step to confirm the suitability of the developed assay to be inhibited 
by αvβ3 antagonism. Different concentrations of cRGDfV were tested to 
determine the effect of this compound on the inhibition of U87-MG cells invasion 
through collagen. cRGDfV was found to reduce the invasion of the U87-MG 
spheroids in a time and dose dependent manner (see Figure 34). The 
concentrations of the cRGDfV used including 100nM, and 10µM were selected 
based on the IC50 and IC10 values that were calculated based on the MTT 
chemo-sensitivity assay which will be explained in detail in the following 
chapter. Briefly the tested concentrations were selected to be not exceeding the 
IC50 and not less than the IC10 to avoid toxicity and guarantee efficiency. 
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Figure 34 cRGDfV reduces U87-MG cells invasion in a concentration and time 
dependent manner. The pictures were taken over 4 days of invasion into 
collagen and analyzed by ImageJ. Scale bar: 100 µm. 
 
2.3.6. Spheroid imaging 
Two methods for imaging spheroids were evaluated; the histological analysis of 
the spheroids and the immunofluorescence labeling of the cells in order to 
facilitate the confocal imaging of the formed spheroids. 
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2.3.6.1 Histology of the spheroids  
The sectioning of spheroids was difficult due to their very small size. Two 
different ways of embedding and sectioning the spheroids were tried, firstly by 
cryo-sectioning as the spheroids were embedded in OTC embedding matrix 
(Cryoteck) and secondly by sectioning the paraffin embedded U87-MG 
spheroids. Due to the small spheroid size cryosectioning was not successful. 
The paraffin embedded sectioning however, resulted in some visualization of 
the spherical structure but further work needs to be done to achieve more 
consistent results (see Figure 35).  
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Figure 35 H&E stained paraffin embedded section of U87-MG spheroid. 
Because of the very small spheroid size the spheroids were not easily 
sectioned after embedding in paraffin. Figure demonstrates the round structure 
of the spheroids with some cells invading out. Scale bar: 25 µm. 
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2.3.6.2 Use of β-actin to label cells for confocal imaging  
Actin is a major multi-functional protein found in all eukaryotic cells. β-actin 
immunolabelling is a subtype of actin, present in most cell types as a part of the 
cytoskeleton and as a cell motility inducer. The β-actin staining was used 
because it is a widely distributed molecule in the cell allowing the visualisation 
of the cell structure and to facilitate the confocal imaging of the formed 
spheroids in addition to show features such as focal adhesions of the invading 
cells. The β-actin immunolabelling of the U87-MG cells was optimised first at a 
2D level and then spheroids were stained on a 3D level (Figure 36 and Figure 
37).  
Nuclear labelingβ-actin overlay
Figure 36 The β-actin labelling of U87-MG cells showing the focal adhesions 
of the cells characterised by light edges. Scale bar: 50 µm. 
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Figure 37 Detection of cells within the spheroid and invading cells by confocal microscopy using β-actin 
staining. Three different views of the spheroid were taken including the spheroid area, the protruding cells 
from the spheroid and the invading cells. Upper scale bar: 25 µm, lower Scale bar: 100 µm.
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2.4 Discussion 
In this part of the study a β3 integrin expressing 3D spheroid invasion model 
was developed in order to mimic the micro-metastatic environment of tumours 
expressing β3 integrin. The developed model was validated using a known 
inhibitor of invasion, LiCl (Nowicki et al., 2008) and a known β3 antagonist 
cRGDfV (Liu et al., 2008). The aim of these validations was to demonstrate that 
the model is fit for measuring inhibition of invasion, and responds to αvβ3 
antagonists, so that the developed model could be employed to investigate the 
pharmacological effect of novel small molecule β3 integrin antagonists.  
During the first trials of the model development, different methods to prepare 
the 3D spheroids were investigated. The liquid overlay method was tried as an 
alternative to hanging drop method. The reason for that was that the liquid 
overlay method produce spheroids in larger amounts of media compared to 
hanging drops and that this could give the cells more nutrients. However, the 
liquid overlay method results in heterogeneous spheroid sizes and so the equal 
size spheroids need to be separated before being used in the collagen invasion 
assay. Therefore the hanging drop method was selected to produce the 
spheroids as it is a method that consistently gives homogenous spheroid sizes 
for the same seeding density (Del Duca et al., 2004), making this a better 
method (Strojnik et al., 2006). 
Through immunolabelling of αv and β3 integrin subunits, the expression of αvβ3 
in U87-MG cells grown as monolayers was confirmed. The MDA-MB-231 cell 
line was used as a negative control and the M14 melanoma cell line in addition 
to the PC3 prostate cancer cell line were known to express the αvβ3 integrin, 
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based on personal communication with F O F A Al-Shammari. M14 cells where 
able to form more compact clumps than PC-3 and MDA-MB-231. This result 
could be due to that the M14 melanoma cell line over expresses αvβ3 
(Desgrosellier and Cheresh, 2010). However, the PC3 prostate cancer cell line 
was characterized by variation in expression of αvβ3 between groups 
(Sheldrake et al.2009) and the MDA-MB-231 cell line was not expressing β3 
integrin. Those clumps were not able to be transferred easily to the collagen 
and did not make a real spherical structure which could be described as 
spheroids. On the other hand, the U87-MG cell line was able to form 
completely compact homogenous spheroids in the hanging drops and these 
were readily transferred to the collagen. The U87-MG showed the best results 
most probably because of the high expression of certain adhesion molecules 
such as cadherins (Asano et al., 2004), αvβ3 and αvβ5 integrins (Reardon et al., 
2011; Bello et al., 2001) compared to PC-3 and MDA-MB-231 cell lines which 
are known to be moderate to low expressers of αvβ3 integrin (Goel et al., 2008); 
(Desgrosellier and Cheresh, 2010). αvβ5 has been found to be involved in 
inducing strong tissue cohesion and inducing spheroid formation (Robinson et 
al., 2003). Integrins and cadherins are involved in inducing and supporting cell-
cell adhesion and cell survival through coupling to the actin cytoskeleton and 
transducing signals from the extracellular environment which are fundamental 
properties involved in spheroid formation (Bates et al., 2000). Although the M14 
cell line is considered as a high expresser of αvβ3 (Sloan et al., 2006) and αvβ5 
integrins based on in-house data, it could not form spheroids and this result 
coincided with the previously published data (Trapp et al., 2010). The lack of 
ability of M14 cells to form spheroids is probably due to the fact that the 
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metastatic melanoma cell lines lack the expression of cadherin (Danen et al., 
1996) compared to the U87-MG cell line which as stated above is characterised 
by high expression of both αvβ3 and αvβ5 integrins and cadherins. Based on the 
work explained in this thesis, the U87-MG cell line was the most suitable cell 
line to run in this model as those cells formed the most successful spheroids. 
The U87-MG spheroids formed by the hanging drop method demonstrated 
consistently spherical structures with a very healthy appearance in the first 
three days until they were transferred to collagen. 
Collagen type I has been chosen to be used as the matrix for the work in this 
thesis because it is known to be the main interstitial matrix component in the 
solid tumours, in addition to its structural features that allow the formation of the 
gel-like architecture to get more realistic features of the cellular invasion 
process (Bruyère et al., 2008); (Sabeh et al., 2009). Gelatin was tried as a 
cheaper alternative to collagen, but the U87-MG cell line showed no invasion in 
gelatine compared to very high and significant invasion in collagen, making 
collagen the preferable option to be used to test the invasion of these cells. A 
possible explanation for this is that the expression of gelatinase is a process 
affected by cellular environment (Liu et al., 2010) and the presence of extra 
components of the tumour microenvironment is required to be expressed in the 
U87-MG cells to induce their invasion in gelatine. Modifying the source of the 
spheroids was tried by starting with spheroids originating from a rich 
environment from the beginning using the liquid overlay method (Günther et al., 
2003) in an aim to exclude the possibility that the presence of a relatively large 
numbers of cells in a relatively small amount of media of about 30 µL in 
hanging drops could lead to the cells being exhausted, but the results showed 
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high variability in the size of resulting spheroids. This variability makes them not 
suitable to be used in an invasion assay which requires that the spheroids used 
must be consistently equal in size.  
Among the important points which need to be taken into consideration when 
performing this 3D spherical invasion assay is seeding the U87-MG spheroids 
in between two gel layers with equal collagen concentrations to be able to mix 
homogeneously with each other to guarantee cellular invasion from the 
spheroids and prevent any possibility for cellular migration on the surface of the 
gel into the interphase between the two collagen layers. Furthermore, during 
the assay the collagen layers were given enough time to polymerize (about 45 
minutes at 37 oC) to avoid any possibility for the spheroids to be embedded in 
contact with the tissue culture plate and so migrating rather than invading (De 
Wever et al, 2010).  
The invasion assay was validated using Lithium chloride, which has been 
investigated as an inhibitor of glioma invasion (Nowicki et al., 2008). Lithium 
chloride is a drug used to treat bipolar disorder and is described to have effects 
on metabolism, neuronal communication and cell proliferation (Phiel and Klein, 
2001). The Lithium chloride mechanism of action is dependent on inhibiting 
glycogen synthase kinase-3 (GSK-3) which is located downstream of many of 
the vital signalling pathways in the cell. GSK-3 is a protein composed of two 
isoforms, GSK-3a and GSK-3b which work in different pathways, mediated by 
numerous kinases including Akt, protein kinase A, protein kinase C and Wnt 
which inactivates GSK-3, causing β-catenin transcription and stabilization 
(Cross et al., 1995). There are many substrates of GSK-3 which are known to 
be involved in cell migration including paxillin, FAK, NF-B, B-catenin and SNAIL 
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(Jope et al., 2007). In this study, Lithium chloride has shown efficiency in 
inhibiting the invasion of U87-MG spheroids in collagen in a time and dose 
dependent manner. The results showed significant inhibitory effect of lithium 
chloride concentrations starting from 10 mM indicating that the model was 
suitable for quantifying inhibition of invasion.  
cRGDfV has also been used as a control to validate the developed assay. 
cRGDfV is a synthetic peptide-based integrin inhibitor that works by mimicking 
the structure of the natural ligands of integrins. cRGDfV is a cyclised peptide 
containing D-phenylalanine to increase stability and integrin affinity. This 
modification resulted in increasing the bioavailability as well as increasing the 
αvβ3 integrin affinity, making cRGDfV a good option to be used to validate the 
developed assay (Eble and Haier, 2006). In this study significant reduction in 
the invasion of the U87-MG spheroids resulted over a range of different 
concentrations of cRGDfV. This result indicates that cRGDfV has a time and 
dose dependent inhibitory effect on the developed model. Based on the fact 
that the cRGDfV is an αvβ3 integrin antagonist, the developed model could 
thus be used to validate a group of novel in-house β3 integrin antagonists.  
2.5 Conclusion  
U87-MG was identified as a suitable αvβ3 integrin expressing cell line that was 
able to form hanging drop spheroids and invade through type I collagen. 
Furthermore, this chapter resulted in optimising the conditions to develop the 
3D spheroid invasion model and validated the developed assay through using 
lithium chloride, a known invasion inhibitor, and cRGDfV, a known β3 integrin 
antagonist. 
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Chapter 3: Evaluation of a group of novel, β3 integrin antagonists using 
the 3D spheroid invasion assay. 
3.1.1 Introduction 
The importance of the β3 integrins arises from their prominence in the 
pathophysiology of many tumours, in addition to their involvement in 
important tumour hallmarks such as angiogenesis (Brooks et al., 1994) and 
metastasis (Natali et al., 1997). Due to the ability of the β3 integrins to interact 
with many components of the extracellular matrix such as fibronectin and 
vitronectin through interaction with the RGD tripeptide sequence, the β3 
integrins are considered as major inducers of the of tumour dissemination 
and attractive targets for inhibiting tumour progression (Ruoslahti and 
Pierschbacher, 1986).  
Among the reported strategies to target integrins; the blockade of ligand 
binding, blocking integrin downstream signalling, and modulation of integrin 
expression (Cox et al., 2010). The blockade of ligand binding is the main 
integrin therapeutic targeting strategy, which has been used for most clinically 
studied inhibitors (Table 2) (Cox et al., 2010). The main challenge associated 
with this methodology is the development of activation and integrin specific 
inhibitors, due to the fact that integrins are large molecules with a high 
possibility for binding to more than one site. Among the approaches in the 
development of compounds that work by blocking ligand binding is the 
development of antagonists which work by selectively binding the integrin while 
it is in the active state (Ahrens and Peter, 2008). Inhibitory antibodies and small-
molecule based integrin antagonists (Shannon et al., 2004); (Harms et al., 
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2004) are examples of drugs that work by blocking the integrin ligand binding 
(Aster and Bougie, 2007). The main problem associated with antibody-based 
integrin antagonists is the possibility of generating neutralising antibodies to the 
drug leading to decreased drug efficacy (Calabresi et al., 2007). On the other 
hand, the main problem associated with small molecule integrin antagonists is 
that many of them are designed around the ligand structure which can lead 
some times to unexpected agonist effects (Weis et al., 2009) or low dose 
associated agonist effects as reported for some RGD-based αVβ3 and αVβ5 
integrin inhibitors (Reynolds et al., 2009) and other oral αIIbβ3 antagonists (Cox 
et al., 2000a). This low dose associated agonist effect could be a significant 
problem when the plasma drug concentration decreases in the period after oral 
dosing, leading to an agonist-like effect due to low concentrations of the 
compound in the blood (Cox, 2004). The design of the effective small molecule 
integrin antagonists depends on detailed understanding of the receptor 
structure and a good understanding of integrin signalling in order to avoid the 
dilemma of agonist-like effects which could arise due to bioavailability and half-
life problems in addition to problems in ligand design. 
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Table 2 Examples of clinically studied integrin inhibitors  
Drug Clinical 
phase  
target Indication  Ref 
Abciximab Approved αIIbβ3 Thrombosis (Coller, 
1985) 
Tirofiban Approved αIIbβ3 Thrombosis (Egbertson 
et al., 1994) 
Cilengitide Terminated 
at Phase III 
αvβ3, 
αvβ5 
Cancer (Stupp et al., 
2014) 
Etaracizumab Phase II 
completed 
successfully 
αvβ3 Arthritis, 
cancer, 
osteoporosis, 
psoriasis, 
restenosis, 
cancer  
(Hersey et 
al.,2010; Cai 
et al., 2006, 
Heckmann 
and Kessler, 
2007, 
Stefanich et 
al., 2011) 
Fluciclatide (18F) Phase II αvβ3, 
αvβ5 
Cancer: 
diagnostics 
(Wirth et al., 
2012) (Mena 
et al, 2014) 
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3.1.2 Aims and objectives  
The aim of this chapter was to evaluate a panel of novel small molecule β3 
integrin antagonists, designed based on detailed understanding of the active 
conformation of the receptor structure and evaluated for their cytotoxic and anti-
invasive properties.  
This aim will be achieved by completing the following objectives: 
1. Assessment of the cytotoxicity of the compounds using an MTT cytotoxicity 
assay  
2. Evaluation of the effects on invasion using the 3D assay optimized in the 
previous chapter. 
3. Comparison of the results of the 3D assay against a standard 2D transwell 
assay. 
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3.2 Material and methods 
3.2.1 Compounds 
The integrin inhibitor cRGDfV was obtained from Enzo Life Science 
(Farmingdale, Norway). For the MTT cytotoxicity assay, cRGDfV was prepared 
at a range of concentrations from1 nM-100 uM as final dilutions using RPMI 
1640 cell culture medium as a diluent. The MTT solution was prepared by 
diluting the MTT stock solution (5 mg/ml) ten times using (RPMI) 1640 full 
media. 
A group of small molecule β3 antagonists synthesized in-house were evaluated 
in this chapter (Table 3). The compounds were initially dissolved in DMSO and 
prepared at a range of concentrations from 0.5 µM-50 µM using RPMI 1640 cell 
culture medium as a diluent with DMSO at a final concentration less than 0.1% 
of the volume of the media. 
3.2.2 Cell lines 
The U87-MG Glioma cell line was obtained from the European Collection of Cell 
Cultures ((ECACC), Salisbury, Wiltshire, England). All cell lines were 
maintained in RPMI 1640 medium, supplemented with 10% foetal bovine 
serum, 2mM L-glutamine, and 1mM sodium pyruvate to form complete growth 
medium. Cell lines were maintained at 37°C in a 5% CO2 humidified 
atmosphere. 
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Table 3: The novel ICT small molecule β3 antagonists with their molecular 
weights. See insert for structures (confidential due to intellectual property 
embargo). 
Compounds  MW  
ICT9055 542 
ICT9072 474 
ICT9073 516 
ICT9081 464 
ICT9082 496 
ICT9084 538 
ICT9085 500 
ICT9086 500 
ICT9087 542 
ICT9088 468 
ICT9091 501 
ICT9092 543 
ICT9093 553 
ICT9094 557 
ICT9095 557 
ICT9096 539 
ICT9097 497 
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3.2.3 MTT Cytotoxicity assay  
All the materials used in this assay were purchased from Sigma-Aldrich (Poole, 
UK). The U87-MG cells were seeded in log phase at low passage number (2-
5). The MTT Cytotoxicity assay was performed in triplicate wells per treatment 
concentration. The U87-MG cells were seeded in a 96-well plate (1x103 cell/180 
μL/well) and incubated overnight at 37°C, 5 % CO2. Serial dilutions of each 
compound were prepared and added to each well in at 10x on-plate 
concentration and incubated at 37°C, 5% CO2 for 4 days. The MTT solution 
was prepared by adding 2 ml of MTT stock solution (5 mg/ml) to 18 ml of 
complete RPMI 1640 media in a 30 ml tube. The supernatant was removed and 
200 μL of the MTT solution per well was added and incubated at 37°C, 5% CO2 
for 4 hours. The MTT solution was removed and 150 μL of DMSO were added 
to each well to dissolve the formed blue formazan crystals. The optical density 
of the plates was read at 550 nm. The optical density was used to calculate the 
% survival of the compounds according to the following equation: 
Percent survival =
Average of the optical density of the wells treated by the compound − blank 
Average of the optical density of control no treatment − blank
× 100 
 
The IC50 which is the compound concentration that causes a decrease of the % 
survival to 50 % was calculated after plotting the compound concentration 
versus the % survival. 
3.2.4 Collagen invasion assay 
The assay was performed as described in chapter 2, section 2.2.5.2  
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3.2.5 Data analysis 
The analysis of the collagen invasion assay was performed by evaluating the 
spheroid invasion area using ImageJ as described in chapter2, section 
2.2.5.2.1.2. The t-test was used in addition to the Kruskal-Wallis test and 
Conover-Inman test to do the statistical analysing of the data, with statistically 
significant results of p values < 0.05 and p < 0.01.  
3.2.6 The 2D invasion model 
The 2D transwell invasion assay was performed as a way to compare the 
results of this assay with the results obtained from the 3D spheroid invasion 
assay. 
3.2.6.1 Coating buffer and Matrigel preparation 
Coating buffer of 0.01 M Tris (pH 8.0) and 0.7 % NaCl was prepared and 
filtered using a 0.2 µm sterile filter unit, allowed to freeze at -20 °C and used 
after two hours of freezing. Matrigel Matrix (Corning Cat. No. 354234) aliquot 
was thawed on ice at 4 °C. All pipettes, syringes, and containers that came in 
contact with Matrigel Matrix were chilled prior to use. Matrigel was mixed with 
the prepared coating buffer to a final concentration of 250µg/ml and placed on 
ice.  
3.2.6.2 2D transwell assay preparation 
The lid from a 24-well permeable support plate (Corning Cat. No. 3422) was 
removed and using sterile forceps the required number of permeable supports 
was transferred into a 24-well plate. 0.1 ml of the diluted Corning Matrigel 
Matrix coating solution was added to each permeable support with avoidance 
of air bubble formation while pipetting. The coated invasion chambers were 
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incubated at 37°C for 2 hours. A U87-MG cell suspension of 5 x 104 cells/mL in 
culture medium was prepared and seeded in 150µL volumes into the upper 
section of the 24 well invasion chambers. (0.75mL) of HBSS or 1% FCS or 
10%FCS were added as chemo attractant to the wells of the 24-well plate via 
the access port. The cell invasion chambers were incubated overnight in a 
humidified tissue culture incubator at 37°C, 5% CO2 atmosphere. 
3.2.6.3 Transwell Processing 
After completing the incubation time, a cotton swab moistened with medium 
was inserted into the top of the Corning® Matrigel® Matrix coated permeable 
support (apical side) and applied gently with firm pressure to rub the area. The 
cells on the lower surface of the membrane were fixed by 70% ethanol for 2 
minutes and allowed to dry inverted for 5 minutes then stained with 
haematoxylin stain for 20 minutes and washed 3 times with distilled water by 
putting the transwells in distilled water filled wells for 2 minutes then drying 
inverted for 5 minutes. Pictures were taken for the stained cells in the basal 
surface using the fluorescence microscope (Leica DMRB, Wetzlar, Germany) 
under 40X objective lens magnification and the cells were directly counted.  
The percent invasion was determined through the following equation; 
Percent Invasion =
Mean number of treated cells invading through coated permeable support membrane 
Mean number of untreated cells invading through coated permeable support membrane 
× 100 
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3.3 Results 
3.3.1 Evaluation of compound toxicity using the MTT assay 
The MTT cytotoxicity assay was performed in order to determine the IC50 
values for the ICT compounds (see Figure 38) to decide the non-toxic 
concentrations to be used in the 3D spheroid invasion assay. The IC50 is 
defined as the drug concentration that is required to cause 50% inhibition in 
vitro. The IC50 values of the compounds were comparable except for the 
ICT9081 which was less toxic effect compared to other compounds (Table4). 
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Figure 38: The results of the MTT cytotoxicity assay that performed on the 
U87-MG cells using 17 novel ICT compounds and the cRGDfV as a control. 
Results presented are an average of 3 independent experiments.  
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Table 4: The IC50 values of the tested ICT compounds  
Compounds IC50 in µM 
ICT 9055 36.9±11.7 
ICT 9072 36.9±8.0 
ICT 9073 18.9±2.6 
ICT 9081 160.8±61.0 
ICT 9082 32.5±14.7 
ICT 9084 36.4±12.4 
ICT 9085 40.9±11.5 
ICT 9086 48.8±5.0 
ICT 9087 35.5±2.0 
ICT 9088 51.3±1.9 
ICT 9091 30.9±8.1 
ICT 9092 46.4±3.5 
ICT 9093 37.9±7.1 
ICT 9094 46.7±7.6 
ICT 9095 42.3±4.6 
ICT 9096 59.2±16.9 
ICT 9097 70.1±18.8 
cRGDfV 69.2±25.5 
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3.3.2 Effects of the ICT compounds on the invasion of the U87-MG 
spheroids in collagen in the 3D assay. 
Using concentrations determined from the MTT assay, concentrations between 
IC10 and IC50 were selected to be tested. The compounds were evaluated 
using the 3D spheroid invasion assay. Figure 39 summarizes the results, with 
the plots for the individual compounds presented in Figure 40, whilst 
representative images and image analysis for active and inactive compounds 
are presented in Figure 41 and Figure 42 respectively. The compounds were 
described to give complete inhibition of spheroid invasion if the percentage of 
invasion compared to the control was less than 40%. They were described to 
give slight inhibition of spheroid invasion if the percentage of invasion 
compared to the control was between 60% and 80%. The compounds were 
described to show moderate inhibition if the percentage of invasion was 
between 40% and 60%. They were described to show no inhibition of spheroid 
invasion if the percentage was more than 80%. 
The compounds ICT9055, ICT9072, ICT9073, ICT9087, ICT9088, ICT9091, 
ICT9094, and ICT9095 significantly reduced the invasion of the U87-MG 
spheroids in collagen in a concentration (Figure 39) and time dependent 
manner (Figure 40) for most compounds compared to the untreated control. 
However, the compounds ICT9081, ICT9082, ICT9085, ICT9086, ICT9092, 
ICT9093, ICT9096, and ICT 9097 showed a minor effect on the invasion of the 
U87-MG spheroids in collagen compared to the untreated controls (Figure 39, 
Figure 40). A summary of the effects of the ICT compounds on the invasion of 
U87-MG spheroids in collagen is demonstrated in (Table5).  
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Table 5: demonstration of the ICT compounds effect on the invasion of the 
U87-mG spheroids 
The compound Concentration Effect  Level of 
significance  
ICT9072, 
ICT9073  
ICT9055 
100 nM and 
10 uM 
complete inhibition 
of  spheroids 
invasion   
p value < 0.01 
ICT9086 10 µM Slight inhibition of 
spheroids invasion  
p value < 0.05 
ICT9086 10 µM No inhibition of 
spheroids invasion  
p value < 0.05 
ICT9094 
 
10 µM moderate inhibition 
of spheroids 
invasion 
p value < 0.05 
ICT9084 10 µM complete inhibition 
of  spheroids 
invasion   
p value < 0.05 
ICT9084 100 nM Slight inhibition of 
spheroids invasion   
p value < 0.01 
ICT9088 10 µM, 100 nM complete inhibition 
of  spheroids 
invasion   
p value < 0.01 
p value < 0.05 for 
100 nM 
 ICT9091 100 nM Slight inhibition of 
spheroids invasion   
p value < 0.05 
ICT9091 10 µM moderate inhibition 
of  spheroids 
invasion   
p value < 0.01 
ICT9085 100 nM Slight inhibition of 
spheroids invasion   
p value < 0.05 
ICT9085 10 µM moderate inhibition 
of  spheroids 
invasion   
p value < 0.01 
ICT9093 10 µM complete inhibition 
of spheroids 
invasion   
p value < 0.01 
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ICT9093 100 nM moderate inhibition 
of spheroids 
invasion   
p value < 0.01 
ICT9081 100 nM No inhibition of 
spheroids invasion 
 
ICT9081 10 µM moderate inhibition 
of spheroids 
invasion 
p value < 0.01 
ICT9095 100 nM moderate inhibition 
of spheroids 
invasion 
p value < 0.01 
ICT9095 10 µM complete inhibition 
of spheroids 
invasion 
p value < 0.01 
ICT9082 100 nM and 10 
µM 
Moderate inhibition 
of spheroids 
invasion. No 
concentration 
dependent effect 
p value < 0.01 
ICT9097 100 nM No inhibition of 
spheroids invasion 
 
ICT9097 10 µM moderate inhibition 
of spheroids 
invasion 
p value < 0.05 
ICT9087 10 µM moderate inhibition 
of spheroids 
invasion 
p value < 0.05 
ICT9087 100 nM Slight inhibition of 
spheroids invasion  
 
ICT9092 100 nM and 10 
µM 
Slight inhibition of 
spheroids invasion   
p value < 0.05 for 
100 nM  
p value < 0.01 for 
10 µM  
ICT9096 100 nM and 10 
µM 
Slight inhibition of 
spheroids invasion   
p value < 0.05 
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Figure 39: summary of the assessment of novel potential β3 antagonists in the 3D spheroid invasion assay. Invasion was assessed at 
day 4 following treatment. Statistically significant inhibition of U87-MG cell invasion in a dose dependent manner is seen for some 
compounds with most have p <0.05 including ICT 9087, ICT 9094, ICT 9072, ICT 9073, ICT 9055, ICT 9091, ICT 9088 and ICT9095 
(n=3). 
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The figure is continued on the next page. 
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Figure 40 Effect of treating the U87-MG spheroids with the ICT compounds 
over time. Significant reduction in the invasion resulted after treatment of the 
U87-MG spheroids with the compounds ICT9055, ICT9072, ICT9073, ICT9087, 
ICT9088, ICT9091, ICT9094, and ICT9095 in a concentration and time 
dependent manner **p<0.01, *p<0.05 (n=3).  
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24hr 72hr
control 100nM 10 µM control 100nM 10 µM
Figure 41 ICT9072 reduced U87-MG invasion in collagen in a time and 
concentration dependent manner. ImageJ analyzed images show that the 
ICT9072 treated spheroids were less able to invade compared to the control 
untreated spheroids. White arrows show invading cells. Scale bar: 100 µm. 
Images shown are representative of 3 independent repeats. 
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Control 10 µM100nM Control 10 µM100nM
72 hr24 hr
Figure 42 ICT9096 showed no effect on the invasion of U87-MG in collagen. 
ImageJ analyzed images show that the invasion of the spheroids treated with 
ICT9096 was comparable to the control untreated spheroids. White arrows 
show invading cells. Scale bar: 100 µm. Images shown are representative of 3 
independent repeats. 
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3.3.5 Do the ICT compounds reversibly bind to their receptors? 
In order to determine whether the binding of the ICT compounds to the integrin 
receptors is reversible or they bind irreversibly as the reversibility is considered 
as important property of the pharmacological compounds. ICT9073 was 
selected as it was demonstrated above to give significant inhibition of the 
invasion of the U87-MG spheroids in collagen. After formation of the U87-MG 
spheroids in the hanging drops, the spheroids were treated with different 
concentrations of ICT9073 for 24 hours whilst they were in the hanging drops 
then washed twice with complete media before they were transferred to 
collagen to make sure that there was no traces of compound left in the media 
surrounding the spheroids. The treated U87-MG spheroids were then observed 
for 4 days. The fact that there was no difference seen to the control in terms of 
inhibition suggests that the binding was reversible and the effect was lost once 
the compound was removed (see Figure 43).  
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Figure 43 ICT9073 binds reversibly to its receptors in the U87-MG spheroids. 
Scale bar: 100 µm (A). The U87-MG spheroids behaved in comparable way to 
the control after removing the ICT9073 indicating that the compound reversibly 
binds to its receptors compared to significant inhibition of invasion when the 
spheroids were exposed to the ICT9073 throughout the experiment (B). N=3. 
**p<0.01, *p<0.05 
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3.3.6 Comparing the ability of the U87-MG cells to invade in the 3D 
invasion model with their invasion in 2D transwell invasion model. 
In an aim to validate the results of using 3D spheroid invasion assay to test the 
effect of the cRGDfV on the invasion of U87-MG cells, the transwell 2D invasion 
assay was optimised and used to test the effect of cRGDfV on the invasion of a 
monolayer of U87-MG cells. The results of both assays were plotted and the 
data was compared.  
3.3.6.1 Optimization of the 2D transwell invasion model to test the 
invasion of the U87-MG cells  
First the seeding density of the U87-MG cells was determined through testing 
two different seeding densities including 5×104 cells/well and 5×105 cells/well. 
The cells were starved for 4 hours under serum-free medium media before 
seeding them in the transwells. The cells showed high ability to invade through 
Matrigel coated transwells. The seeding density 5×104 cell/well was selected to 
be the better density and used for further work, because it resulted in clear 
difference between the invasions towards different concentrations of FCS as a 
chemo attractant compared to the other seeding density (see Figure 44).  
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Figure 44 U87-MG cells invasion through Matrigel coated transwells. Scale bar: 100 µm. Two seeding densities were tested 
including. (A) 5×104 cell/well and (B) 1×105 cell/well to determine the best one to be used for further studies. The seeding 
density 5×104 cell/well was selected to be the optimum density, because a clear difference was detected between the invasion 
towards the 10% FCS media, 1% FCS media and Hanks balanced solution. **p<0.01, *p<0.05 (n=3).
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3.3.6.2 The effect of cRGDfV on the ability of the U87-MG cells to invade in 
2D transwell invasion model compared to its effect on their invasion in 
the 3D invasion model. 
Different concentrations of cRGDfV were used; the IC50 as obtained in the MTT 
cytotoxicity assay (Figure 38), 100 fold less than the IC50 and 10 fold above the 
IC50. cRGDfV showed a concentration dependent reduction in the U87-MG cell 
invasion through Matrigel coated transwells towards 10 % FCS compared to the 
control untreated U87-MG cells (see Figure 45).  
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Figure 45 cRGDfV reduces cell invasion in a concentration dependent manner. 
(A) The pictures of the transwells after invasion of the untreated U87-MG cells 
towards different chemo attractants including 1%FCS, 10% FCS and hanks 
balanced solution Scale bar: 100 µM. (B) Graphic representation shows a 
comparison between the invasion through transwells for the treated U87-MG 
cells and untreated controls.**p<0.01, *p<0.05 (n=3). 
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To compare the effect of cRGDfV on the invasion of the U87-MG cells through 
Matrigel coated 2D transwells with its effect on the invasion of U87-MG cells 
from 3D spheroids in collagen, the results of the two assays were plotted and 
the data was compared that is stating the obvious. cRGDfV showed a 
significantly more potent effect on the invasion of U87-MG cells through Matrigel 
coated 2D transwells compared to its effect on the invasion of U87-MG cells 
from spheroids in collagen (Figure 46)  
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Figure 46 Comparison between the invasion of the U87-MG cells in the 2D 
transwell assay and there invasion in 3D spheroid assay under the effect of 
cRGDfV. Graphical presentation showing more potent effect for cRGDfV on the 
invasion of U87-MG cells through Matrigel coated 2D transwells compared to 
its effect on the invasion of U87-MG cells in 3D spheroid invasion assay. The 
chart shows a decrease in the percentage of invasion from 100% for the control 
to 7.2% for the cells treated with 1 mM of cRGDfV in the 2D transwells, 
compared to a much lower decrease in the invasion from 100% for the control 
to 67% for the spheroids treated with 100 mM of cRGDfV in the 3D spheroid 
invasion assay. 2D transwell controls of untreated U87-MG cells invading 
towards 10% FCS as chemoattractant and the 3D control was the untreated 
spheroids **p<0.01, *p<0.05 (n=3). 
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3.3.6.3 Further comparison of the 2 assays using the novel β3 antagonists 
For further comparison of the two assays, two of the novel compounds 
screened in the 3D assay were selected; the first was ICT9073 as it was 
among the compounds that were efficient in inhibiting the invasion of the U87-
MG spheroids in collagen, whilst the second, ICT9085 showed less activity in 
inhibiting the invasion of the U87-MG spheroids. 
A range of concentrations of ICT9073 (Figure 47) and ICT9085 (Figure 48) 
were used, the IC50, 100-fold less than the IC50 and 100-fold above the IC50. 
ICT9073 (Figure 47) and ICT9085 (Figure 48) demonstrated a concentration 
dependent reduction in U87-MG cell invasion through the Matrigel coated 
transwells towards 10 % FCS containing media, as a chemoattractant, 
compared to the untreated control U87-MG cells  
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Figure 47 ICT9073 reduces the U87-MG cells invasion in a concentration 
dependent manner. Scale bar: 100 µM. (A) The control represents the 
transwells after invasion of the untreated U87-MG cells towards different 10% 
FCS. The U87-MG cells were treated with different concentrations of ICT9073 
and the invasion was investigated towards 10% FCS as chemo attractant. (B) 
Graphical representation of the data showing a comparison between the 
invasions of the ICT9073 treated U87-MG cells and untreated controls 
**p<0.01, *p<0.05 (n=3). 
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Figure 48 ICT9085 reduces cell invasion in a concentration dependent manner 
using the 2D invasion assay Scale bar: 100 µM. (A) the transwells after 
invasion of the untreated U87-MG cells towards different chemo attractants 
including 1%FCS, 10% FCS and hanks balanced solution. The U87-MG cells 
were treated with different concentrations of ICT9085 and the invasion was 
investigated towards 10% FCS as chemoattractant. (B) Graphical 
representation of the data showing a comparison between the invasions of the 
ICT9085 treated U87-MG cells and untreated controls **p<0.01, *p<0.05 (n=3). 
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In order to compare the effect of the ICT9073 on the invasion of the U87-MG 
cells through Matrigel coated 2D transwells with its effect on the invasion of 
U87-MG spheroids in collagen, the results of the two assays were plotted and 
by comparing the data, there was more potent effect for ICT9073 on the 
invasion of U87-MG cells through Matrigel coated 2D transwells compared to 
the noticed effect on the invasion of U87-MG spheroids in collagen (Figure 49)  
In an aim to compare the effect of the ICT9085 on the invasion of the U87-MG 
cells through Matrigel coated 2D transwells with its effect on the invasion of 
U87-MG spheroids in collagen, the results of the two assays were plotted and 
compared together. ICT9085 showed a moderate effect on the invasion of the 
U87-MG spheroids in collagen compared to a more potent effect on the 
invasion of U87-MG cells through Matrigel coated 2D transwells. This result 
indicates the possibility of presence of delivery problems with the compound 
ICT9085 rather than structural problems (Figure 49). 
 
 
. 
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Figure 49: Comparison between the invasion of the U87-MG cells in 2D transwell assay and their invasion in 3D spheroid assay under 
the effect of ICT9073 and ICT9085. Different sets of concentrations of the two compounds were tested using the 2D assay to be 
comparable to the previously tested concentrations using the 3D assay. The control in the 2D transwell assay was the untreated U87-
MG cells invading towards 10% FCS. The control in the 3D invasion assay was the untreated U87-MG spheroids. The graphic 
presentation of the data showed a more potent effect for ICT9073 and ICT9085 on the invasion of U87-MG cells through Matrigel coated 
2D transwells compared to its effect on the invasion of U87-MG cells in 3D spheroid invasion assay **p<0.01, *p<0.05. (n=3).
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3.4 Discussion 
In this chapter, the 3D spheroid invasion assay was used to evaluate a number 
of novel small molecular β3 antagonists developed in-house at the ICT. 
Although there were very little differences in cytotoxicity between the 
compounds, there were significant differences in their antagonistic capabilities. 
The novel compounds; ICT 9087, ICT 9094, ICT 9072, ICT 9073, ICT 9055, ICT 
9091, ICT 9088 and ICT9095 showed a dose and time dependent reduction in 
U87-MG spheroid invasion in collagen. On the other hand, the compounds 
ICT9081, ICT9082, ICT9086, ICT9092 ICT9096, ICT 9097, ICT 9085, and ICT 
9093 showed a minor effect on the invasion of the U87-MG spheroids in 
collagen. Only αvβ3 integrin antagonism was observed as the U87-MG cells 
don’t express αIIbβ3 integrin, raising the need to have dual αvβ3 and αIIbβ3 
integrin expressing cell line and this is the subject which will be addressed in 
the next chapter. 
By examining the structure-activity relationship of the compounds tested. A 
tetrahydronaphthyridine functional group, in addition to the cis conformation 
were common features for most of the active compounds including ICT 9087, 
ICT 9094, ICT 9055, ICT 9091, ICT 9088.  
In contrast, most of the compounds which were found to have minor activity had 
an unsaturated naphthyridine in their structure including ICT9081, ICT9082, 
ICT9096, ICT 9097, and ICT 9093.  
Although the compound ICT9086 had the tetrahydronaphthyridine group which 
is generally associated with activity, the Trans conformation of the structure 
could be the reason behind the lower activity of this compound. However, by 
comparing ICT9094 and ICT9095 the Trans compound is more active than the 
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corresponding cis one indicating that the SAR of this set of compounds is not 
straightforward.  
The high activity which characterised the compounds ICT 9072 and ICT 9073 
could be associated with the presence of the amino-pyridine group. 
The compound ICT9092 showed minor activity compared to ICT 9055 although 
the absolute configuration of the chiral centre is the same in both compounds. 
The difference is that the ICT9092 has a shorter carbon chain between the Arg 
mimetic and cyclobutane and a longer carbon chain in the Asp mimetic 
concluding that the shorter linker to the tetrahydronaphthyridine is not tolerated. 
The reversibility is among the basic important properties of the pharmacological 
compounds which should be taken in consideration (Udenfriend et al., 1958, 
Caille et al., 1996, Serafimova et al., 2012, Blazer et al., 2010). The reversibility 
of the pharmacological compounds is important as it prevents the permanent 
binding of the compound to the receptor and so prevents unwanted permanent 
blocking of the receptor. From further studies carried out in this chapter with one 
of the most active compounds from the initial screen, it was seen that the action 
of the compound was reversible, thus this compound is interesting to progress 
to further studies. 
The 2D transwell invasion assay was selected to retest some of the compounds 
as a way to compare the results of the 3D invasion assay with the more 
commonly used 2D assay. In relation to the dose response effect, both the 
spheroid invasion assay and the transwell assays were comparable, although 
the transwell assay demonstrated a more potent effect. This result could be 
because the spheroid invasion assay may be more representative to the in vivo 
situation due to the presence of collagen which separates the compound and 
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the cells compared to direct contact between the cells and the compound in the 
transwell assay. The presence of collagen mimics the extracellular matrix in 
vivo and forms as a physical barrier leading to a more realistic situation (De 
Wever et al., 2004) compared to the transwells assay in which the cells are 
mixed as a suspension with the compound (Valster et al., 2005). Furthermore, 
the conformation of the U87-MG cells in a spheroid means that not all the cells 
are directly exposed to the compound and again contributes to explaining the 
higher resistance to treatment observed in the 3D invasion assay (de Sampaio 
et al., 2012) compared to the 2D transwells in which the tumour cells present as 
suspension in direct contact with the treatment compound (Moutasim et al., 
2011). As a result of this, the spheroid invasion assay could be considered 
more reflective to the in vivo/clinical situation (Cheng et al., 2014) where a drug 
must penetrate through layers of cells in the tumour tissue. The comparison 
between the 3D spheroid assay and the 2D transwell assay compared to the in 
vivo situation has been previously used as a tool for real and more detailed 
understanding of the compounds mechanisms of action. The same 
concentrations of GSK-3 inhibitors were able to cause higher level of inhibition 
of U87-MG cells invasion in the transwells compared to the 3D spheroid assay 
(Williams et al, 2011).  
Studying the efficacy of a compound by two different methods such as the 3D 
invasion assay and the 2D transwells assay could help in characterizing a 
problem, if present, associated with compound penetration. For example the 
compound ICT9085 didn’t demonstrate a high effect when it was tested by the 
3D invasion assay but in contrary it gave a high efficacy when tested by the 2D 
assay which could indicate that ICT9085 does not penetrate tissue well, rather 
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than having low affinity for the target integrin. Consequently, the spheroid 
invasion assay could be able to give an idea about the problems associated 
with drug delivery and so could be considered closer to what could be seen in 
the clinic with this compound.  
3.5 Conclusion  
In conclusion this chapter has demonstrated encouraging structure-related 
activity for a group of novel small molecule β3 integrin antagonists using the 3D 
spheroid invasion assay indicating that future work is warranted on this group of 
compounds. αvβ3 integrin antagonism was observed as the U87-MG cells don’t 
express αIIbβ3 integrin, raising the need to have dual αvβ3 and αIIbβ3 integrin 
expressing cell line and this is the subject that will be addressed in the next 
chapter. Furthermore, this chapter has demonstrated the importance of assay 
selection for a specific parameter, with results with potentially more relevance to 
the clinical situation with the 3D spheroid invasion assay compared to the 2D 
transwell assay. 
 
 
 
 
 
 
 
 
 
 
146 
 
4. Chapter 4 Development of αIIbβ3 integrin expressing cell line models 
4.1 Introduction 
As has been reviewed previously in this thesis, the importance of the integrins 
arises from their involvement in many signalling pathways controlling diverse 
biological processes such as angiogenesis, cellular adhesion, motility, invasion, 
migration, proliferation and apoptosis (Desgrosellier and Cheresh, 2010); 
(Varner and Cheresh, 1996). Amongst the important properties of integrins is 
regulating each other’s function and redundancy through a complex network of 
cross talk between the different integrin types (Wang et al., 2014). 
Consequently targeting the integrins as a therapeutic strategy involves targeting 
more than one integrin because of this interaction between the different 
integrins (Engebraaten et al., 2009); (Mor-Cohen et al., 2014); (Diaz-Gonzalez 
et al., 1996); (Sheldrake and Patterson, 2014). The ICT is developing a group of 
novel new αIIbβ3 and αvβ3 integrin dual antagonists and as part of this project a 
key aim is to develop models expressing these integrins in order to evaluate the 
effects of the antagonists on the invasion of cells carrying these target integrins. 
The importance of αvβ3 arises from its involvement in the tumourgenesis of 
many tumours in addition to its effect in activation of endothelial cells leading to 
activating angiogenesis (Liu et al., 2008); (Brooks et al., 1995). The importance 
of the αIIbβ3 integrin arises from its expression on the platelets making it a very 
important part of the metastatic process in addition to its expression in some 
kinds of tumours such as prostate carcinoma and aggressive metastatic 
melanoma (Engebraaten et al., 2009, Tuszynski et al., 1989, PUERSCHEL et 
al., 1996, Trikha et al., 1998, Millard et al., 2011b, Hynes, 2002, Gay and 
Felding-Habermann, 2011). According to previous published reports and work 
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done in-house, the expression of the αIIbβ3 integrin in tumour cell lines is seen to 
be much lower than αvβ3 integrin. In addition, the expression of αIIbβ3 integrin is 
found to decrease with culturing in vitro (Honn et al., 1992), due mostly to loss 
of the host specific factors during continuous passages (Chen et al., 1997). 
Consequently, having the αIIbβ3 integrin in an in vitro model, either for purposes 
of therapeutic targeting or for studying the signaling pathways involved for this 
integrin, needs permanent transfection, of the cells under study, with the αIIbβ3 
integrin. The full length of the αIIb integrin subunit as well as the β3 subunit has 
been cloned into mammalian expression vectors by many authors and the 
cloned vectors used to transfect different kinds of tumour cell lines (Trikha et al., 
2002a), (Ren et al., 2009), (Liu et al., 2007).  
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4.1.2 Aims and objectives  
Thus the main aim of this chapter is to develop cell lines that express both αIIbβ3 
and αvβ3 integrins in order to screen for dual integrin antagonism in assays 
including the developed 3D invasion assay. Figure 50 shows a flow chart of the 
overall methodology for the work in this chapter. 
The aims will be achieved by the following objectives: 
1. Cloning of the αIIb integrin subunit into a mammalian expression vector 
2. Using the cloned vector to transfect either a β3 integrin expressing cell 
line to produce a cell line that expresses functional αIIbβ3 integrin or to 
transfect into a non β3 expressing cell line, to which a β3 integrin could 
also be transfected.. 
3. Evaluation of the success of the transfection by PCR, 
immunofluorescence and Western blotting.  
 
149 
 
Conformation of the 
transfection success 
PCRImmunofluorescenceWestern blotting  
Cloning  αIIb integrin into mammalian vector
Transfect
Cell line that express β3 integrin Cell line doesn’t express β3 integrin
Transfect with  β3 expressing vector. 
αIIbβ3 integrin expressing cell line 
Or 
First option Second option 
Figure 50 Schematic representation of the overall methodology followed in this 
chapter.  
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4.2 Materials and methods 
All tissue culture plastics and reagents were obtained from Sigma-Aldrich (Poole, 
UK) unless otherwise specified. The human bladder cancer cell line EJ-138 and 
glioma cell line U87-MG were obtained from the European Collection of Cell 
Cultures ((ECACC), Salisbury, Wiltshire, England). The glioblastoma cell line 
LN229, the leukaemia cell line K562 and the human umbilical vein cell line 
HUVECs were all obtained from American Type Culture Collection ((ATCC), LGC 
Standards, UK). All molecular biology reagents used were obtained from Sigma-
Aldrich (Poole, UK) unless otherwise specified. The Primers IIb-3 HindIII For, IIb-
13 HindIII For, GPIIb HindIII For, GPIIb 748F, GPIIb 2400R, and GPIIb EcoR1 
Rev were obtained from Invitrogen. The vector PCR-4-TOPO was obtained from 
Life Technologies. The mammalian expression vector pcDNA3 was obtained 
from Invitrogen. 
4.2.1 Preparation of the αIIb integrin subunit 
Two sources for the αIIb clone were used. The first source was the cell lines 
LN229 or K562. The second source was the bacterial vector PCR-4-TOPO (Life 
Technologies. catalogue number IRCMp5012E0219D). The full length of the αIIb 
integrin subunit was cloned in the mammalian expression vector pcDNA3 
(Invitrogen, cat number: A-150228). 
4.2.1.1 Amplification of the αIIb integrin subunit from the human cell lines 
LN229 or K562. 
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Previous work at the ICT (M. Sutherland, personal communication) has 
identified the human cell lines HUVECs, LN229 and K562 as a good source for 
the αIIb integrin subunit for cloning. As described below, RNA was extracted 
then converted into cDNA and amplified using PCR reaction before 
confirmation through visualisation on an agarose gel.  
A specific modification was made to the published primers to ensure that the 
resulting αIIb insert could be cloned into the mammalian expression vector 
pcDNA3 which is used in our laboratories (Liu et al., 2007), (see Figure 51). 
The modification done on the primers design used was because the cloning 
site of the pcDNA3 vector does not contain a structure that fits with the 
restriction enzyme NheI that fits with the published primers, (see Figure 51). 
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Published methodology
HEL cells
RNA extraction
RT
CDNA
PCR
GATGCTAGCCTGGGAGGTTGTGGAAGAAGGAAG
GCTAAGCTTGTGTAGGCTGCACCATCACTCCC
PCR product
GPIIb NheI For
GPIIb HindIII rev
Primers used 
 
GATAAGCTTCTGGGAGGTTGTGGAAGA
AGGAAG
GPIIb HindIII For  9external 
primer)
CAGAGCCTCTCCTTTGACTC GPiib 748F ( internal 
primer)
CTCCCTCTCACCTTCTTCTG GPiib 2400R(internal 
primer)
GCTGAATTCGTGTAGGCTGCACCATCA
CTCCC
GPIIb EcoR1 Rev (external 
primer)
HUVEC
LN229
K562 
RNA extraction
RT
C DNA
PCR
PCR
Transfect into
cells 
Study methodology
Primers used
Figure 51 U87-MG Transfection with αIIb expressing gene. (A) The published 
methodology in which the pcDNA3.1 vector was used. (B) The used 
methodology in which the pcDNA3 vector was used with the modifications done 
on the primers to fit with the cloning site of the pcDNA3 vector. 
 
 
A 
B 
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4.2.1.1.1 RNA extraction from HUVECs, LN229 or K562 cell lines 
The RNA extraction was performed using RNeasy Mini Kit, Qiagen according to 
the manufacturer’s instructions as follows. LN229 or K562 cell lines were grown 
in suspension (not more than 1 x 107 cells/ flask). LN229 and K562 cell lines 
were maintained in RPMI 1640 medium, supplemented with 10% foetal bovine 
serum, 2 mM L-glutamine, and 1 mM sodium pyruvate. HUVECs cell line was 
maintained in EBM-2 Basal Medium (Lonza) supplemented with single Quots 
kit growth factors (Lonza). All cell lines were maintained at 37°C in a 5% CO2 
humidified atmosphere. The number of cells was determined and centrifuged 
for 5 min at 1000 rpm then all supernatant was removed carefully by aspiration. 
The cell pellet was vortexed and 350 μL of buffer RLT were added. The cell 
lysate was pipetted directly into a QIA shredder spin column, placed in a 2 ml 
collection tube and centrifuged for 2 min at full speed.1 volume of 70% ethanol 
was added to the homogenized lysate, and mixed well by pipetting. 
Up to 700 μL of the sample, including any precipitate that may have formed 
was transferred to the used RNeasy spin column and centrifuged for 15 sec at 
10,000 rpm. The flow-through was discarded. 
700 μL buffer RW1 was added to the RNeasy spin column and centrifuged for 
15 sec at 10,000 rpm to wash the spin column membrane. The flow-through 
was discarded. 500 μL Buffer RPE were added to the RNeasy spin column and 
centrifuged for 15 sec at 10,000 rpm with the flow-through discarded. This step 
was repeated twice to wash the spin column membrane.  
The RNeasy spin column was placed into a new 1.5 ml collection tube and 30–
50 μL RNase-free water were added directly to the spin column membrane. 
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The lid was gently closed and the RNase-free water was centrifuged for 1 min 
at 8000 x g (10,000 rpm) to elute the RNA. 
4.2.1.1.2 Reverse transcription-polymerase chain reaction (RT-PCR). 
The Reverse transcription-polymerase chain reaction was carried out using a 
Revert Aid H Minus First Strand cDNA Synthesis Kit (Thermo Scientific) 
according to the manufacturer’s instructions and as described in (Abdallah et 
al., 2005), (Torres et al., 2008). 
Briefly, 0.5 μg of poly (A) mRNA, 1 μL oligo (dT) 18 primer and nuclease free 
water to final of volume 12 μL were heated to 65°C for 5 minutes then chilled in 
ice. 4 μL of 5X reaction buffer, 1 μL RiboLock RNase Inhibitor (20 unit/μL), 2 μL 
of 10 mM dNTP Mix and 1 μL of RevertAid H Minus M-MuLV Reverse 
Transcriptase (200 unit/μL) were added to the reaction tube, mixed, centrifuged 
and incubated for 60 min at 42 °C. The reaction was terminated by heating to 
70°C for 5 min then stored at -70 °C. 
4.2.1.1.3 Polymerase chain reaction (PCR). 
The PCR was performed according to manufacturer’s instructions using an 
RNeasy Mini Kit (QIAGEN). Briefly; the reaction mix was prepared from 3 µL of 
the reverse transcription reaction product plus 0.2 µL of Taq DNA Polymerase 
(250 U® QIAGEN), 2μL of 10X buffer, 0.4 μL of 10 mm dNTPs, 1 μL of each of 
the reverse and forward primers (see Table 5). The reaction was performed 
under conditions included 94°C for 3 min, then 35 cycles of 94°C for 30 sec, 
58°C for 30 sec, 72°C for 3 min and 30 sec; finally 5 min at 72°C for the final 
extension. 
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4.2.1.1.4 Gel electrophoreses 
A solution of 1X TAE buffer was prepared by diluting one part of 5X solution in 
four parts of distilled water. Agarose gel at a concentration of 1% was prepared 
by dissolving 0.5 gram of agarose in 50 ml of 1X TBE buffer by boiling the 
solution. After the agarose was completely dissolved, it was cooled to 50°C and 
2.5 µL of 10 mg/ml ethidium bromide stock was added. 5 µL of PCR product 
was mixed with 5 μL of loading dye and loaded on the gel as a sample. 3 µl of 
1000 bp DNA ladder was mixed with 3 µl of loading dye and loaded on gel. 
Agarose gel electrophoreses was run for 30 minutes in TAE buffer at 100V 
using horizontal electrophoresis apparatus (RAD). After the electrophoresis 
was completed the gel was visualized under ultraviolet illumination on a Bio-
Rad Molecular Imager® FX (Bio-Rad, UK) and the gel images were analysed 
using Quantity One 1-D Analysis Software (Bio-Rad, UK). 
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Table 5: The primers used 
Primer Sequence 
Primer 
name 
Comment  
ACAAGCTTAAGATGGCCAGAGCTTTGTGTC 
IIb-3 
HindIII 
For 
Different 
options for the 
forward primer 
used to amplify 
the whole αIIb 
gene 
Selected to fit 
with the 
cloning site of 
the pcDNA3 
vector  
ATAAGCTTGGAAGAAGGAAGATGGCCAGAG 
IIb-13 
HindIII 
For 
GATAAGCTTCTGGGAGGTTGTGGAAGAAGGAAG 
GPIIb 
HindIII 
For 
CAGAGCCTCTCCTTTGACTC 
GPIIb 
748F 
Used to 
amplify part of 
the αIIb gene  
Selected to 
confirm the 
success of the 
cloning  
CTCCCTCTCACCTTCTTCTG 
GPIIb 
2400R 
GCTGAATTCGTGTAGGCTGCACCATCACTCCC 
GPIIb 
EcoR1 
Rev 
Reverse 
primer  
Selected to fit 
with the 
cloning site of 
the pcDNA3 
vector 
 
4.2.1.2. Alternative source of the αIIb subunit from a commercial bacterial 
vector 
Because the different PCR trials did not result in the target product, the 
bacterial vector PCR-4-TOPO (Life Technologies, catalogue number 
IRCMp5012E0219D) was used as an alternative source for the αIIb insert which 
was cloned into the human vector pcDNA3 (Invitrogen, cat number: A-150228) 
(see Figure 52). Briefly, the PCR4-TOPO plasmid was extracted from DH5α 
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bacteria then the αIIb insert was restricted using EcoRI restriction enzyme and 
run on a gel. The work flow for preparing the αIIb subunit is demonstrated in 
Figure 53. 
αIIb expressing gene EcoR1EcoR1
Pcr4-topo contain αIIb expressing gene 
Transfect the cloned vector
into cellls
Figure 52 PCR4-TOPO plasmid was extracted from bacteria then the αIIb insert 
was restricted and cloned into pcDNA3 human plasmid which is used to 
transfect the U87-MG cells. 
 
158 
 
PCR-4-TOPO purification  from Bacteria using QIAGEN Plasmid Mini Kit
Plasmid restriction with EcoRI
Plasmid extraction from gel using Qiaquick Gel Extraction Kit
Ligation of αIIb insert with Pcdna3 vector using T4 DNA Ligase kit 
Transformation of the ligated plasmid  in JM109 competent cells
Purification of the ligated plasmid from bacteria using QIAGEN Plasmid Mini Kit
Ligated plasmid restriction with EcoRI for confirmation 
Ligated plasmid restriction with BamHI for further confirmation 
Cloned plasmid  purification using QIAGEN Plasmid Midi and Maxi Kits
The PCR confirmation
Sequencing 
Transfection
PCR-4-TOPO :  trade bacterial vector containing  the αIIb integrin insert  
Figure 53 Schematic representation for the steps followed in cloning the αIIb 
integrin subunit into the pcDNA3 mammalian expression plasmid before being 
used for further transfection trials. 
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4.2.1.2.1 Preparation of agar plates 
50 ml LB agar was made by weighing out 0.5 g NaCl, 0.5 g Tryptone, 0.25 
g Yeast Extract, 0,75g Agar and (dH2O) up to 50mL in an Erlenmeyer 
flask all from Sigma-Aldrich (Poole, UK). The whole contents were swirled 
to mix. The top of the flask was covered with aluminium foil, labelled and 
autoclaved on the liquid setting for 20 minutes at 124°C. After cooling to 
55°C, Ampicillin was added to a final concentration of 100 µg/ml. The 
plates were poured and allowed to cool then stored at 4°C until being 
used. 
4.2.1.2.2 Streaking plates  
The vector PCR-4-TOPO was purchased in a form of a stab culture of 
DH5α bacteria transfected with the vector PCR-4-TOPO. The growing 
bacteria within the stab culture were touched using a sterile pipette tip and 
ran lightly over the plate to spread the bacteria over one-third of the area 
of the plate to create the first streak. A new sterile pipette tip was passed 
through the first streak and spread over the next one-third section of the 
plate to form the second streak. A new third sterile pipette tip was passed 
through the second streak and spread the over the last one-third section 
of the plate, to create the third streak (see Figure 54). The plate was 
incubated overnight at 37°C. Single colonies appeared next day as a 
white dots growing on the solid medium.  
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Streak 1
Streak 2
Streak 3
 
Figure 54: Streaking procedure on the agar plates for the DH5α bacteria 
transfected with the vector PCR-4-TOPO. 
4.2.1.2.3 LB liquid media preparation 
50 ml LB liquid media was made by weighing out 0.5 g NaCl, 0.5 g Tryptone, 
0.25 g Yeast Extract, and adding 0.5 g NaCl etc. were dissolved in distilled 
water to a final volume of 50 ml in an Erlenmeyer from Sigma-Aldrich (Poole, 
UK). The whole contents were swirled to mix then autoclaved and allowed to 
cool to 55°C in a water bath. For the preparation of the selective LB media 
Ampicillin was added to a final concentration of 100µg/ml and stored at 4°C 
until use. 
4.2.1.2.4 Inoculating Bacteria in LB liquid media 
Using a sterile pipette tip a single colony from the streaked LB agar plate was 
touched and the tip was dropped into the liquid LB media containing the 
antibiotic and mixed gently then incubated at 37°C for 18hr while shaking. After 
incubation, the growth appeared as a cloudy haze in the media. The negative 
control of LB media containing antibiotic without inoculating bacteria was ran 
with the sample and there was no growth observed after overnight incubation.  
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4.2.1.2.5 Plasmid extraction from bacteria 
Plasmid was extracted using a QIAGEN Plasmid Mini Kit according to the 
manufacturer’s instructions. A single colony was picked from a freshly streaked 
selective plate and inoculated into 5 ml LB starter medium and Incubated for 
approximately 8 h at 37°C with vigorous shaking (300 rpm). 5 μL of the starter 
culture was diluted into 3 ml selective LB medium and grown at 37°C overnight 
with vigorous shaking (300 rpm). The growing bacterial cells were harvested by 
centrifugation (6000 x g for 15 min) at 4°C and suspended in 0.3 ml of kit Buffer 
P1. Then 0.3 ml of kit Buffer P2 was added and mixed thoroughly then 
incubated for 5 min at room temperature (15–25°C). 0.3 ml of chilled kit Buffer 
P3 was added, mixed and incubated on ice for 5 min. The mixture was 
centrifuged at maximum speed in a micro centrifuge for 10 min. The 
supernatant containing the plasmid DNA was removed. 700 µL volume of 
isopropanol was added to the supernatant and incubated at room temperature 
for 10 minutes and then centrifuged at 12,000xg for 10 minutes. The 
supernatant was removed and the DNA pellet was washed with 500 μL of 70% 
ethanol for 10 minutes then the ethanol was carefully poured of and the DNA 
was solved by adding 40 μL water. The plasmid concentration was determined 
by Nano drop 1000 spectrophotometer (Thermo Scientific) and was found to be 
2.4μg/μL. 
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4.2.2 Cloning  
4.2.2.1 Isolation of the αIIb subunit from the vector PCR-4-TOPO 
The isolated plasmid PCR-4-TOPO was restricted with plasmid restriction 
enzyme EcoRI (catalogue number R0101L, New England Bio labs) according 
to the manufacturer’s instructions. Briefly, 20 units of the enzyme EcoRI were 
added to 1 μg of the extracted plasmid PCR-4-TOPO and mixed with 1 μL of 
10X EcoRI buffer (catalogue number R0101L, New England Bio labs) then 
incubated overnight at 37°C in 10 μL reaction volume (see Figure 55). The 
restricted plasmid was loaded on a 1% agarose gel and ran for an hour on 90 
volts using Bio-Rad gel apparatus (Bio-Rad, UK).  
αIIb expressing gene EcoR1EcoR1
3
2
4
1
αIIb insert 
gel 
Cut
piece
of gel Gel  
extractio
n
Figure 55 the PCR4-TOPO plasmid containing the αIIb expressing gene was restricted 
with the EcoRI restriction enzyme (1) and loaded on gel (2) then the αIIb insert was 
extracted from gel (3) and loaded on gel again to verify the results (4).  
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4.2.2.2 αIIb subunit extraction from gel 
The αIIb DNA fragment was extracted from the gel using QIAquick Gel 
Extraction Kit (Qiagen, catalogue number28704) according to the 
manufacturer’s protocol (see Figure 55). Briefly, the αIIb DNA fragment was 
excised from the agarose gel with a clean, sharp scalpel. The gel slice was 
weighed in a tube and was found to be 0.55 g. 1650 μL of Buffer QG was 
added to the 0.55 g gel slice (100 μL buffer for every 100 mg of gel and 
incubated at 50°C for 10 min until the gel slice had completely dissolved). 
During the incubation time the tube was vortexed every 2–3 min until the gel 
slice has dissolved completely and the colour changed to yellow. The QIAquick 
spin column was placed in the 2 ml collection tube provided in the kit. The DNA 
was applied to the QIAquick column and centrifuged for 1 min. The flow-
through was discarded and placed QIAquick column in the same collection 
tube. The DNA was eluted by adding 50 μL of water to the centre of the 
QIAquick membrane and the column was centrifuged for 1 min. The DNA 
concentration was determined using Nano drop 1000 spectrophotometer 
(Thermo Scientific) and was found to be 37.4ng/μL. 100ng of the DNA was 
loaded on 0.7% agarose gel and ran for an hour on 90 volts using Bio-Rad gel 
apparatus (Bio-Rad, UK) to confirm the results of the gel extraction.  
4.2.2.3 Preparation of the pcDNA3 vector for cloning 
The pcDNA3 plasmid was restricted with the restriction enzyme EcoRI 
(catalogue number R0101L, New England Bio labs) according to 
manufacturer’s instructions. Briefly, 20 units of the enzyme EcoRI were added 
to 1 μg of the pcDNA3 plasmid vector and mixed with 1 μL of 10Xbuffer then 
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incubated over night at 37°C in 10 μL reaction volume. The restricted plasmid 
was treated with alkaline phosphatase, calf intestinal ((CIP), bio labs, catalogue 
number SM0290S). Briefly 0.5 μg DNA was suspended in 10 μL of 1X NE 
Buffer and 0.25 units of CIP were added and incubated for 60 minutes at 37°C. 
The treated pcDNA3 vector was loaded on 0.7% agarose gel and ran for an 
hour on 90 volts using Bio-Rad gel apparatus (Bio-Rad, UK) to confirm that the 
plasmid has been changed into a straight DNA strand.  
4.2.2.4 αIIb subunit and pcDNA3 vector ligation 
The extracted αIIb subunit and the CIP treated pcDNA3 vector were ligated 
using a T4 DNA Ligase Ligation Kit (Bio labs, catalogue number M0202) 
according to manufacturer’s instructions. Briefly, 2 μL of 10X T4 DNA Ligase 
Buffer, 50 ng of pcDNA3 vector DNA, 50 ng of the αIIb insert, 1 μL of T4 DNA 
Ligase, and up to 20 μL nuclease-free water were set up in a micro-centrifuge 
tube and gently mixed by pipetting. The mixture then was incubated at 16°C 
overnight then chilled on ice for the transformation reaction (see Figure 56). 
4.2.2.5 Plasmid Transformation in JM109 competent bacterial cells 
The purified plasmid was transformed into JM109 competent cells (Stratagene, 
UK, Catalogue number 200235) according to manufacturers’ protocol. Briefly, 
15 ml BD Falcon polypropylene round-bottom tube pre-chilled on ice. SOC 
medium was preheated to 42°C. JM109 competent cells were thawed on ice. 
100 μL of the thawed cells was added into the pre-chilled tube. 0.8 μL of β-
mercaptoethanol was added to the cells. The tube was swirled gently and the 
cells were incubated on ice for 10 minutes with continuous swirling every 2 
minutes. 50 ng of the ligated vector was added to the competent cells tube and 
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swirled gently. The tubes were incubated on ice for 30 minutes then the tube 
was heated in a 42°C water bath for 45 seconds. The tube was then incubated 
on ice for 2 minutes. 0.9 ml of preheated (42°C) SOC medium was added to 
the tube containing the competent cells and the ligated vector and incubated at 
37°C for 1 hour with shaking (225-250 rpm). 200 μL of the transformation 
mixture were placed on LB agar plates containing Ampicillin and incubated at 
37°C overnight. Next day the bacterial growth was observed and the bacteria 
were streaked as described in 4.2.1.2.2. After observing single colonies in the 
streaked plate, 6 different single colonies were picked and inculcated in 6 
different tubes containing 3 ml of LB media containing antibiotic in each tube as 
described in 4.2.1.2.4. After overnight growth observation the plasmid was 
extracted from the bacteria in each tube using the QIAGEN Plasmid Mini Kit as 
described in 4.2.1.2.5. The resulting extracted plasmids were restricted using 
the restriction enzyme EcoRI (catalogue number R0101L, New England Bio-
labs) according to what described in 4.2.2.3. The plasmid extracted from the 
bacteria with the most promising results was the one which could produce the 
right size bands on gel after restriction reaction and so was selected for 
completing the rest of the work (see Figure 56). 
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αIIb expressing gene EcoR1EcoR1
pcDNA3 EcoR1EcoR1
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Figure 56 The process of cloning the αIIb subunit in to the pcDNA3 plasmid starting by 
the ligation step (1) then the transformation of the cloned plasmid into JM109 
competent cells (2).The plasmid was extracted from different bacterial colonies (3) and 
loaded on gel to find sample which give the right sized isolated bands (4).  
4.2.2.6 Further confirmation using the BamHI restriction enzyme 
As long as the restriction enzyme EcoR1 was used to restrict both the αIIb 
subunit and the pcDNA3 vector, the αIIb subunit could be cloned into the vector 
in either the right or wrong direction. To confirm that the cloning was done 
successfully in the right direction, the restriction enzyme BamHI was used. The 
pcDNA3 and the αIIb subunit contain sequences that could be restricted by the 
BamHI restriction enzyme. The cloning would be wrong if the constructs after 
restriction were 8.1 kb and 500 bp bands. However, the cloning would be right 
if the constructs after restriction were 5.8 kb and 2.7 kb (see Figure 57).  
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results on gel
Figure 57 the plasmid restriction with BamHI for further confirmation of the success of 
the cloning using the BamHI restriction enzyme. 
 
The extracted plasmid was restricted using the BamHI restriction enzyme 
(catalogue number R0136S, New England Bio labs) according to 
manufacturer’s instructions. Briefly, 20 units of the enzyme BamHI were added 
to 1 μg of the extracted cloned vector and mixed with 1 μL of the 10 × buffer 
then incubated over night at 37°C in 10 μL reaction volume. The restricted 
plasmid was loaded on 1% agarose gel and ran for an hour on 90 volts using 
Bio-Rad gel apparatus (Bio-Rad, UK). 
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4.2.2.7 Further confirmation of the success of cloning using PCR 
The PCR was performed using Taq DNA Polymerase (250 U®, QIAGEN) 
according to manufacturer’s instructions briefly as follows; 3 µL of the cloned 
plasmid DNA, 0.2 µL Taq DNA Polymerase enzyme, 2μL of 10X buffer, 0.4 μL 
of 10 mm dNTPs, and 1 μL of each of the reverse and forward primers as 
described in (Table 6) using the following conditions; 94°C for 3 min, then 35 
cycles of 94°C for 30 sec, 58°C for 30 sec, 72°C for 3 min and 30 sec; followed 
by 5 min at 72°C for final extension. 
Table 6 The primers used to amplify the whole αIIb subunit in the cloned vector 
 
 
Primer Sequence Primer 
name 
 
GATGCTAGCCTGGGAGGTT
GTGGAAGAAGGAAG 
GPIIb FOR Used to 
amplify the 
whole αIIb gene 
to confirm 
cloning  
GCTAAGCTTGTGTAGGCTGC
ACCATCACTCCC 
GPIIb REV Used to 
amplify the 
whole αIIb gene 
to confirm 
cloning  
CAGAGCCTCTCCTTTGACTC 
 
GPIIb 748F Used to 
amplify part of 
the αIIb gene to 
confirm the 
results  
CTCCCTCTCACCTTCTTCTG 
 
GPIIb 2400R Used to 
amplify part of 
the αIIb gene  
to confirm the 
results  
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4.2.2.8 Scale–up of Plasmid DNA purification  
The cloned confirmed vector was extracted in the larger amounts required for 
transfection using a QIAGEN Plasmid Midi Kit (Qiagen, catalogue number; 
12743) according to manufacturer’s instructions. Briefly, 100 µL of the starter 
culture which was found to contain the right cloned vector were diluted in 25 ml 
of the LB medium containing Ampicillin in a final concentration of 100ug/ml and 
grown at 37°C for 12–16 h with vigorous shaking of 300 rpm. The bacterial cells 
were harvest by centrifugation at 6000 x g for 15 min at 4°C and the bacterial 
pellet was suspended in 4 ml of Buffer P1 and 4 ml P2 buffer were added and 
mixed thoroughly by vigorously inverting the sealed tube and incubated at room 
temperature for 5 min. 4 ml of chilled P3 buffer were mixed by vigorously 
inverting the tube then left on ice for 15 min. The tube was centrifuged at 
≥20,000 x g for 30 min at 4°C. The supernatant containing the plasmid DNA 
was removed. A QIAGEN-tip 100 was equilibrated in a 4 ml buffer QBT and the 
column was allowed to empty by gravity flow. The supernatant containing the 
cloned plasmid was added to the equilibrated QIAGEN-tip and allowed to 
empty by gravity flow. The QIAGEN-tip was washed twice with Buffer QC. The 
DNA was eluted with 5 ml buffer QF and precipitated by adding 3.5 ml room-
temperature isopropanol to the eluted DNA then mixed and centrifuged 
immediately at ≥15,000 x g for 30 min at 4°C. The DNA pellet was washed with 
2 ml of room-temperature 70% ethanol, and centrifuged at ≥15,000 x g for 10 
min. The pellet was air-dried for 5–10 min and re-dissolved in 500 µL volume of 
TE buffer pH 8.0. 
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4.2.2.9 Sequencing of the cloned vector 
Sequencing for the αIIb insert of the cloned extracted vector was carried out by 
Source Bioscience, Nottingham.UK.  
4.2.3 Transfection into mammalian cells 
4.2.3.1 Determining the optimum antibiotic concentrations for stable 
transfection 
The vector pcDN3 contains a selection marker for G418. The appropriate 
antibiotic concentration was determined through running dose response curves. 
Briefly, cells were diluted to 5 x 105 cells/ml and 2 mL of cell suspension were 
seeded in each well of a 6 well plate. A range of G418 concentrations (Sigma-
Aldrich. Poole, UK) were tested by addition to the wells in triplicate, with control 
wells where no antibiotic was added. Cells were observed and pictures were 
taken over 21 days. The selection concentration that results in total cell death 
within 3 weeks after addition of the antibiotic was selected as the optimal 
concentration for generating a stably transfected cell line.  
In order to determine the optimum conditions needed to perform successful 
transfection, different transfection reagents from different manufacturers were 
tested including ExGen 500 and Effectene.  
4.2.3.2 Transfection using ExGen 500 
The day before transfection 2.4x105 cells/well were seeded in a 6 well plate in 2 
mL complete growth media. The transfection reagent ExGen 500 (Catalogue 
number R0511, Cosmo Bio Co, LTD) was used to transfect the cells with the 
cloned vector according to the manufacturer’s protocol. Briefly, 3 μg of DNA of 
the cloned vector and empty pcDNA vector) were diluted separately in 200 μL 
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of 150 mM NaCl in two tubes, vortexed and spun down gently. 9.87 μL ExGen 
500 (COSMO BIO CO, LTD) were added to each tube and vortexed 
immediately for 10 sec, then incubated for 10 minutes at room temperature. 
200 μL of the ExGen 500/DNA mixture was added to each well. The plate was 
rocked back and forth gently to achieve good distribution of the complexes. The 
transfection reagent is kept on the cells for 24 hr before adding the selection 
antibiotic G418 at a final concentration of 800ug/ml for 21 days. 
4.2.3.3 Transfection using Effectene  
4.2.3.3.1 Transfection of adherent cells  
The transfection reagent Effectene (Qiagene, catalogue number 301425) was 
used to transfect the cells with the cloned vector according to manufacturer’s 
protocol. Briefly, the day before transfection, 4.0x105 cells/well were seeded in 
6 well plate. In the day of the transfection, the media over the cells was 
removed and replaced by new 1600 µL of full media. DNA enhancer mixture 
was prepared by adding 0.4 µg DNA of the cloned vector or 0.4 µg of empty 
pcDNA3 vector to 100 µL enhancer buffers and 3.2 µL of DNA-condensation 
buffer then incubated at room temperature for 5 minutes. 25 μL Effectene 
transfection reagent was added to the DNA-Enhancer mixture and mixed by 
pipetting then incubated for 10 minutes at room temperature until the formation 
of the transfection-complex. 1 ml of the growth medium was added to the tube 
containing the transfection complexes and mixed by pipetting up and down 
twice then added drop-wise onto the cells. The cells were incubated with the 
transfection complexes under their normal growth conditions for 24 hrs. For 
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stable transfected cell line the cells were challenged by 800 µg/mL final 
concentration for 21 days until the appearance of resistance colonies. 
4.2.3 3.2 Transfection of suspension cells  
The U87-MG cells are adherent cells which upon reaching 50-60% confluence 
tend to detach from the flask and form floating clumps. Because of this semi-
adherent nature, a transfection of suspension cells protocol was tried using 
Effectene (Qiagen, catalogue number 301425) according to manufacturer’s 
protocol. Briefly, on the day of transfection, 7.0 x 105 cells/well were suspended 
a 24-well plate. 0.2 µg DNA of the cloned vector or 0.2 µg of the empty 
pcDNA3 vector was dissolved in 60 µL Buffer EC and 1.6 µL of DNA-
condensation buffer to form the DNA-Enhancer mixture then incubated at room 
temperature for 5 minutes. 5 µL Effectene transfection reagent was added to 
the DNA-Enhancer mixture and mixed by pipetting then incubated for 10 
minutes at room temperature until the formation of the transfection-complex. 
350 µL of the growth medium was added to the tube containing the transfection 
complex and mixed then added onto the cells. The cells were incubated with 
the transfection complexes under their normal growth conditions for 24 hrs. For 
preparing a stably transfected cell line, the U87-MG or the EJ-138 cells were 
challenged by G418 (800 µg/mL) for 21 days until appearance of resistance 
colonies. 
4.2.3.4 Establishment of pure cell clones using limiting dilution cloning  
Limiting dilution cloning was performed for the αIIb transfected cells and the 
mock transfected cells for up to three weeks under different concentrations of 
G418 (Sigma, catalogue number A1720-5g) to result in pure cell clones. Briefly, 
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cells were diluted to give 1 cell/100 μL before being seeded in a 96 well plate. 
100 μL of the cell suspension was placed into each well of a 96 well plate and 
the cells were allowed to adhere overnight. The next day 100 μL of G418 
containing medium was added to the first row in a final concentration of 1.4 
mg/ml. G418 was added to the following rows in decreasing concentration by 
0.2 mg/ml. Medium without G418 was added for the last row to result in a list of 
concentrations of 1400 µL/mL, 1200 µL/mL, 1000 µL/mL, 800 µL/mL, 600 
µL/mL, 400 µL/mL, 200 µL/mL, 0 µL/mL. Cells were incubated at standard 
conditions. The G418 concentration which was just below the one which 
demonstrated complete cell death was considered as the appropriate G418 
concentration for selection. The cells in the well which contain the selected 
G418 concentration were transferred into 24 well plates and allowed to 
proliferate till they were 60% confluent before further PCR analysis 
4.2.3.5 Establishment of pure cell clones using Ring cloning 
αIIb transfected cells and the mock transfected cells were kept under antibiotic 
challenge until the formation of separate colonies. The media was removed and 
the cells were washed twice with PBS. Rings of cut off pipette tips were placed 
over individual colonies using high vacuum grease (Dow Corning GmbH, 
Wiesbaden, Germany) to form a tight seal then trypsin/EDTA solution was 
added to each well and incubated for 5-10 minutes at 37°C before the trypsin 
with cells were gently removed from the well to be re-seeded into 24 well plates 
and allowed to grow to 70-90% confluence before doing the PCR confirmation 
of expression. 
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4.2.3.6 PCR confirmation of the correct transfection of the cell line 
In order to confirm that the transfected cell lines to expressed αIIb integrin at the 
mRNA level, the cell RNA was extracted and converted into cDNA and amplified 
using a PCR reaction before being seen on gel as described in 4.2.1 using the 
primers in following table 6  
Table 6: Primers used into sequencing  
Primer Sequence 
Primer 
name 
 
CAGAGCCTCTCCTTTGACTC 
GPIIb 748F Used to 
sequence 
the first 
part of the 
αIIb gene  
CTCCCTCTCACCTTCTTCTG 
GPIIb 
2400R 
Used to 
sequence 
the second 
part of the 
αIIb gene  
5'-CTGGAAGAGGCTGGGGAGTC-3 
Alpha IIb  
For 
Used to 
sequence 
the third 
part of the 
αIIb gene  
5'-GCATAGGGGAGGGAGGACAC-3 
Alpha IIb  
rev 
Used to 
sequence 
the fourth 
part of the 
αIIb gene  
 
4.2.3.7 Assessment of αIIb protein expression in the transfected cell lines 
In order to confirm successful transfection, two methodologies were applied to 
the transfected cells immunocytochemistry and Western blotting. 
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3.2.3.7.1 Immunocytochemistry  
Fibrinogen was diluted (Sigma, Poole, UK) to 10 µg/ml, 0.05 M Na Phosphate 
and 0.15 M NaCl all dissolved in PBS and the pH was adjusted to pH 7.4. The 
solution was filter sterilized and used to prepare fibrinogen coated cover slips by 
coat 22×22mm cover slips which were then stored at 4 °C overnight. The next 
day the cover slips were washed three times with PBS and were then ready to be 
used.  
1×105 cells/ml were seeded on fibrinogen coated cover slips in 2 mL aliquots in 
6 well plates and incubated over night at 37 °C, 5% CO2 Cells were allowed to 
attach to cover slips overnight. The next day the media was removed and the 
cells were washed twice with HBSS to remove unbound cells. The bound cells 
were fixed using 1 ml of 4% paraformaldehayde, then left for 10 minutes at RT 
in fixative and then washed with phosphate buffered saline. The cells were then 
permeabilized by TritonX-100 for five minutes and washed again with PBS. The 
cells were treated with 300 μL of the blocking agent of 5% BSA/PBS (Sigma, 
UK) for 1 hour at room temperature to prevent non-specific binding. Anti-CD41 
antibody (catalogue number, EPR4330. Rabmabs®) was diluted (1:50) in the 
blocking agent then added to the cells and kept at 4oC overnight. The next day, 
the cells were washed with blocking agent 3 times for 10 minutes. Finally, the 
cells were incubated with Goat Anti-Rabbit (TRITC) (Abcam, ab6718) or 
Donkey Anti-Rabbit (FITC) (Abcam, ab6798) diluted in the blocking agent 
(1:200). The cells were then washed 3×10 minutes with PBS. The cover slips 
were then mounted with Vectashield mounting medium containing DAPI (1.5 
µg/ml) (Vector Laboratory) and stored at -20°C until being analyzed. 
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4.2.3.7.2 Western blotting  
4.2.3.7.2.1 Preparation of cell lysate 
Protein lyses buffer was prepared from Protease Inhibitor Cocktail (PIC) with 
EDTA, 7M urea, 2M thiourea, 4 % CHAPS, 0.1%SDS and 0.05% Sodium 
deoxycholate, all dissolved in PBS up to 1 ml. αIIb transfected U87-MG or EJ-
138 cells at 70-80% confluence, washed twice in 10 ml PBS and then 
harvested by cell scraper and centrifuged at 1000 rpm for 5 minutes. The 
prepared cell pellet was thawed on ice and suspended in 200 µL of the protein 
lyses buffer. The cells were homogenised by sonication using 6 cycles, 
repeated 3 times with incubating on ice for 30 seconds between each time. The 
samples were then centrifuged at 13000 rpm for 25 minutes at 4oC. 
4.2.3.7.2.2 Bradford assay 
In order to determine the protein concentration in the prepared cell lysate, the 
Bradford assay (Bradford 1976) was performed. 50 μL of different 
concentrations of BSA were prepared by serial dilution as follows, 2 mg/ml, 1 
mg/ml, 0.5 mg/ml, 0.25 mg/ml, 0.125 mg/ml, and 0.0625 mg/ml. 50 µL of 20 
folds diluted proteins samples were prepared. 1.5 ml of the Bradford assay 
were added to the BSA dilutions, samples and blanks then incubated for 15 
minutes before being read by spectrophotometer using 595 nm wave lengths. 
4.2.3.7.2.3 Electrophoresis 
10 ml of 10% of separating gel solution were prepared and pipetted between 
plates of the gel apparatus. 1 ml of isopropanol was layered on the top of the 
gel solution and left for 10 minutes to polymerise the gel then removed and 
washed with methanol before adding the stacking gel. 10 well comb was 
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inserted between gel plates inside the stacking gel. Samples of 80 µg/well of 
protein were mixed with loading buffer and heated for 10 minutes at water bath 
for 10 minutes at 60oC. The gel was transferred to an electrophoresis 
apparatus (Bio-Rad, UK) where the electrode buffer was added and the 
samples were loaded and ran at 80 V for the first 20 minutes then 150 V for the 
next hour. 
4.2.3.7.2.4 Blotting and detection 
The PVDF (Amersham) membrane was soaked in methanol for 30 seconds 
then washed with water for 1 minute. The blotting paper, fibre pads, the gel 
containing the separated samples and the PVDF membrane were placed in 
transfer buffer to equilibrate for 10-15 minutes. The transfer stack was 
assembled and the transfer was started at 80 mA for 1.5 hours. Coloured 
molecular weight maker was used to judge the transfer of proteins to the PVDF 
membrane. Membrane was transferred and incubated in 5% BSA blocking 
buffer at room temperature for 1 hour. The αIIb primary antibody was added in 
1:2000 in 5% BSA and incubated on shaker overnight at 4°C with shaking. The 
next day, the buffer was removed and washed for 15 minutes three times with 
washing buffer (1 ml Tween/litre of PBS) at room temperature with shaking. 
The secondary antibody was added in 1:3000 of BSA blocking buffer and 
incubated for 1 hr at room temperature with shaking then washed as previously 
described.  
The developing kit (ECL Prime Western Blotting Detection Reagent, catalogue 
number RPN2232) was used according to manufacturer’s protocol. Briefly, 50 
ml developing solution (Kodak professionals) was added to 450 ml of tap water 
and 75 ml fixing solution (Kodak professionals) was added to 425 ml tap water 
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and poured into separate trays for developing then 1 litter of tap water was 
added for washing. The PVDF membrane was removed from washing buffer 
and placed in fresh container. 15 μL ECL reagent B plus 600 μL ECL reagent A 
were mixed in an eppendorf tube and added to the PVDF membrane and 
spread over it then incubated for 5 minutes. The film was placed over the 
plastic containing the PVDF membrane in dark then the cassette was closed. 
After 10 minutes of exposure the film was removed from cassette in dark and 
placed into developing solution for approximately 5 minutes with agitation. The 
film was then rinsed in water and placed into fixing solution for at least 1 minute 
with agitation. Finally the film was rinsed in the water tray and washed 
thoroughly with running water to remove any traces of fixing solution. 
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4.3 Results 
4.3.1 Amplification of αIIb subunit of the αIIbβ3 integrin 
Trials to amplify the full length sequence of the αIIb integrin, using the primers, 
GPIIb HindIII and GPIIb EcoRI Rev, from different sources of cDNA including 
HUVEC, LN229 and K562 were not successful (see Figure 58 [A]). The PCR 
was repeated again using various primer combinations as an aim to determine 
the main problem with the reaction. There was no problem either in the reaction 
conditions or in the GPIIb EcoRI Rev primer or in the internal primers GPIIb 
748F, GPIIb 2400R. Later the reaction was repeated with a new forward 
primer, GPIIb HindIII but again there were no successful results (see Figure 58 
[B], [C] and [D]). 
Nested PCR, which is a repeat of PCR using the product of the previous 
reaction as a template, was then tried using conditions which resulted in a 
product with a bright band with completely different size from GPIIb indicating 
that the primer which was used was binding to another region of the cDNA. The 
reaction was repeated using a hot start step before adding the polymerase 
enzyme in an aim to avoid non-specific amplification of the DNA, but resulted in 
the same results as the nested PCR trial. 
The conditions of the reaction were changed by increasing or decreasing the 
final concentration of the MgSO4 or by adding DMSO as an enhancer to the 
PCR reaction but the αIIb was not detected in the gel [data not shown]. 
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Figure 58: Attempts to amplify the αIIb gene by PCR. Expected product size is 
3100 bp [A]. The primers, GPIIb HindIII and GPIIb EcoRI. No product observed. 
[B], [C] LN229 cDNA used as template; the internal primers worked but no 
product was obtained from amplification of entire gene. LN229 cDNA used as 
template and both of the internal primers worked. [D] Primers GPIIb HindIII and 
GPIIb EcoRI. No product observed. [E] HUVEC cDNA used as template; 
internal primers (GPIIb 748F GPIIb 2400R) and (GPIIb Hind, F-13 GPIIb EcoR) 
worked but no product was obtained from amplification of entire gene using 
GPIIb HindIIIFGPIIb Eco R. [F] HUVEC cDNA, hot start 70 °C and DMSO 5% 
were used. No product observed. 
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4.3.2. Cloning 
4.3.2.1 PCR-4-TOPO as an alternative source of αIIb subunit  
After the amplification of cDNA obtained from cancer cell lines failed, the 
bacterial vector PCR-4-TOPO was used as an alternative source for the αIIb 
insert. The plasmid was extracted from bacteria and restricted with EcoR1 
(Figure 59(A)). 
4.3.2.2 The plasmid pcDNA3 linearization 
The pcDNA3 plasmid was linearized after treatment with the restriction enzyme 
EcoRI and CIP (see Figure 59(B)).  
4.3.2 3 Gel extraction and preparation for ligation 
The αIIb DNA fragment and the linearised pcDNA3 vector were extracted from 
the gel (see Figure 59). 
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Figure 59 The first stage of the cloning the αIIb subunit into the pcDNA3 vector 
(A) PCR-4-TOPO plasmid was extracted from bacteria and restricted with 
EcoR1. The upper band shows the vector back bone (4 kb) and the lower band 
is the αIIb insert which is 3.2 kb size. (B) The linearised pcDNA3 was restricted 
with EcoR1, treated with CIP and urn on gel; a 5.4 kb band was detected. (C) 
The bands were extracted from gel and shown on gel again to confirm that the 
bands are ready for ligation. The αIIb insert is 3.2 Kb size and the pcDNA3 with 
a size of 5.4 kb.  
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4.3.2.4 Selection of the correct bacterial colony 
After the extracted αIIb subunit and the CIP treated pcDNA3 vector were ligated, 
the ligated vector was transformed into JM109 Competent Cells. The next day 
bacterial growth was observed indicating that the transformation was 
successful. The resulting bacteria were streaked on an agar plate. The next 
day there was bacterial growth observed on the streaking area with single 
colonies noticed on the last streak. 6 single colonies were picked and 
inoculated in LB media as previously described. The next day there was 
bacterial growth noticed in the all 6 tubes of media. Plasmid was extracted from 
the bacteria in the 6 tubes and restricted with restriction enzyme EcoRI as 
described previously. The resulting restricted plasmids were loaded onto gel to 
determine which colony contains the correctly cloned plasmid. Plasmid 
extracted from colony number 5 showed two bands with 3.2 kb size for the αIIb 
subunit and 5.4 kb for the pcDNA3 backbone (Figure 60 (A)). For further 
confirmation, the restricted plasmid extracted from colony number 5 was loaded 
on a gel with the restricted αIIb subunit and the linearized pcDNA3 and the sizes 
of the bands were comparable (Figure 60 (B)).  
In addition, the extracted vector from colony number 5 was restricted with the 
restriction enzyme BamHI to check the direction of insertion (Figure 57). To 
confirm that the cloning has been done successfully in the right direction the 
BamHI restricted vector was loaded on gel. The length of the resulting bands 
was 2.7 kb and 5.8 kb indicating that the αIIb subunit was cloned correctly in the 
pcDNA3 vector (Figure 60(C)). 
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Figure 60 (A) The resulting restricted plasmids were loaded on gel to 
determine the colony which contains the correctly cloned plasmid. The plasmid 
extracted from colony number 5 gave two bands with 3.2 kb size for the αIIb 
subunit and 5.4 kb for the pcDNA3 backbone. (B) Comparison of restricted 
vector for colony 5 with αIIb subunit and linearized pcDNA3. (C) The extracted 
plasmid was restricted with BamHI. Observed band sizes match αIIb subunit 
and linearized pcDNA3 the Two bands resulted with sizes 2.7Kb and 5.8 Kb 
indicating that the cloning was correct.  
 
 
 
185 
 
4.3.2.5 PCR confirmation of the cloning  
Two sets of primers were used to amplify the whole (AlphaIIb For, Alpha IIb 
Rev) and part (GPIIb 748F, GPIIb 2400R) of the αIIb subunit and the results 
confirmed that the cloned part was αIIb integrin subunit (see Figure 61). The 
PCR using the primers (AlphaIIb For, Alpha IIb Rev) resulted in 3.2 kb size 
band which matches the expected size of the whole αIIb integrin subunit and the 
primers (GPIIb 748F, GPIIb 2400R) resulted in 1.7 kb size band which matches 
the expected size of the internal part of the αIIb integrin subunit (see Figure 61). 
BA
3200 bp
1700 bp
Figure 61: PCR confirmation of the cloning indicted that the cloning was 
correct. (A), 1.7 kb size which supposed to be the internal part of the αIIb 
integrin. (B), 3.2 kb size which was supposed to be the whole αIIb integrin. 
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4.3.2.6 Sequencing 
For further confirmation of the results, the cloned vector was sent to sequence 
the αIIb subunit to confirm that it is compatible with the published structure of 
the cDNA of the Homo sapiens αIIb integrin subunit. The primers (T7 For, 
740For, 2400R, 222For) were used to amplify the 1st, 2nd, 3rd and final part of 
the αIIb integrin subunit gene and the results showed complete compatibility 
with the published αIIb integrin subunit gene sequence (see Figure 62) 
indicating that the cloned vector was correct and contains the αIIb integrin 
subunit and was ready to be used to transfect human cell lines.  
187 
 
NNNNNNCNAN CTCGGNTNNN TAGTAACGGCCGCCAGTGTGCTGGAATTCGCCCTTGCCTGGGAGGTTGTGGAAGAAGGAA
GATGGCCAGAGCTTTGTGTCCACTGCAAGCCCTCTGGCTTCTGGAGTGGGTGCTGCTGCTCTTGGGACCTTGTGCTGCCC
CTCCAGCCTGGGCCTTGAACCTGGACCCAGTGCAGCTCACCTTCTATGCAGGCCCCAATGGCAGCCAGTTTGGATTTTCA
CTGGACTTCCACAAGGACAGCCATGGGAGAGTGGCCATCGTGGTGGGCGCCCCGCGGACCCTGGGCCCCAGCCAGGAGGA
GACGGGCGGCGTGTTCCTGTGCCCCTGGAGGGCCGAGGGCGGCCAGTGCCCCTCGCTGCTCTTTGACCTCCGTGATGAGA
CCCGAAATGTAGGCTCCCAAACTTTACAAACCTTCAAGGCCCGCCAAGGACTGGGGGCGTCGGTCGTCAGCTGGAGCGAC
GTCATTGTGGCCTGCGCCCCCTGGCAGCACTGGAACGTCCTAGAAAAGACTGAGGAGGCTGAGAAGACGCCCGTAGGTAG
CTGCTTTTTGGCTCAGCCAGAGAGCGGCCGCCGCGCCGAGTACTCCCCCTGTCGCGGGAACACCCTGAGCCGCATTTACG
TGGAAAATGATTTTAGCTGGGACAAGCGTTACTGTGAAGCGGGCTTCAGCTCCGTGGTCACTCAGGCCGGAGAGCTGGTG
CTTGGGGCTCCTGGCGGCTATTATTTCTTAGGTCTCCTGGCCCAGGCTCCAGTTGCGGATATTTTCTCGAGTTACCGCCC
AGGCATCCTTTTGTGGCACGTGTCCTCCCAGAGCCTCTCCTTTGACTCCAGCAACCCAGAGTACTTCGACGGCTACTGGG
GGTACTCGGTGGCCGTGGGCGAGTTCGACGGGGATCTCAACACTACAGAATATGTCGTCGGTGCCCCCACTTGGAGCTGG
ACCCTGGGAGCGGTGGAAATTTTGGATTCCTACTACCAGAGGCTGCATCGGCTGCGCGGA NAGCANATGGCGTCGTATTT
TGGGCATTCAGTGGNTGTCACTGACGTCAACGGGGATGGGAGGCATGATCTGCTGGTGGGCGCTNCNCTGTATATGGAGA
GCCGGGNNNANCGAAAACTGGNCGAANTGGGNGTGTGTATTNNTTCCTGCANCCNNGAGGNCCCCACGNNNTGGGNNCNN
CAGCTCNGCTGACTNNNCNNNNNNTCTANGGGCGATNCGGNNNTGCNTCNNACCNNGGCNACTNNNCNNANGNTNNANGA
NNNCNNNNTNCNCNACGGGNCCNNNNNGNNNNNNNNNGNGNNCNGNNANNNNNNNNANNNNNTCNNCCNNNNCNGNNNNG
NCCNTNNNNNNNNNNNNNNNNNNNNNNNNNGNCNNNNACTNNNNANANN
T7 For A
NNNNNNNNNNCN GCTACTGGGGGTACTCGGTGGCCGTGGGCGAGTTCGACGGGGATCTCAACACTACAGAATATGTCGTC
GGTGCCCCCACTTGGAGCTGGACCCTGGGAGCGGTGGAAATTTTGGATTCCTACTACCAGAGGCTGCATCGGCTGCGCGG
AGAGCAGATGGCGTCGTATTTTGGGCATTCAGTGGCTGTCACTGACGTCAACGGGGATGGGAGGCATGATCTGCTGGTGG
GCGCTCCACTGTATATGGAGAGCCGGGCAGACCGAAAACTGGCCGAAGTGGGGCGTGTGTATTTGTTCCTGCAGCCGCGA
GGCCCCCACGCGCTGGGTGCCCCCAGCCTCCTGCTGACTGGCACACAGCTCTATGGGCGATTCGGCTCTGCCATCGCACC
CCTGGGCGACCTCGACCGGGATGGCTACAATGACATTGCAGTGGCTGCCCCCTACGGGGGTCCCAGTGGCCGGGGCCAAG
TGCTGGTGTTCCTGGGTCAGAGTGAGGGGCTGAGGTCACGTCCCTCCCAGGTCCTGGACAGCCCCTTCCCCACAGGCTCT
GCCTTTGGCTTCTCCCTTCGAGGTGCCGTAGACATCGATGACAACGGATACCCAGACCTGATCGTGGGAGCTTACGGGGC
CAACCAGGTGGCTGTGTACAGAGCTCAGCCAGTGGTGAAGGCCTCTGTCCAGCTACTGGTGCAAGATTCACTGAATCCTG
CTGTGAAGAGCTGTGTCCTACCTCAGACCAAGACACCCGTGAGCTGCTTCAACATCCAGATGTGTGTTGGAGCCACTGGG
CACAACATTCCTCAGAAGCTATCCCTAAATGCCGAGCTGCAGCTGGACCGGCAGAAGCCCCGCCAGGGCCGGCGGGTGCT
GCTGCTGGGCTCTCAACAGGCAGGCACCACCCTGAACCTGGATCTGGGCGGAAAGCACAGCCCCATCTGCCACACCACCA
TGGCCTTCCTTCGAGATGAGGCAGACTTCCGGGACAAGCTGAGCCCCATTGTGCTCAGCCTCAATGTGTCCCTACCGCCC
ACGGAGGCTGGAATGGCCCCTGCTGTCGTGCTGCATGGAGACACCCATGTGCAGGAGCAGACACGAATCGTCCTGNNTGN
NGGGNANGATGACGTATGTGTGCCCCAGCTTCAGCTCACTGCCANCNTGANGGGCTCCCGNTCTANTTGGGGCAGATATG
NCCTNNNCTGNNATGNNNCANCANNAGGGCNNNGGGGNCTATGAANCANANNTGNNNNACNNCCNGGGNGCCNNNTNNNN
NNGGNNANNANNNNNGGNTTNGAANANNNNNNNNGNNNNNNANANGNAATNANNNNGGNGNGNCTNNNNNNNNNNNNNNN
CNNNANANANNNCNNNGNNNCNNANTTTNNNNNNNNNNNNNNNNNNNNNNNNNTCNTNNNNNNNNNNNNNNN
740 For B
NNNNNNCTGNANGAG TTCCCTCGCAGCTCCN  CTTGGGCCTCTGCCCGGACCGGCACGTCCAGCAGCACAATCTTGCTGTT
TGGATTCTGGCTGTTCTTGCTCCGTATCTGCAGCTGGAAGGACACAGACTCCCCAGCCTCTTCCAGATTCCCCACGCTCA
CCAACATCGCGATTCCTATCTGGGCGTTCTTCTTCATGGGGTTGCCCAGCTCACACAGCACCACCCTGGTCTCATTCTCC
TTCTTCTGATTACAGATGAGTCTCTCAAAGCCCTCGACATTGCTTAGGGCCCGCATGTAGTGGGCGCCCTGGGGCAGGTG
CACGGCCAGCTCTGCTTCATAGGCCCCCTCGCCCTCGTTGGCTGCGTCCATCTGCAGCTCCAGGACATTATCTGCCCCAA
CTAGGAGCGGGGAGCCCGTCACGCTGGCAGTGAGCTGAAGCTGGGGCACACATACGTCATCTTCCCCACAGTCCAGGACG
ATTCGTGTCTGCTCCTGCACATGGGTGTCTCCATGCAGCACGACAGCAGGGGCCATTCCAGCCTCCGTGGGCGGTAGGGA
CACATTGAGGCTGAGCACAATGGGGCTCAGCTTGTCCCGGAAGTCTGCCTCATCTCGAAGGAAGGCCATGGTGGTGTGGC
AGATGGGGCTGTGCTTTCCGCCCAGATCCAGGTTCAGGGTGGTGCCTGCCTGTTGAGAGCCCAGCAGCAGCACCCGCCGG
CCCTGGCGGGGCTTCTGCCGGTCCAGCTGCAGCTCGGCATTTAGGGATAGCTTCTGAGGAATGTTGTGCCCAGTGGCTCC
AACACACATCTGGATGTTGAAGCAGCTCACGGGTGTCTTGGTCTGAGGTAGGACACAGCTCTTCACAGCNNNTTCAGTGA
ATCTTGCACCAGTAGCTGGACAGAGGCCTTCACCACTGGCTGANCTCTGTACACAGCCACCTGGTGGGCCCCGTANNCTC
CCACGATCAGGTCTGGGTATCCGTTGTCATCNATGTCTACNGNNCCTCGAAGGGANAAGCCAAANGCAGANCCTGTGNNN
2400 R C
ATTCCTGCCTGGGAGGTTGTGGAAGAAGGAAGATGGCCAGAGCTTTGTGTCCACTGCAAGCCCTCTGGCTTCTGGAGTGGGTGCTGCTGC
TCTTGGGACCTTGTGCTGCCCCTCCAGCCTGGGCCTTGAACCTGGACCCAGTGCAGCTCACCTTCTATGCAGGCCCCAATGGCAGCCAGTT
TGGATTTTCACTGGACTTCCACAAGGACAGCCATGGGAGAGTGGCCATCGTGGTGGGCGCCCCGCGGACCCTGGGCCCCAGCCAGGAGG
AGACGGGCGGCGTGTTCCTGTGCCCCTGGAGGGCCGAGGGCGGCCAGTGCCCCTCGCTGCTCTTTGACCTCCGTGATGAGACCCGAAAT
GTAGGCTCCCAAACTTTACAAACCTTCAAGGCCCGCCAAGGACTGGGGGCGTCGGTCGTCAGCTGGAGCGACGTCATTGTGGCCTGCGCC
CCCTGGCAGCACTGGAACGTCCTAGAAAAGACTGAGGAGGCTGAGAAGACGCCCGTAGGTAGCTGCTTTTTGGCTCAGCCAGAGAGCGGC
CGCCGCGCCGAGTACTCCCCCTGTCGCGGGAACACCCTGAGCCGCATTTACGTGGAAAATGATTTTAGCTGGGACAAGCGTTACTGTGAAG
CGGGCTTCAGCTCCGTGGTCACTCAGGCCGGAGAGCTGGTGCTTGGGGCTCCTGGCGGCTATTATTTCTTAGGTCTCCTGGCCCAGGCTC
CAGTTGCGGATATTTTCTCGAGTTACCGCCCAGGCATCCTTTTGTGGCACGTGTCCTCCCAGAGCCTCTCCTTTGACTCCAGCAACCCAGAG
TACTTCGACGGCTACTGGGGGTACTCGGTGGCCGTGGGCGAGTTCGACGGGGATCTCAACACTACAGAATATGTCGTCGGTGCCCCCACT
TGGAGCTGGACCCTGGGAGCGGTGGAAATTTTGGATTCCTACTACCAGAGGCTGCATCGGCTGCGCGGAGAGCAGATGGCGTCGTATTTT
GGGCATTCAGTGGCTGTCACTGACGTCAACGGGGATGGGAGGCATGATCTGCTGGTGGGCGCTCCACTGTATATGGAGAGCCGGGCAGAC
CGAAAACTGGCCGAAGTGGGGCGTGTGTATTTGTTCCTGCAGCCGCGAGGCCCCCACGCGCTGGGTGCCCCCAGCCTCCTGCTGACTGG
CACACAGCTCTATGGGCGATTCGGCTCTGCCATCGCACCCCTGGGCGACCTCGACCGGGATGGCTACAATGACATTGCAGTGGCTGCCCC
CTACGGGGGTCCCAGTGGCCGGGGCCAAGTGCTGGTGTTCCTGGGTCAGAGTGAGGGGCTGAGGTCACGTCCCTCCCAGGTCCTGGACA
GCCCCTTCCCCACAGGCTCTGCCTTTGGCTTCTCCCTTCGAGGTGCCGTAGACATCGATGACAACGGATACCCAGACCTGATCGTGGGAGC
TTACGGGGCCAACCAGGTGGCTGTGTACAGAGCTCAGCCAGTGGTGAAGGCCTCTGTCCAGCTACTGGTGCAAGATTCACTGAATCCTGCT
GTGAAGAGCTGTGTCCTACCTCAGACCAAGACACCCGTGAGCTGCTTCAACATCCAGATGTGTGTTGGAGCCACTGGGCACAACATTCCTC
AGAAGCTATCCCTAAATGCCGAGCTGCAGCTGGACCGGCAGAAGCCCCGCCAGGGCCGGCGGGTGCTGCTGCTGGGCTCTCAACAGGCA
GGCACCACCCTGAACCTGGATCTGGGCGGAAAGCACAGCCCCATCTGCCACACCACCATGGCCTTCCTTCGAGATGAGGCAGACTTCCGG
GACAAGCTGAGCCCCATTGTGCTCAGCCTCAATGTGTCCCTACCGCCCACGGAGGCTGGAATGGCCCCTGCTGTCGTGCTGCATGGAGAC
ACCCATGTGCAGGAGCAGACACGAATCGTCCTGGACTGTGGGGAAGATGACGTATGTGTGCCCCAGCTTCAGCTCACTGCCAGCGTGACG
GGCTCCCCGCTCCTAGTTGGGGCAGATAATGTCCTGGAGCTGCAGATGGACGCAGCCAACGAGGGCGAGGGGGCCTATGAAGCAGAGCT
GGCCGTGCACCTGCCCCAGGGCGCCCACTACATGCGGGCCCTAAGCAATGTCGAGGGCTTTGAGAGACTCATCTGTAATCAGAAGAAGGA
GAATGAGACCAGGGTGGTGCTGTGTGAGCTGGGCAACCCCATGAAGAAGAACGCCCAGATAGGAATCGCGATGTTGGTGAGCGTGGGGAA
TCTGGAAGAGGCTGGGGAGTCTGTGTCCTTCCAGCTGCAGATACGGAGCAAGAACAGCCAGAATCCAAACAGCAAGATTGTGCTGCTGGAC
GTGCCGGTCCGGGCAGAGGCCCAAGTGGAGCTGCGAGGGAACTCCTTTCCAGCCTCCCTGGTGGTGGCAGCAGAAGAAGGTGAGAGGGA
GCAGAACAGCTTGGACAGCTGGGGACCCAAAGTGGAGCACACCTATGAGCTCCACAACAATGGCCCTGGGACTGTGAATGGTCTTCACCTC
AGCATCCACCTTCCGGGACAGTCCCAGCCCTCCGACCTGCTCTACATCCTGGATATACAGCCCCAGGGGGGCCTTCAGTGCTTCCCACAG
CCTCCTGTCAACCCTCTCAAGGTGGACTGGGGGCTGCCCATCCCCAGCCCCTCCCCCATTCACCCGGCCCATCACAAGCGGGATCGCAGA
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Figure 62 (A) Sequencing of the first area of the of the cloned αIIb integrin 
subunit gene using the primer (7TFor), (red). (B) Sequencing of the second 
area of the of the cloned αIIb integrin subunit using the primer (740For), (green). 
(C) Sequencing of the third area of the of the αIIb integrin subunit using the 
primer (2400R), (blue). (D) Sequencing of the fourth area of the of the αIIb 
integrin subunit using the primer (222For), (yellow). 
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4.3.3 Mammalian Cell Transfection 
4.3.3.1 Establishing G418 concentrations 
As part of the initial data for the transfection experiments, the G418 
concentration was established by setting up kill curves for the wild type U87-
MG cells under exposure to increasing concentrations of G418. 800µg/mL was 
the minimum inhibitory concentration which was able to kill 100% of the cells 
within 21 days of exposure (see Figure 63).  
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Figure 63 Determination of toxicity of G418 on U87-MG. (A) Cell morphology 
after 21 days exposure. Scale bar: 100 µM. (B) Cell survival after 7 days 
exposure to G418 measured by MTT assay. n=3.  
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4.3.3.2 Attempted transfection of U87-MG 
Different kits and with different conditions were tried to obtain transfection of 
the U87-MG cells (see Figure 64). U87-MG transfection was challenging 
because these cells start to detach once they reach 50-60 % confluency and 
form spheroids, which are very hard to transfect. The transfection process 
needs the presence of a mono layer of cells before transfection and for this 
purpose the cells were seeded at not more 30-40% confluence before 
transfection. However, this low seeding density resulted in the problem of high 
death rates after transfection (see Figure 64 (A-D)). 
4.3.3.2.1 Transfection using X gene 500 
The first trial using X gene 500 as transfection reagent was done in six well 
plates (9.61 cm2). High detachment of the U87-MG cells was noticed after 
transfection (Figure 64 (A)). PCR showed no band of the predicted size found 
upon trying to amplify the whole αIIb subunit (see Figure 65). 
The transfection was repeated using the same previously used amount of 
Xgene reagent but in a 10 cm dish (55 cm2) to decrease the toxicity on the 
cells. The reagent was left on the cells for 48 hours to try to increase efficacy of 
transfection, but there was high cell death after transfection (see Figure 64 B). 
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Figure 64 Summary of methods attempted to transfect U87-MG cells with αIIb. 
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Figure 65 PCR was carried out for the cDNA extracted from the U87-MG 
transfected with αIIb cloned vector and empty vector using X gene 500 as a 
transfection reagent. No band of the predicted size was found upon trying to 
amplify the whole αIIb subunit. 
4.3.3.2.2 Transfection using Effectene. 
Effectene was used according to the manufacturer's protocol for adherent cells 
in 10 mm plates for 24 and 48 h. High detachment of the cells after transfection 
was noticed with high cell death (see Figure 64 (C, D)). 
Because of the ability of the U87-MG cells to detach from the plastic surface 
and form floating clumps they were next treated as suspension cells according 
to manufacturer’s protocol. After 24 hr of transfection the cells had a healthy 
appearance and maintained the same morphology after completing the 
selection time with G418 (see Figure 66). 
192 
 
A B
Figure 66 The morphology of the transfected U87-MG cells. Scale bar: 100 
µM. (A) The successfully transfected U87-MG cells appeared healthy and 
remained attached and proliferating for 21 days under G418 (800 µg /ml). (B) 
The unsuccessfully transfected cells appeared dead and detached. 
4.3.3.3 Evaluation of transfection success 
4.3.3.3.1 Evaluation of transfection using PCR 
The efficacy of transfection was evaluated using PCR in the first week of 
transfection, by trying first to amplify the whole αIIb gene (Figure 67 (A)). There 
was no results detected but because of the presence of a bright smear in the 
area of the αIIb transfected cells. The PCR was repeated using internal primers 
to amplify an internal part of the αIIb gene. A band at 1700 bp was observed, 
indicating that the transfection was successful at the DNA level in the first week 
of transfection (Figure 67 (B)). The PCR was repeated for the mock and the 
αIIb transfected cells in the third week after transfection and the results indicated 
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that the αIIb expression decreased by time to return back to be comparable with 
the mock cells (Figure 67 (B)). 
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Figure 67 (A) Attempted amplification of the whole αIIb gene. Smear band was 
detected in the area of the αIIb transfected cells. (B) PCR confirmation using the 
internal primers (GPIIb 748F, GPIIb 2400R). Strong band (1700 bp size) was 
detected indicating successful transfection on the PCR level in the first week of 
transfection. αIIb expression returned to baseline after 3 weeks.  
4.3.3.3.2 Evaluation of transfection using Immunocytochemistry 
The primary antibody (Anti-CD41/αIIb) was used to stain the αIIb-U87-MG cells 
and the mock cells during the first week of transfection and after 3 weeks (see 
Figure 68). 1 week after of transfection, the transfected αIIb-U87-MG cells 
demonstrated foci of the αIIb integrin expression which appeared to be localized 
to the focal adhesions compared to the mock ones which demonstrated a 
distribution of the expression all over the cell body. 3 weeks after of 
transfection, the αIIb-U87-MG cells demonstrate a similar level of expression to 
the mock cells. The αIIb integrin was distributed over the cell body with no signs 
of localisation to the focal adhesions. These results are compatible with the 
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PCR results which demonstrated that the transfected αIIb-U87-MG cells were 
losing the αIIb expression with time.  
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Figure 68: The immunocytochemistry results of the αIIb-U87-MG cells and the 
mock cells in the first week and the third week after transfection. Scale bar: 50 
µM. n=3. In the first week, the αIIb-U87-MG cells demonstrated foci of the αIIb 
expression appeared to be localized on the focal adhesions whereas mock-
transfected cells showed distribution of the expression over the cell body. After 
3 weeks of transfection, the αIIb-U87-MG cells demonstrate a comparable 
expression level to the mock cells.  
4.3.3.4 EJ-138 transfection with αIIb integrin subunit 
Based on the previous work in the above sections, only the αIIb transient 
transfection of the U87-MG cells was successful. Therefore in an aim to solve  
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this problem a non β3 integrin expressing cell line (Figure 69), EJ-138 was tried, 
as it was hypothesised that the high overall integrin expression in the U87-MG 
cells could be the reason for rejecting αIIb permanent expression by these cells. 
The eventual strategy would be, if αIIb transfection was successful, to also 
transfect β3 and av subunits to form functional αIIbβ3 and avβ3 integrins. 
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Figure 69 Immunocytochemistry evaluation of β3 integrin subunit expression in 
the wild type EJ-138 cell line. Scale bar: 50 µM. U78-MG cell line was used as 
a positive control. The β3 integrin expression was evaluated using the primary 
β3 antibody (sc-46655) to investigate the possibility of using the EJ-138 cell line 
as alternative choice to the U87-MG cell line. The EJ-138 cell line was found to 
be negative for the β3 subunit.  
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4.3.3.4.1 G418 toxicity test on EJ-138 cells 
The G418 concentration to use for transfecting EJ-138 cells was established by 
making kill curve for the wild type EJ-138 cells under increasing concentrations 
of G418. 500 mg/mL was the minimum inhibitory concentration which was able 
to kill 100% of the cells within 21 days of exposure (see Figure 70).  
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Figure 70 Toxicity test was done for the EJ-138 under different concentrations 
of G418. (A) Images were taken for the cells under different concentrations of 
G418 after 21 days exposure. Scale bar: 100 µM (B) Cell survival after 7 days 
exposure to G418 measured by MTT assay. n=3.  
The EJ-138 cell line was transfected with either the cloned vector or the empty 
vector to develop the αIIb transfected or the mock transfected cell lines. The EJ-
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138 cells were able to form isolated colonies after 3 weeks of selection with 
G418 500 µg/mL. The formed colonies were isolated with ring cloning. The αIIb-
EJ-138 cells showed difference in morphology compared to the EJ-138 mock 
cells. The αIIb-EJ-138 cells had the tendency to form clumps in the over 
confluent conditions (above 90% confluence) compared to the EJ-138 mock 
cells which grew in monolayers (see Figure 71).  
A B C
Confluent Over confluent 
Figure 71 Morphology of the EJ138-αIIb transfected cells compared to the non-
transfected and the mock transfected EJ-138 cells. (A) The EJ138-αIIb 
transfected cells tend to form clumped structures when over-confluent. In 
contrast, (B) non-transfected EJ-138s, and (C) mock transfected EJ-138s tend 
to remain growing  as a monolayer even when over-confluent. Scale bar: 100 
µM. 
4.3.3.4.2 Confirmation of EJ-138 transfection using PCR 
PCR confirmation was done for the EJ-138-αIIb transfected cells after 30 days 
selection time of using the two αIIb integrin internal primers; GPIIb 748F and 
198 
 
GPIIb 2400R. The EJ-138-αIIb transfected cells demonstrated high expression 
compared to the mock transfected cells and to the αIIb transfected U87-MG cells 
after three weeks of antibiotic selection. This result confirms, at the PCR level, 
that the EJ-138-αIIb transfected cells were successfully transfected and that the 
previous problems could be due to the nature of the U87-MG cell line which 
could not accept the αIIb integrin (see Figure 72). 
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Figure 72 PCR to detect αIIb expression using internal primers (1700 bp 
expected size). PCR was done, after finishing three weeks of selection time, for 
the EJ138-αIIb, αIIb-U87-MG and the mock cells. The EJ138-αIIb cell line 
demonstrated high expression using internal primers for the αIIb integrin internal 
part (1700 bp size) compared to no expression in the mock EJ-138 cell line and 
low expression in the transfected U87-MG cells and the mock transfected cells 
indicating that the EJ-138 were successfully transfected on the PCR level. 
 
4.3.3.4.3 Confirmation of EJ-138 transfection using immunolabelling  
Immunolabelling was done to confirm the expression of the αIIb integrin by the 
transfected EJ-138 cells compared to the mock cells. The results indicated that 
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the EJ138-αIIb transfected cells were able to demonstrate expression of α IIb 
compared to no expression in the mock cells (see Figure 73). The αIIb integrin 
distributed over the cell body with no signs of localisation to the focal adhesions 
which was seen in week 1 for U87-MG cells. This result was unsurprising since 
cell surface localisation and integrin function require a functional heterodimer, 
not a single subunit. The U87-MG cells express β3 integrin subunit which is 
needed to express αIIb integrin on the surface of the cells (Duperray et al., 1989) 
compared to the EJ-138 cells which does not express the required β3 subunit to 
partner αIIb.  
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Figure 73 Immunolabelling of the αIIb integrin expression in the EJ138-αIIb and 
the mock cells. The EJ138-αIIb cell line was found to be positive for the αIIb 
integrin compared to no expression in the mock cells. Scale bar: 50 µM. 
 
4.3.3.4.4 Confirmation of EJ-138 transfection using Western blotting 
The EJ138-αIIb transfected cells showed a band of size 132 kDa, which is 
consistent with pro-αIIb compared to no expression seen for the mock cells or 
platelet lysate which expressed a band of size 113 kDa, which is consistent 
with mature αIIb. (see Figure 74). Both the α IIb and the β3 subunits are required 
for pro-αIIb processing into mature αIIb and transportation to the cell surface 
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(Mitchell et al., 2006). Because the β3 integrin subunit is not expressed in the 
EJ-138 cell line, only the pro-αIIb is expected to be seen in the αIIb transfected 
EJ-138 cells. 
A
Pro-αIIb
αIIb
123
113
β actin
B C
Figure 74 Western blot to detect αIIb protein in (A) the αIIb transfected EJ-138, 
(B) human platelet lysate and (C) the mock cells. Human platelet lysate was 
used as a positive control for the expression of mature αIIb integrin subunit. 
Only the band for pro-αIIb was seen in the αIIb transfected EJ-138 because, 
these cells do not express the β3 integrin subunit which is required for pro-αIIb 
processing into mature αIIb. 
 
4.3.3.6 EJ-138 transfection with β 3 integrin subunit 
The β3 cloned vector Plasmid 26653: β3-integrin-YFP (Addgene. Cambrige. 
USA) was used to transfect the EJ-138 cells with the β3 integrin subunit (see 
Figure 75). 
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Figure 75 The map of the plasmid 26653: β3-integrin-YFP as published on the 
website of Addgene. USA. 
The plasmid was recovered, extracted and verified as previously described in 
4.2.2. The plasmid was verified using HindIII and BglII restriction enzymes 
resulting in two bands one was 5513 bp which is the vector back bone plus the 
YFP insert and the other band was the β3-integrin insert which was 2387bp 
(see Figure 76, Figure 77). 
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Plasmid extracted from bacteria
Plasmid 26653:β3-integrin-YFP isolated from bacteria
Agar plates were streaked  to grow bacteria that contain the plasmid
Bacteria was Inoculated in LB liquid media
Detecting the transfected cells by fluorescence microscope 
Results  confirmation using the HindIII, BgIII restriction enzymes
Two bands: plasmid back 4800 bone, β3 integrin subunit 2387
Aliquots stored in glycerol
Transfection 
select the transfected cells by ring cloning and grow them separately in
24- well plates to form pure colonies
The cells tend to lose the fluorescence after  splitting 
(the transfection is transient )   
Figure 76: Schematic representation demonstrates a summary of the β3 
integrin transfection procedure. 
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Figure 77 Confirmation of the plasmid identity using the HindIII, BgIII restriction 
enzymes as recommended by (Addgene) resulting into two bands: the first 
one(A) is the plasmid back bone which is 4800 bp plus the YFP insert which is 
713 bp, the second band (B) is the β3 integrin subunit which is 2387 bp. 
 
The transfection was detected by fluorescence microscope and indicated 
successful transfection of the EJ138-αIIb cells with the plasmid β3-integrin-YFP 
but with low efficiency (see Figure 78). 
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Figure 78 Transfection of αIIb integrin was permanent whereas the β3 integrin 
(detected by fluorescence microscopy) was expressed transiently with lower 
efficiency. Scale bar: 50 µM. 
 
As an aim to prepare permanent homogenous population of β3-transfected EJ-
138 cells, ring cloning was done, but the cells lost the expression of the β3 
integrin after splitting, indicating that the β3 integrin transfection was transient 
(Figure 79). 
In a second attempt to prepare a permanently transfected EJ-138 cells, the 
transfection was repeated using the DNA of two vectors, the β3-integrin-YFP 
and the cloned vector pcDNA3-αIIb in ratio of 1:1. The transfected cells were 
only permanently transfected with the αIIb subunit without the β3 subunit (Figure 
79).  
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Figure 79 Immunolabelling of β3 integrin subunit expression in the EJ138-αIIb, 
mock, and the wild type EJ-138 cell line. All cell lines were found negative 
expressers for the β3 integrin subunit. 
 
4.3.3.7 Comparison of growth rates of transfected and wild-type EJ-138 
cells 
The growth curve of the EJ-138-αIIb cells was similar to the growth curve of the 
wild type EJ-138 cells (see Figure 80 ). However, the two cell lines varied in 
terms of morphology. The αIIb transfected EJ-138 cells demonstrated a clumpy 
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structure when highly confluent compared to no clumps seen in the wild type 
EJ-138 cells (see Figure 71). 
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Figure 80 The growth curves of the αIIb transfected EJ-138 cells compared to 
the wild type EJ-138 cells. The growth curve of the EJ-138-αIIb cells was similar 
to the growth curve of the wild type EJ-138 cells. 
4.3.3.8 Testing the ability of the αIIb integrin subunit transfected EJ-138 
cells to form hanging drop spheroids 
 In order to investigate possible effects of the transfection on the morphology 
and behavior of the transfected EJ-138-αIIb cells compared to the wild type 
cells, (1×103 cells ) hanging drop clumps of both cell lines were prepared and 
compared. The hanging drops clumps of the αIIb transfected EJ-138, mock and 
the wild type EJ-138 cells had a comparable loose structure of cell clumps, 
although the αIIb transfected EJ-138 gave a slightly more compact structure 
compared to the mock and wild type. The structure of the αIIb transfected EJ-
138 clumps were not compact enough to be considered as a spheroids or to be 
208 
 
transferred into collagen and therefore couldn’t be used in their current situation 
in the 3D spheroid invasion assay (see Figure 81). 
A B C
Figure 81 Comparison between the morphology of the hanging drops clumps 
of the αIIb transfected EJ-138, mock and the wild type EJ-138 cells. Scale bar: 
100 µM. The images which taken in the third day of seeding the hanging drops 
demonstrated that the structures of the clumps were comparable, although the 
αIIb transfected EJ-138 cells demonstrated slightly more compact structure.  
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4.4 Discussion 
Among the aims of this work was to prepare a tumour invasion model 
expressing both the αvβ3 and αIIbβ3 integrins to be used to evaluate novel β3 
integrin dual antagonists. From in-house screening carried out at the ICT 
(personal communication, M. Sutherland), no adherent cell line was found that 
had αIIbβ3 integrin expression, although a considerable number of cell lines were 
found to express the αvβ3 integrin.  
Two strategies were used to fulfill this aim, either transfecting a β3 integrin 
expressing cell line with an αIIb integrin subunit, or alternatively transfecting a 
non β3 integrin expressing cell line with both the αIIb and the β3 integrin subunits. 
A number of previous studies had successfully cloned the αIIb and the β3 integrin 
subunits into cells resulting in the formation of a functional αIIbβ3 integrin. The 
αIIb and the β3 integrin subunits were successfully transfected into Chinese 
Hamster Ovary cells (Liu et al., 2007, Ren et al., 2009) and into a human 
melanoma cell line (Trikha et al., 2002a). 
Cloning the αIIb integrin subunit into a suitable vector was the first requirement, 
and to do this, the first step was to amplify the αIIb gene using polymerase chain 
reaction (PCR). The templates used in the PCR reactions were cDNA extracted 
from different cell lines which had been shown in house to express the αIIb at 
the gene level. Successful trials were only able to amplify part of the gene, but 
none were able to amplify the whole αIIb gene. A possible reason for this was 
that there was incomplete cDNA synthesis during the reverse transcriptase 
reaction (Trikha et al., 1998). The incomplete cDNA synthesis resulted in 
production of an incomplete template which was then used in the PCR reaction 
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and resulted in amplification of part of the αIIb gene. Thus as an alternative 
option, the bacterial vector PCR-4-TOPO containing the αIIb construct was used 
as an alternative source for the αIIb gene. This vector was a successful source 
because extracting the αIIb gene from the vector didn’t include a reverse 
transcriptase reaction which was the expected reason behind the failure of the 
cell lines to act as a source of the αIIb gene. 
The efficiency of cloning was tested in three different ways: first PCR to confirm 
the identity of the cloned αIIb gene; second using the restriction enzymes to 
confirm that the αIIb gene was cloned in the right direction, and third sequencing 
the whole αIIb gene to confirm the absence of mistakes or genetic modifications 
in the cloned αIIb gene.  
U87-MG cells were selected for cloning in the first instance for two reasons: 
firstly these cells express the αvβ3 integrin (Reardon et al., 2011) so they could 
express the αIIbβ3 integrin by redistribution of β3 between the αv and αIIb 
subunits. The second reason to choose these cells was that it had been 
already established that they could be used successfully in the 3D spheroid 
invasion assay as described previously in this thesis. However, the U87-MG 
was not transfected permanently with the αIIb integrin subunit. The suggested 
hypothesis to explain the failure of the permanent transfection of αIIb was 
probably the expression of both αvβ3 and αvβ5 in the U87-MG cells, and so 
adding another αIIbβ3 integrin through transfection with αIIb could be associated 
with high oncogene expression (Reardon et al., 2011) which could lead to a 
kind of oncogene induced senescence (Desgrosellier and Cheresh, 2010), a 
proliferative exhaustion found in specific stages of in vitro cell culture and 
associated with functional, adhesion, and morphology changes of cells 
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(Campisi, 1999). The U87-MG cells could tend to reject the transfected αIIb 
gene as a way to keep alive and avoid entering into senescence. Another 
hypothesis to explain the failure of the permanent transfection could be due to 
the high expression of H-Ras in the U87-MG cells (Blum et al., 2005). H-Ras 
was found to inhibit the constitutively active state of αIIbβ3 integrin in platelets 
(Blum et al., 2005) and U87-MG cells were found to express significant 
amounts of H-Ras in addition to K-Ras and N-Ras (Blum et al., 2005). 
Therefore, the high expression of H-Ras in U87-MG cells could be the reason 
behind losing αIIbβ3 expression. Furthermore, the β3 integrin subunit needs to 
be in excess (~60%) in the cell before transfection with the αIIb integrin subunit 
in order to achieve expression of αIIbβ3 integrin on the cell surface (Mitchell et 
al., 2006). This indicated that it was not enough to transfect a β3 expressing 
cell line with the αIIb subunit in order to have αIIbβ3 integrin expression, with 
transfection with other subunits such as β3 likely to be a required step too. 
The previously mentioned results indicated the need to find an alternative non- 
β3 integrin expressing cell line to be transfected with the αIIb gene then to be 
transfected by the β3 subunit as a second step. The selected non integrin 
expresser cell line was the EJ-138 human bladder cancer cell line. The EJ-138 
cell line was considered a good option due to its ability to be transfected readily 
(personal communication, M. Sutherland) in addition to its response to 
challenge by G418 and formation of isolated colonies separated by ring cloning. 
The formation of isolated colonies indicated the success of the transfection to 
form cells that were able resist the G418 challenge and that these colonies were 
homogenously composed of the transfected EJ-138 cells originating from single 
cells.  
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The protein detected by Western blotting in the αIIb transfected EJ-138 cells was 
pro-αIIb (132 bp) which is seen in the endoplasmic reticulum and not αIIb (113bp), 
because the EJ-138 cells are not β3 integrin subunit expressers and αIIb and β3 
complex formation has been found to be a prerequisite for surface expression of 
the αIIb integrin (Jennings and Phillips, 1982). The pro- αIIb and the β3 subunits in 
the endoplasmic reticulum form complexes with each other in order to be 
transported to the Golgi apparatus. Here further modifications take place before 
the cleavage of the pro-αIIb into two mature chains which are transferred to 
plasma membrane as mature αIIb (Duperray et al., 1989).  
4.5 Conclusion  
In conclusion, this chapter describes preliminary work needed to develop a dual 
αvβ3 and αIIbβ3 integrin expressing model. The αIIb integrin subunit was cloned 
into a mammalian vector and permanently transfected EJ-138-αIIb cells were 
prepared. Permanent transfection of the EJ-138-αIIb cells with the β3 integrin 
subunit is the required next step for preparing an αIIbβ3 integrin expressing cell 
line. 
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Chapter 5: Overall discussion and future work 
5.1 Overall discussion and future work 
Although current cancer therapies have demonstrated considerable success, 
there are still many problems associated with the disease. One of the main 
reasons behind this is the inability to control the tumour dissemination process 
(Francia et al., 2011, Hanahan and Weinberg, 2011). As a way to solve this 
problem, much effort has been devoted to develop new agents aimed at 
stopping tumour dissemination through targeting the molecules involved in the 
process, in addition to developing assays for evaluating these new agents. 
Integrins are amongst molecules which are over-expressed during cancer 
progression (Desgrosellier and Cheresh, 2010). Integrins are important 
because they form a link between cancer cells and extracellular matrix 
molecules (Hanahan and Weinberg, 2011). Consequently they are considered 
as attractive targets for inhibition of the tumour progression process (Danhier et 
al., 2012, Ruoslahti and Pierschbacher, 1986) because of their involvement in 
important tumour hallmarks such as angiogenesis (Brooks et al., 1994) and 
metastasis (Natali et al., 1997). Integrins are targeted through three main 
strategies: blocking of integrin downstream signalling, modulation of integrin 
expression, and the blockage of ligand binding. The latter is considered as the 
main and most efficient integrin therapeutic targeting strategy due to the 
significant advances in the understanding of the nature of ligand–integrin 
interactions in addition to an increased understanding of the integrin structure 
(Cox et al., 2010). Among the examples of integrin-ligand-binding blockers are 
small-molecule based integrin antagonists and antibody-based integrin 
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antagonists (Shannon et al., 2004; Harms et al., 2004, Aster and Bougie, 
2007). An issue with antibody-based integrin antagonists is that their presence 
may lead to the generation of neutralizing antibodies leading to reduction in 
antagonist efficacy (Calabresi et al., 2007). The small molecule integrin 
antagonists are considered the best approach, due to the possibility of oral 
administration in addition to the relative low costs, although the currently 
designed compounds may cause unexpected agonist effects (Weis et al., 2009) 
associated with low doses (Reynolds et al., 2009, Cox et al., 2000a). A detailed 
understanding of the receptor structure and understanding of integrin signalling 
are the main requirements for designing effective new small molecule integrin 
antagonists. This is in order to avoid the problem of agonist-like effects 
previously noticed in oral αIIbβ3 integrin antagonists such as orbofiban, 
sibrafiban, and lotrafiban which lead to the termination of their clinical trials for 
treatment of coronary syndromes (Cox, 2004). Furthermore the addition of 
cilengitide to glioblastoma therapy in a phase III clinical trial failed to increase 
the overall survival and lead to stopping the development of cilengitide as an 
anticancer drug (Stupp et al. 2014). The problem of agonist-like effects was not 
only an issue with the structure of the compounds, but was also associated with 
other factors such as problems with bioavailability, in addition to the under-
dosing which emerged during the different dosing intervals. Furthermore lack of 
understanding of the complete role of the integrin in signalling could contribute 
to this problem (Cox et al., 2010). 
Of all the integrins to target in anticancer therapy, αvβ3 integrin is considered to 
be important due to its high expression on the surface of many solid tumours 
and endothelial cells in addition to its important role in inducing metastasis in 
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tumours such as melanoma, glioblastoma, prostate and breast cancers 
(Francia et al., 2011, Hanahan and Weinberg, 2011). 
The overall aim in this thesis was to develop an assay that could assess αIIbβ3 
and αvβ3 integrin dual antagonists. This aim was partially fulfilled through 
developing an αvβ3 integrin expressing 3D spheroid invasion assay and using 
this assay to evaluate a group of novel small molecule αvβ3 integrin 
antagonists. The work involved choosing a suitable αvβ3 integrin expressing cell 
line that was able to form hanging drop spheroids and invade in collagen and 
on meeting these criteria; U87-MG was used to establish a 3D spheroid 
invasion assay. The assay was validated using a known anti-invasive agent 
and a known β3 antagonist then finally the validated assay was used to 
evaluate a novel series of small molecule αvβ3 antagonists. 
The 3D spheroid gel invasion assay was used through this project, because it 
took into consideration the 3D nature of the tumour mass and the cell-cell 
interactions between the tumour cells in addition to the tumour-extracellular 
matrix interaction. Assays which focused on cancer cells themselves and 
ignored the extracellular components such as collagen were found to be 
inadequate because they did not take in consideration the interaction between 
the cancer cells and the host tissue environment (Denys et al., 2008, De Wever 
et al., 2004). Furthermore, the spherical model took into account the cell-cell 
contacts within the tumour mass and put more restrictions on the viability and 
cellular growth mimicking what was observed in the tumours while they were 
growing in vivo (Friedrich et al., 2009). 
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Furthermore, the 3D spherical invasion model is important in identifying the 
mechanisms that control invasion and analysing the effect of extracellular 
environment on cancer invasion making it very useful for future work. This 
model was membrane-free and kept the morphology of the cell; in addition to 
that it allowed for real-time monitoring. The 3D spheroid model is considered an 
important tool for the negative selection of compounds which did not have 
effect in inhibiting the invasion of the U87 spheroids and could result in 
economical savings in the future through significant reduction in animal testing 
as those compounds could be excluded at the in vitro level. Furthermore, 
experimentally it was proved that some drugs may be only effective in three-
dimensional assay but not on the two-dimensional culture, as demonstrated in 
some target-specific compounds when the target was only expressed in the 
three-dimensional tumour environment (Wang et al., 2002).  
Considerable improvements have been recently made in the field of 3D 
invasion assays. Among the important improvements is the use of structural 
scaffolds, which are mostly polystyrene 3D architectures placed on 2D culture 
plates and show high compatibility with 2D assays. The 3D scaffolds are used 
to support 3D invasion assays in addition to tumour models and show 
improvements in the field of drug screening through showing how organs and 
tissues are produced into scaffolds as recently shown in a study using 
bioengineered 3D scaffolds to track glioblastoma spheroid growth and invasion 
with fluorescence confocal microscopy (Heffernan et al.2014). Gelatine and 
thiolated hyaluronic acid were chemically cross linked with thiol poly ethylene 
glycol polymers to form structural 3D scaffolds with high resistance to 
hydrolysis for more than 30 days. The invasion of U87 spheroids cultured on 
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the hydrogel scaffolds was tracked and analysed by confocal microscopy. The 
invasion of the spheroids in artificial, 3D tumour microenvironment is 
associated with the cell type and the gel stiffness (Heffernan et al.2014). 
High importance was given to prepare the two collagen gel layers in equal 
concentrations before seeding the spheroids to guarantee equal homogeneous 
mixing of the two layers and avoid formation of interphase layer between them 
which could lead to spherical migration rather than the invasion. Furthermore, 
for the same purpose the collagen layers were given enough time to polymerize 
(45 minutes at 37 oC) to avoid seeded spheroids sinking to the surface of the 
tissue culture plate leading to migration rather than invasion.  
The novel β3 antagonist small molecule compounds; ICT9087, ICT9094, 
ICT9072, ICT9073, ICT9055, ICT9091, ICT9088 and ICT9095 in addition to the 
control cRGDfV demonstrated a statistically significant dose and time 
dependent reduction in U87-MG spheroids invasion in collagen. By investigating 
the structure of the active compounds, the presence of functional groups 
including the tetrahydronaphthyridines and aminopyridines generally have good 
activity and could be behind the activity noticed for a sub-group of compounds.  
The compounds were designed to be reversible in their effect. The reversibility 
of the compounds is an important feature to investigate (Blazer et al., 2010), 
and is among the features which should be taken in consideration during 
design, and needs to be tested before further progression. On the other hand, 
the irreversibility of the pharmacological compounds could be a problem as it 
results in covalent binding to the target receptor and in this case the effect 
cannot be stopped until the synthesis of new receptors, which could result in 
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interfering with biological functions and unwanted effects (Udenfriend et al., 
1958, Caille et al., 1996, Serafimova et al., 2012, Blazer et al., 2010). However 
the irreversibility in the pharmacological compounds could be a favourable 
property if high selectivity and specificity is taken in consideration as a basic 
condition, such as with ASS234, which is a multi-target compound designed for 
use in Alzheimer's disease and showed irreversible inhibition of human 
monoamine oxidase enzyme. This enzyme works by catalyzing the oxidative 
deamination of monoamines by using oxygen to remove an amine group from 
monoamine molecule to result in aldehyde and ammonia (Esteban et al.2014).  
Regulating each other’s function through a complex network of cross talk was 
among the important properties of different integrin types (Wang et al., 2014). 
Because of this relation between integrins, a therapeutic strategy should 
involve targeting more than one integrin (Engebraaten et al., 2009, Mor-Cohen 
et al., 2014, Diaz-Gonzalez et al., 1996). The αIIbβ3 integrin has been shown to 
interact with the αvβ3 integrin in inducing tumour metastasis and because of this 
interaction they were targeted individually before to induce anti-tumour effect 
(Zhao et al.,2014; Trikha et al., 2002b). Our interest in dual targeting is in 
contrast to the much more common strategy of highly selective targeting of αvβ3 
or αIIbβ3 (Engebraaten et al., 2009, Mor-Cohen et al., 2014, Diaz-Gonzalez et 
al., 1996). The importance of the αIIbβ3 integrin as a target comes from its 
involvement in the metastatic process through its expression both on platelets 
and on tumour cells (Trikha et al., 1998, Millard et al., 2011b) such as prostate 
carcinoma in which the αIIbβ3 integrin plays an important role in the tumour 
invasion process (Sheldrake, et al, 2009; Hynes, 2002, Gay and Felding-
Habermann, 2011). 
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Among the further aims of this project was developing a cell line expressing 
both αIIbβ3 and αvβ3 integrins to be utilized in the spheroid invasion assay to 
allow full evaluation of compounds which have been designed as dual 
αvβ3/αIIbβ3 antagonists. 
The initial steps needed to fulfil this aim were completed in the fourth chapter of 
this thesis through firstly cloning the αIIb subunit into a pcDNA3 mammalian 
vector, and secondly by permanently transfecting the EJ-138 cell line with the 
cloned vector to produce the EJ-138-αIIb cell line, following a lack of success to 
clone into U87-MG cells. 
The EJ-138 cell line was successfully transfected with the αIIb integrin subunit as 
shown by PCR, immunocytochemistry, and Western blotting. This success 
could be due to that the EJ-138 cell line was relatively easily transfected 
compared to U87-MG cells and that could be due to properties associated with 
the cell membranes such as improved permeability, in addition to the EJ-138 
cells being very responsive to G418 selection in the formation of isolated 
colonies. The αIIb transfected EJ-138 cells expressed pro-αIIb (132 bp) and not 
αIIb (113bp). This result was because the formation of αIIb and β3 integrin 
complex was a required step before surface expression of the αIIb (Jennings and 
Phillips, 1982) and the EJ-138 cells were not β3 integrin subunit expressers.  
The results demonstrated in this thesis are considered promising having 
identified active anti-invasive compounds from a set of compounds designed to 
be dual αvβ3/αIIbβ3 antagonists. Future work is warranted for further 
investigation of the specificity of the compounds and characterization of their 
mechanism of action.  
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5.2 Suggested future work  
Among the suggested methodologies for further confirmation of the role of the 
ICT compounds as β3 antagonists is performing a knockdown for the ITGB3 
gene (Hynes, 2002). This gene codes for the β3 integrin subunit and 
comparison of cell behaviour of knockdown cells to cells treated with the ICT 
compounds can determine if the effect of the knockdown is comparable to the 
effect of the ICT compounds, and therefore give further confirmation of the 
integrin antagonism mechanism of action of the compounds (Cheng et al., 
2014). 
In addition to studying the effects of novel β3 antagonists on the invasion of the 
cells in 3D environment in vitro, it is important to study their effect in vitro on 
other features that characterise tumour dissemination such as adhesion, 
migration and angiogenesis. Lead compounds can then be selected to progress 
to in vivo studies.  
As a further confirmation of the effect of the novel β3 antagonists on tumour 
invasion, it is suggested to study their effect on the invasion of multi-layered 
spheroids. One of the possible methodologies for forming homogenously sized 
multi-layered spheroids is using the layered spheroids method which depends 
on centrifuging cell suspension at low speed in a tube before allowing them to 
settle and form spheroids (Fennema, 2013). 
The developed invasion model could also be used to study compounds 
targeting other elements of the tumour dissemination process such as 
chemokines, and polysialic acid decoration of neural cell adhesion molecule 
(NCAM) (Amoureux et al,2010; Desgrosellier and Cheresh, 2010). According to 
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many clinical studies many human cancers such as breast, lung, prostate, 
colon, and melanoma are characterized by up regulation of chemokine and their 
receptors which play important roles in metastasis of these cancers to vital 
organs and lymph nodes, such as adherence of tumour cells to endothelium, 
extravasations from blood vessels, angiogenesis, proliferation and activation of 
vital signalling pathways (Shim et al. 2009). NCAM is a the key inducer of cell 
adhesion in the central nervous system and the attachment of the polycyclic 
acid (PSA) chain to the NCAM gives special properties to the molecule. In the 
adult PSA- NCAM is expressed in many neuroendocrine tumours, and it’s 
expression is associated with highly aggressive, disseminating tumours 
(Gascon et al. 2007). 
In order to further improve the spheroid model, the supporting cells in the 
tumour microenvironment could be taken into consideration, either by growing 
the spheroids in the presence of monolayers of the supporting cells, or by 
growing spheroids of co-cultures of both the U87-MG cell line and epithelial 
cells or tumour fibroblasts (Hsiao et al. 2009). The resulting model could then 
be more representative of the in vivo tumour microenvironment.  
In order to permanently transfect the EJ-138-αIIb cell line with the β3 integrin 
subunit, an antibiotic selection marker is recommended to be cloned in the the 
β3 cloned vector, for example, plasmid 26653, β3-integrin-YFP (Addgene, 
Cambrige, USA) to increase the efficacy of the β3 transfection process and 
induce the possibility of antibiotic selection of the transfected cells to result in a 
permanently transfected cell line. However it will be crucial to assess that the 
co-transfection of αIIb and β3 integrins results in a functionally stable αIIbβ3 
integrin. In order to prepare a dual αvβ3/αIIbβ3 expressing in vitro invasion model, 
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among the suggested procedures is to either prepare co-cultures of spheroids 
composed of both U87-MG cells and EJ-138-αIIbβ3 cells, or to further transfect 
the EJ-138-αIIbβ3 cell line with αv, and assess the ability of those spheroids to 
invade through collagen in order to be used for further studies. 
 
5.3 Conclusion 
In conclusion, this work has resulted in development and validation of an in 
vitro 3D spherical αvβ3 integrin expressing model for tumour invasion, which 
has been used to evaluate a group of novel small molecule β3 integrin 
antagonists with encouraging results.  
Initial steps have also been taken to construct a cell line which expresses both 
αIIbβ3 and αvβ3 integrin to use in the model to allow evaluation of these 
compounds for dual αvβ3/αIIbβ3 integrin antagonism 
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M. S. Zraikat, R. M. Phillips, L. H. Patterson, H. M. Sheldrake and  S. D. Shnyder
DEVELOPMENT OF IN VITRO MODELS OF INVASION FOR THE PHARMACOLOGICAL  
INVESTIGATION OF SMALL MOLECULE INHIBITORS OF TUMOUR PROGRESSION
Institute of Cancer Therapeutics, University of Bradford, West Yorkshire, BD7 IDP, UK
• At the Institute of Cancer
Therapeutics strategies are being
investigated which target ways of
modulating the tumour
dissemination process.
• This includes developing small
molecule antagonists of the β3
integrins
• One of the challenges in evaluating
novel molecules is to have
relevant, validated experimental
models.
• The aim of the work presented here
is to develop and validate an in
vitro spheroid-based invasion
assay to evaluate one of the key
aspects of tumour dissemination.
Introduction
• A panel of human tumour cell lines
known to express the molecular
targets of interest where evaluated
for their ability to form hanging drop
spheroids.
• One cell line, U87-MG human
glioma, demonstrated consistent
spheroid formation and was
progressed to the invasion assay.
• The assay was subsequently
validated using a known inhibitor of
glioma cell invasion, LiCL.
Methodology
Conclusion
• This work has established a 
validated assay for the evaluation 
of novel small molecular inhibitors 
of invasion .
• Work is now underway to evaluate 
novel β3 integrin antagonists using 
the assay.
Figure3: Determination of the ability of
four different cell lines to form
spheroids by hanging drop method.
Only U87-MG cells demonstrated
consistent spheroid formation and
growth.
Figure 5: Detection with confocal 
microscopy of both cells within the 
spheroid and invading cells using β-
actin immunolabelling.
Figure2: U87-MG cells express αv and
β3 integrin subunits. 
Figure 4: Cell invasion is seen over
time for U87-MG spheroids in collagen 
Figure 6: Validation of the assay: LiCL 
inhibits U87-MG invasion in a time 
and concentration dependent manner. 
Figure 1: Spheroid-based invasion
assay (adapted from Nowicki et
al., 2008. Neuro-oncology 10(5): 690-
699).
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DEVELOPMENT OF IN VITRO MODELS OF INVASION FOR THE PHARMACOLOGICAL  
INVESTIGATION OF SMALL MOLECULE INHIBITORS OF TUMOUR PROGRESSION
Institute of Cancer Therapeutics, University of Bradford, West Yorkshire, BD7 IDP, UK
• Small molecule antagonists of the β3
integrins can suppress the tumour
dissemination process.
• One of the challenges in evaluating
novel molecules is to have relevant,
validated experimental models.
• The aim of this work is to validate an
in vitro spheroid-based invasion
assay to evaluate one of the key
aspects of tumour dissemination.
Introduction
• The human glioma cell line, U87-MG,
demonstrated consistent spheroid
formation and invasion and thus was
selected from a panel of cell lines for
further studies.
• The assay was validated using lithium
chloride as a known inhibitor of
invasion, and cRGDfV a known β3
antagonist.
• A novel series of small molecules
were evaluated as β3 antagonists.
Methodology
Figure 1: Validation of the assay: LiCl 
inhibits U87-MG invasion in a time and 
concentration dependent manner. 
A: Phase contrast microscopy.
B: Cells stained with Hoechst 33342
Figure 2 : U87-MG is a suitable model 
for evaluation of β3 antagonism: 
inhibition of invasion using the β3 
antagonist, cRGDfV.
control 100nM 10 µM
A
B
A: Phase contrast microscopy.
B: Area of analysis using Image J software
Conclusions
• This work has established a validated assay for the evaluation of novel small molecular 
inhibitors of invasion .
• This assay has demonstrated encouraging activity for some novel small molecule β3 integrin
antagonists and future work is warranted on these compounds.
Figure 4 : Assessment of novel potential β3 antagonists in the invasion assay. Statistically 
significant inhibition of  invasion in a dose dependent manner is seen  for some compounds 
Figure 3 : Sample images for novel potential β3 
antagonists evaluated  in the invasion assay .
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A: Examples of ICT compounds which inhibited U87-MG
cells invasion.
B: Example of ICT compounds which did not inhibit
invasion of the U87-MG cells.
The expression of the β3 integrin
subunit in the U87-MG cell line
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Effect of ICT9073 on the invasion of U87-MG spheres 
in collagen 
Control
ICT9073 100 nM
ICT9073 10 uM
P<0.01**
P<0.05*
A
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10X
 
The ICT9073 showed a reduction in the invasion of the U87-MG spheroids in collagen in a 
concentration and time dependent manner. (A) Image-J analyzed pictures show that the 
ICT9073 treated spheroids were not able to invade compared to the control untreated 
spheroids. (B) Graphical representation of the data shows a significant inhibition of the U87-MG 
spheroids invasion upon treatment with different concentrations of ICT9073. 
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24hr 72hr
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Effect of ICT9055 on the invasion of U87-MG spheres in 
collagen 
Control
ICT9055 10 uM
ICT9055 100 nM
P<0.01**
P<0.05*
A
B
10X
The ICT9055 was able to reduce the invasion of the U87-MG spheroids in collagen in a 
concentration and time dependent manner. (A) Image-J analyzed pictures showed that the 
ICT9055 treated spheroids were not able to invade compared to the control untreated 
spheroids. (B) Graphical representation of the data shows a significant inhibition of the U87-MG 
spheroids invasion upon treatment with different concentrations of ICT9055. 
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Control 10 µM100nM Control 10 µM100nM
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Effect of ICT9094 on the invasion of U87-MG spheres 
in collagen 
Control
ICT9094 100 nM
ICT9094 10 uM
P<0.01**
P<0.05*
24hr 72hr
A
B
10X
 The invasion of the U87-MG spheroids in collagen after treatment with ICT9094. (A) Image-J 
analyzed pictures show that the treated spheroids with a concentration of 10 µM of ICT9094 
were not able to invade compared to the control untreated spheroids. (B) Graphical 
representation of the data shows a significant inhibition of the U87-MG spheroids invasion upon 
treatment with 10 µM ICT9094. 
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Control 10 µM100nM Control 10 µM100nM
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Effect of ICT9084 on the invasion of U87-MG spheres 
in collagen 
Control
ICT9084 100 nM
ICT9084 10 uM
P<0.01**
P<0.05*
**
24 hr 72 hr
A
B
10X
ICT9084 showed a concentration and time dependent reduction in the U87-MG spheroids 
invasion in collage. (A) Image-J analyzed pictures show that the treated spheroids with a 
concentration of 10 µM of ICT9084 were not able to invade compared to the control untreated 
spheroids. The spheroids treated with the 100 nM were able to invade but in less level 
compared to the control. (B) Graphical representation of the data shows a significant inhibition 
of the U87-MG spheroids invasion upon treatment with 10 µM ICT9084. 
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Control 10 µM100nM Control 10 µM100nM
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Effect of ICT9088 on the invasion of U87-MG spheres 
in collagen 
Control
ICT9088 100 nM
ICT9088 10 uM
P<0.01**
P<0.05*
24 hr 72 hr
A
B
10X
ICT9088 showed concentration and time dependent inhibition of the U87-MG spheroids 
invasion in collagen (A) Image-J analyzed pictures showed that the ICT9088 treated spheroids 
were not able to invade compared to the control untreated spheroids. (B) Graphical 
representation of the data shows a significant inhibition of the U87-MG spheroids invasion upon 
treatment with different concentrations of ICT9088. 
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Control 10 µM100nM Control 10 µM100nM
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Effect of ICT9091 on the invasion of U87-MG 
spheres in collagen 
Control
ICT9091 100 nM
ICT9091 10 uM
P<0.01**
P<0.05*
24 hr 72 hr
10X
ICT9091 caused a concentration and time dependent reduction in the U87-MG spheroids 
invasion in collagen. (A) Image-J analyzed pictures show that the spheroids treated with 100 
nM of ICT9091 invaded in less level compared to the control untreated spheroids. The treated 
spheroids with a concentration of 10 µM were not able to invade compared to the control. (B) 
Graphical representation of the data shows a significant inhibition of the U87-MG spheroids 
invasion upon treatment with 10 µM of ICT9091. 
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Effect of 1CT 9095 on the invasion of U87-MG 
spheres in collagen 
Control
ICT9095 100 nM
ICT9095 10 uM
P<0.01**
P<0.05*
24 hr 72 hr
10X
ICT9095 caused a concentration and time dependent reduction in the U87-MG spheroids 
invasion in collagen. (A) Image-J analyzed pictures show that the spheroids treated with 100 
nM of ICT9095 invaded in less level compared to the control untreated spheroids. On the other 
hand, 10 µM ICT9095 caused a significant inhibition of the treated spheroids compared to the 
control. (B) Graphical representation of the data shows a significant inhibition of the U87-MG 
spheroids invasion upon treatment with ICT9095. 
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Control 100nM 10 µM Control 100nM 10 µM
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Effect of ICT 9081 on the invasion of U87-MG spheres 
in collagen 
Control
ICT9081 100 nM
ICT9081 10 uM
P<0.01**
P<0.05*
24 hr 72 hr
A
B
10X
The ICT9081 showed a minor effect on the invasion of U87-MG spheroids in collagen. (A) 
Image-J analyzed pictures show that the spheroids treated with 100 nM of ICT9081 invaded 
in a comparable level compared to the control untreated spheroids. On the other hand, the 
invasion of the spheroids treated with 10 µM ICT9081 was inhibited to a minor extent 
compared to the control. (B) Graphical representation of the data shows a minor inhibition of 
the U87-MG spheroids invasion upon treatment with10 µM ICT9081. 
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Effect of ICT9082 on the invasion of U87-MG spheres 
in collagen 
Control
ICT9082 100 nM
ICT9082 10 uM
PP<0.05*
P<0.01**
24 hr 72 hr
A
B
10X
The ICT9082 showed a minor effect on the invasion of U87-MG spheroids in collagen. (A) 
Image-J analyzed pictures show that the invasion of the spheroids treated with ICT9081 was 
inhibited to a minor extent compared to the control untreated spheroids. (B) Graphical 
representation of the data shows a minor inhibition of the U87-MG spheroids invasion upon 
treatment with ICT9081. 
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Control 10 µM100nM Control 10 µM100nM
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Effect of ICT9086 on the invasion of U87-MG spheres 
in collagen 
Control
ICT9086 100 nM
ICT9086 10 uM
PP<0.05*
P<0.01**
24 hr 72 hr
A
B
10X
The ICT9086 showed a minor effect on the invasion of U87-MG spheroids in collagen. (A) 
Image-J analyzed pictures show that the invasion of the spheroids treated with 10 µM ICT9086 
was inhibited to a minor extent compared to the control untreated spheroids. (B) Graphical 
representation of the data shows a minor inhibition of the U87-MG spheroids invasion upon 
treatment with 10 µM ICT9086. 
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Control 10 µM100nM Control 10 µM100nM
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Effect of ICT9087 on the invasion of U87-MG spheres in 
collagen 
Control
ICT9087 100 nM
ICT9087 10 uM
PP<0.05*
P<0.01**
24 hr 72 hr
A
B
10X
The ICT9087 showed a minor effect on the invasion of U87-MG spheroids in collagen. (A) 
Image-J analyzed pictures show that the invasion of the spheroids treated with ICT9087 was 
inhibited to a minor extent compared to the control untreated spheroids. (B) Graphical 
representation of the data shows a significant minor inhibition of the U87-MG spheroids 
invasion upon treatment with ICT9087. 
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Control 10 µM100nM control 10 µM100nM
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Effect of ICT9092 on the invasion of U87-MG spheres in 
collagen 
Control
ICT9092 100 nM
ICT9092 10 uM
PP<0.05*
P<0.01**
24 hr 72 hr
A
B
10X
The ICT9092 showed a minor effect on the invasion of U87-MG spheroids in collagen. (A) 
Image-J analyzed pictures show that the invasion of the spheroids treated with ICT9092 was 
inhibited to a minor extent compared to the control untreated spheroids. (B) Graphical 
representation of the data shows a significant minor inhibition of the U87-MG spheroids 
invasion upon treatment with 10 µM and 100 nM ICT9092. 
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Control 10 µM100nM Control 10 µM100nM
0
2
4
6
8
10
12
14
16
18
20
0 1 2 3 4
Ar
ea
 o
f i
nv
as
io
n 
Days
Effect of ICT9096 on the invasion of U87-MG spheres in 
collagen 
Control
ICT9096 100 nM
ICT9096 10 uM
PP<0.05*
P<0.01**
72 hr
24 hr
A
B
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The ICT9096 showed no effect on the invasion of U87-MG spheroids in collagen. (A) Image-J 
analyzed pictures show that the invasion of the spheroids treated with ICT9096 was 
comparable to the control untreated spheroids. (B) Graphical representation of the data shows 
no inhibition of the U87-MG spheroids invasion upon treatment with ICT9096. 
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Control 10 µM100nM Control 10 µM100nM
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Effect of ICT9097 on the invasion of U87-MG spheres in 
collagen 
Control
ICT9097 100 nM
ICT9097 10 uM
PP<0.05*
P<0.01**
72 hr24 hr
A
B
10X
The ICT9097 showed no effect on the invasion of U87-MG spheroids in collagen. (A) Image-J 
analyzed pictures show that the invasion of the spheroids treated with 100 nM ICT9097 was more 
than the control untreated spheroids, on the other hand the spheroids treated with 10 µM showed 
comparable behavior to the control (B) Graphical representation of the data shows no inhibition of the 
U87-MG spheroids invasion upon treatment with ICT9097. 
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Effect of ICT9085 on the invasion of U87-MG spheres in 
collagen 
Control
ICT9085 100 nM
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PP<0.05*
P<0.01**
72 hr24 hr
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ICT9085 showed a minor effect on the invasion of U87-MG spheroids in collagen. (A) Image-J 
analyzed pictures show that the invasion of the spheroids treated with 100 nM ICT9085 was 
comparable to the control untreated spheroids, while the invasion of the spheroids treated with 
10 µM was inhibited to a minor extent compared to the control. (B) Graphical representation of 
the data shows a significant minor inhibition of the U87-MG spheroids invasion upon treatment 
with 10 µM ICT9085. 
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Effect of ICT9093 on the invasion of U87-MG spheres in 
collagen 
Control
ICT9093100 nM
ICT9093 10 uM
PP<0.05*
P<0.01**
72 hr24 hr
A
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10X
ICT9093 showed a minor effect on the invasion of U87-MG spheroids in collagen. (A) Image-J 
analyzed pictures show that the invasion of the spheroids treated with ICT9093 was inhibited to 
a minor extent compared to the control untreated spheroids.(B) Graphical representation of the 
data shows a significant minor inhibition of the invasion of the U87-MG spheroids treated with 
different concentrations of ICT9093. 
 
 
 
